<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003834.pub3" GROUP_ID="SCHIZ" ID="961500062414582349" MERGED_FROM="" MODIFIED="2015-10-14 13:49:00 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="73" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2015-10-14 13:49:00 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Lithium for schizophrenia</TITLE>
<CONTACT MODIFIED="2015-10-14 13:49:00 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Vice-chairman</POSITION><EMAIL_1>Stefan.Leucht@lrz.tum.de</EMAIL_1><MOBILE_PHONE>+49 151 270 42590</MOBILE_PHONE><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-10-14 13:49:00 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Vice-chairman</POSITION><EMAIL_1>Stefan.Leucht@lrz.tum.de</EMAIL_1><MOBILE_PHONE>+49 151 270 42590</MOBILE_PHONE><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON><PERSON ID="z1301311112022346974199538643931" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Bartosz</FIRST_NAME><LAST_NAME>Helfer</LAST_NAME><POSITION>Wissenschaftlicher Mitarbeiter (Researcher)</POSITION><EMAIL_1>bartosz.helfer@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 6415</PHONE_1><FAX_1>+49-89-4140-4987</FAX_1></ADDRESS></PERSON><PERSON ID="13468438652653628973110207120503" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Dold</LAST_NAME><EMAIL_1>markus.dold@lrz.tu-muenchen.de</EMAIL_1><EMAIL_2>markus.dold@lrz.tum.de</EMAIL_2><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>Medical University of Vienna</ORGANISATION><ADDRESS_1>Währinger Gürtel 18-20</ADDRESS_1><CITY>Vienna</CITY><ZIP>1090</ZIP><COUNTRY CODE="AT">Austria</COUNTRY></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="11851ACB82E26AA201DC7B3E5EEBF8BE" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>McGrath</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>j.mcgrath@uq.edu.au</EMAIL_1><MOBILE_PHONE>0407 149 609</MOBILE_PHONE><ADDRESS><DEPARTMENT>Queensland Centre for Mental Health Research</DEPARTMENT><ORGANISATION>The Park Centre for Mental Health</ORGANISATION><ADDRESS_1>Wolston Park Road</ADDRESS_1><ADDRESS_2>Wacol</ADDRESS_2><CITY>Brisbane</CITY><ZIP>4076</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 3271 8694</PHONE_1><FAX_1>+61 7 3271 8698</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-09-15 21:05:15 +0100" MODIFIED_BY="Laura E  Prescott">
<UP_TO_DATE>
<DATE DAY="20" MONTH="1" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="1" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="9" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-14 10:20:16 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-10-14 10:05:27 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>The results of 2 update searches (2012, 2015) added to the review; new data did not change the overall conclusions of the review. Substantial changes have been made to the structure of the review, with the addition of a 'Summary of findings' table and the updating of the risk of bias of the trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-10-14 10:20:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>2012 search updated, no new studies found. Results from 2012 search added to review; 2 new studies included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-10-14 10:11:47 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-14 10:11:47 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>New review format.</P>
<P>2002 update: a number of individual patient data were received from the original authors. This enabled us to examine whether the data were normally distributed. An amendment was added to the methods section.<BR/>
<BR/>2006 update: of 4 potentially relevant studies, 3 were not appropriately randomised and one had to be classified as 'awaiting assessment'.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Queensland Health</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>German Research Network on Schizophrenia, German Federal Ministry of Education and Research BMBF (grant 01 GI 993x)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-14 11:24:47 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-12-04 11:19:18 +0000" MODIFIED_BY="[Empty name]">Lithium for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>To examine whether the drug lithium alone is an effective treatment for schizophrenia and schizophrenia-like illnesses. To look at whether lithium is an effective treatment when added on as an extra treatment with antipsychotic drugs.</P>
<P>
<B>Background</B>
</P>
<P>People with schizophrenia often have two main types of symptoms with their illness, the acute symptoms of hearing voices or seeing things (hallucinations) and strange beliefs (delusions). Examples of chronic symptoms are low mood/depression, social withdrawal, and memory problems. The main treatment for schizophrenia is antipsychotic drugs. However, many people with schizophrenia do not respond fully to these drugs, and certain symptoms of the illness can remain when only an antipsychotic is given. In these cases, various add-on medications are used, among them lithium. Lithium stabilises a person's mood and is used as an add-on treatment with antipsychotics for schizophrenia. Lithium can reduce mania and depression.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The update search in 2012 detected two further studies that met required standards, and no further studies were found in the 2015 search. This review now includes 22 randomised studies, with a total of 763 participants. The studies randomised people with schizophrenia or similar illnesses into groups that received either lithium or placebo (dummy drug), lithium or antipsychotic drugs, lithium plus antipsychotic drugs, or antipsychotic drugs alone.</P>
<P>
<B>Key results</B>
</P>
<P>The findings in this review show that there is no good quality evidence that lithium on its own is effective for people with schizophrenia or schizoaffective disorder. There is some low quality evidence for the effectiveness of lithium as an add-on treatment with antipsychotic drugs, but this result is inconclusive. Few studies reported on the side effects of lithium (such as kidney and thyroid problems).</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Most of the studies were small, of short duration, and poorly reported. The review authors rated the quality of evidence for the main outcomes to be low or very low quality. Further large and well-designed trials are needed.</P>
<P>Ben Gray, Senior Peer Researcher, McPin Foundation (<A HREF="http://mcpin.org/">http://mcpin.org/</A>), wrote this plain language summary.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-10-14 09:50:48 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary anti-psychotic drug treatment. In these cases, various add-on medications are used, among them lithium.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-09-29 10:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>To assess whether:<BR/>1. Lithium alone is an effective treatment for schizophrenia, schizophrenia-like psychoses and schizoaffective psychoses; and<BR/>2. Lithium augmentation of antipsychotic medication is an effective treatment for the same illnesses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-10-14 09:50:48 +0100" MODIFIED_BY="[Empty name]">
<P>In July 2012, we searched the Cochrane Schizophrenia Group&#8217;s Study-Based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. This search was updated on January 20, 2015. For the first version of the review, we also contacted pharmaceutical companies and authors of relevant studies to identify further trials and obtain original participant data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) of lithium compared with antipsychotics or placebo (or no intervention), whether as sole treatment or as an adjunct to antipsychotic medication, in the treatment of schizophrenia or schizophrenia-like psychoses or both.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted data independently. For dichotomous data, we calculated random-effects meta-analyses, risk ratios (RRs), and 95% confidence intervals (CI) on an intention-to-treat basis. For continuous data, we calculated mean differences (MD) and 95% confidence intervals. We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) to create 'Summary of findings' tables and assessed risk of bias for included studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>The update search in 2012 detected two further studies that met our inclusion criteria. We did not find any further studies that met our inclusion criteria in the 2015 search. This review now includes 22 studies, with a total of 763 participants (median mean age: 35 years, range: 26 to 72 years). Most studies were small, of short duration, and incompletely reported. As we detected a high risk of bias in many studies, the overall methodological quality of the included sample was rather low.</P>
<P>Three small studies comparing lithium with placebo as the sole treatment showed no difference in any of the outcomes we analysed.</P>
<P>In eight studies comparing lithium with antipsychotic drugs as the sole treatment, more participants in the lithium group left the studies early (eight RCTs; n = 270, RR 1.77, 95% CI 1.01 to 3.11, low quality evidence).</P>
<P>Thirteen studies examined whether the augmentation of antipsychotic drugs with lithium salts is more effective than antipsychotic drugs alone. More participants who received lithium augmentation had a clinically significant response (10 RCTs; n = 396, RR 1.81, 95% CI 1.10 to 2.97, low quality evidence). However, this effect became non-significant when we excluded participants with schizoaffective disorders in a sensitivity analysis (seven RCTs; n = 272, RR 1.64, 95% CI 0.95 to 2.81), when we excluded non-double-blind studies (seven RCTs; n = 224, RR 1.82, 95% CI 0.84 to 3.96), or when we excluded studies with high attrition (nine RCTs; n = 355, RR 1.67, CI 0.93 to 3.00). The overall acceptability of treatment (measured by the number of participants leaving the studies early) was not significantly different between groups (11 RCTs; n = 320, RR 1.89, CI 0.93 to 3.84, very low quality evidence). Few studies reported on side effects. There were no significant differences, but the database is too limited to make any judgement in this regard. For example, there were no data on thyroid dysfunction and kidney problems - two major and well-known side effects of lithium.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence base for the use of lithium in schizophrenia is limited to 22 studies of overall low methodological quality. There is no randomised trial-based evidence that lithium on its own is an effective treatment for people with schizophrenia. There is some GRADE low quality evidence that augmentation of antipsychotics with lithium is effective, but the effects are not significant when more prone-to-bias open RCTs are excluded. Nevertheless, further large and well-designed trials are justified. These should concentrate on two target groups: (1) people with no affective symptoms, so that trialists can determine whether lithium has an effect on the core symptoms of schizophrenia, and (2) people with schizoaffective disorders for whom lithium is widely used in clinical practice, although there is no evidence to support this use.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-10-14 10:11:30 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is often a chronic and disabling psychiatric disorder; it afflicts approximately one per cent of the population worldwide, with little gender differences. Its typical manifestations are 'positive' symptoms, such as fixed false beliefs (delusions) and perceptions without cause (hallucinations); 'negative' symptoms, such as apathy, lack of drive, and disorganisation of behaviour and thought; and catatonic symptoms, such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable, with 80% to 90% not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>In this review, we examined the role of lithium in the treatment of schizophrenia, schizophrenia-like psychoses, and schizoaffective psychoses. Lithium is traditionally used for affective psychoses, especially the acute treatment of mania, and for relapse prevention in bipolar affective psychoses. Companion reviews examined carbamazepine (<LINK REF="REF-Leucht-2014" TYPE="REFERENCE">Leucht 2014</LINK>), valproate (<LINK REF="REF-Schwarz-2008" TYPE="REFERENCE">Schwarz 2008</LINK>), and benzodiazepines (<LINK REF="REF-Dold-2012" TYPE="REFERENCE">Dold 2012</LINK>) as sole or adjunctive treatments for schizophrenia.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>The efficacy of lithium has been identified in a number of psychiatric conditions &#8211; it can reduce mania and depression, work as a prophylactic agent in both disorders, and augment the effect of many antidepressants and possibly antipsychotics. Lithium influences virtually every neurotransmitter system, so its efficacy is most probably not due to one specific biochemical mechanism (<LINK REF="REF-Jope-1999" TYPE="REFERENCE">Jope 1999</LINK>). Additionally, it has been shown that lithium alters ionic transport and hormonal and circadian regulation as well as mechanisms of gene expression (<LINK REF="REF-Lenox-2003" TYPE="REFERENCE">Lenox 2003</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>Despite the introduction of antipsychotic (neuroleptic) medication in the 1950s, there is still a sizeable minority of people with schizophrenia and related conditions that do not have complete remission of symptoms (<LINK REF="REF-Schooler-1993" TYPE="REFERENCE">Schooler 1993</LINK>). Over the last 40 years, a variety of adjunctive treatments have been used to treat schizophrenia (<LINK REF="REF-Christison-1991" TYPE="REFERENCE">Christison 1991</LINK>). These are often used in addition to antipsychotics in an attempt to alleviate the symptoms of the disease, such as hallucinations and delusional beliefs, although they have also been used instead of antipsychotics. Treatments such as lithium (indicated for bipolar affective disorder), carbamazepine (<LINK REF="REF-Leucht-2014" TYPE="REFERENCE">Leucht 2014</LINK>), benzodiazepines (<LINK REF="REF-Dold-2012" TYPE="REFERENCE">Dold 2012</LINK>), beta-blockers (<LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>), and electroconvulsive therapy (<LINK REF="REF-Tharyan-2005" TYPE="REFERENCE">Tharyan 2005</LINK>) have all been used for people whose psychoses did not respond to traditional therapy. The situation has improved somewhat with the re-introduction of clozapine, which has proven efficacy for those that have not responded to traditional medications (<LINK REF="REF-Essali-2009" TYPE="REFERENCE">Essali 2009</LINK>). There is evidence that some other 'atypical' antipsychotics are also more effective for the treatment of those with treatment-resistant schizophrenia, but overall the differences between antipsychotics are small (<LINK REF="REF-Leucht-2013" TYPE="REFERENCE">Leucht 2013</LINK>). However, many individuals with psychoses have suboptimal responses to treatment, and clinicians are faced with the choice of changing to alternate types of medication or augmenting existing neuroleptics with other drugs or treatments.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-09-29 13:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>To assess whether:</P>
<P>1. Lithium alone is an effective treatment for schizophrenia, schizophrenia-like psychoses and schizoaffective psychoses; and<BR/>2. Lithium augmentation of antipsychotic medication is an effective treatment for the same illnesses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-10-14 10:11:30 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials (RCTs). If a trial was described as 'double blind' but implied randomisation, we included such trials in a sensitivity analysis (see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>). If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in statistically significant differences, we did not add the data from these lower quality studies to the results of the better trials, but presented such data within a subcategory. We excluded quasi-randomised studies, such as those that allocated by alternate days of the week. Where people were given additional treatments as well as lithium, we only included data if the adjunct treatment was evenly distributed between groups and it was only the lithium that was randomised.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder, and delusional disorder, again, by any means of diagnosis.</P>
<P>We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible, If studies reported the information we clearly highlighted in the Characteristic of included studies and text, the current clinical state (acute, early postacute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment-resistant illnesses).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Lithium alone: any dose.</LI>
<LI>Placebo (or no intervention).</LI>
<LI>Lithium in combination with any antipsychotic treatment: any dose.</LI>
<LI>Placebo (or no intervention) in combination with any antipsychotic treatment.</LI>
<LI>Antipsychotics alone: any dose.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped all outcomes into short-term (up to 12 weeks), medium-term (13 to 26 weeks), and long-term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-09-29 10:29:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Response to treatment</HEADING>
<P>1.1 Clinically relevant response as defined by the authors<BR/>1.2 Relapse - as defined by each of the studies</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Acceptability of treatment</HEADING>
<P>1.1 Leaving early due to any reason</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Service utilisation</HEADING>
<P>2.1 Hospital admission<BR/>2.2 Days in hospital<BR/>2.3 Change in hospital status</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Clinical response</HEADING>
<P>3.1 Clinically significant improvement of global state<BR/>3.2 Average score/change in global state<BR/>3.3 Clinically significant improvement in mental state as defined by each of the studies<BR/>3.4 Average score/change in mental state<BR/>3.5 Clinically significant response on depressive symptoms as defined by each of the studies<BR/>3.6 Average score/change in depressive symptoms<BR/>3.7 Clinically significant response on manic symptoms as defined by each of the studies<BR/>3.8 Average score/change in manic symptoms<BR/>3.9 Clinically significant response on negative symptoms as defined by each of the studies<BR/>3.10 Average score/change in negative symptoms<BR/>3.11 Clinically significant response on positive symptoms as defined by each of the studies<BR/>3.12 Average score/change in positive symptoms<BR/>3.13 Additional drug use<BR/>3.13.1 Antipsychotics<BR/>3.13.2 Benzodiazepines</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Behaviour</HEADING>
<P>4.1 General behaviour<BR/>4.2 Specific behaviours<BR/>4.2.1 Social functioning<BR/>4.2.2 Employment status during trial (employed/unemployed)<BR/>4.2.3 Occurrence of violent incidents (to self, others, or property)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Adverse events</HEADING>
<P>5.1 General adverse events<BR/>5.2 Specific adverse events<BR/>5.2.1 Allergic reactions<BR/>5.2.2 Blood dyscrasia, such as agranulocytosis<BR/>5.2.3 Central nervous system (ataxia, nystagmus, drowsiness, fits, diplopia, tremor)<BR/>5.2.4 Death (suicide and non-suicide deaths)<BR/>5.2.5 Gastrointestinal (nausea, vomiting, diarrhoea)<BR/>5.2.6 Kidney dysfunction<BR/>5.2.7 Movement disorders (extrapyramidal side effects, including neuroleptic malignant syndrome)<BR/>5.2.8 Thyroid dysfunction (goitre, thyroid hypofunction)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Economic (cost of care)</HEADING>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-10-14 10:11:30 +0100" MODIFIED_BY="[Empty name]">
<P>The methods section of reviews of the Cochrane Schizophrenia Group are continuously improved; hence, the methods sections of previous versions of this review can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-10-14 10:11:30 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cochrane Schizophrenia Group&#8217;s Trials Register</HEADING>
<P>On January 20, 2015, the Trials Search Co-ordinator (TSC) searched the Cochrane Schizophrenia Group&#8217;s Study-Based Register of Trials using the following search strategy:</P>
<P>*Lithium* in Intervention of STUDY</P>
<P>In such study-based register, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics.</P>
<P>The Cochrane Schizophrenia Group&#8217;s Register of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, hand-searches, grey literature, and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group&#8217;s Module</A>). There are no language, date, document type, or publication status limitations for inclusion of records into the register.</P>
<P>For previous searches, please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-09-29 10:32:43 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected references of all included studies for further relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>For the original search, we contacted the first author of each included study for information regarding unpublished trials and additional information (however, this was not done in this update).</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-10-14 09:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>We present the methods used in data collection and analysis for the current update below; for previous methods, please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
</P>
<STUDY_SELECTION MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>Review authors SL and BH independently inspected all citations from the searches to identify relevant abstracts (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Where disputes arose, we acquired the full report for more detailed scrutiny. If citations met inclusion criteria, we obtained full reports of the papers for more detailed inspection. SL and BH independently inspected those articles (with the help of a Chinese translator, if necessary, and in this case, only once). Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>We initially planned that reviewers MD and BH would extract data from newly included studies, resolving any disagreement by consensus. However, the update search yielded only new studies in the Chinese language, so we had to employ a Chinese translator, Yijun Wang, in order to extract the data. Thus, double extraction was not possible in the case of the two new included studies (<LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> and <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, predesigned simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only in the following cases:</P>
<UL>
<LI>a. if the psychometric properties of the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and</LI>
<LI>b. if the measuring instrument had not been written or modified by one of the trialists for that particular trial.</LI>
</UL>
<P>Ideally, the measuring instrument should have been either i) a self-report or ii) completed by an independent rater or relative (not the therapist); however, this was often not reported clearly.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided to primarily use endpoint data and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>, Chapter 9.4.5.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the standard deviation when multiplied by two is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); c) if a scale started from a positive value (such as Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases, skew is present if 2 SD &gt; (S-S min), where SD is the standard deviation, S is the mean score, and S min is the minimum score. Endpoint scores on scales often have a finite start and endpoint and these rules can be applied. When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We entered skewed data from studies of less than 200 participants in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we entered such data into syntheses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week, or per month), to a common metric (e.g., mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that a 50% improvement in a scale-derived score, such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), can be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 'Summary of findings' table</HEADING>
<P>We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used GRADE profiler (<LINK REF="REF-GRADE-Profiler" TYPE="REFERENCE">GRADE Profiler</LINK>) to import data from RevMan 5 (<LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes that we rated as critical or important to patient care and decision-making. We selected the following main outcomes for inclusion in the 'Summary of findings' tables:</P>
<OL>
<LI>Response to treatment - clinically relevant response as defined by the authors</LI>
<LI>Acceptability of treatment - leaving early due to any reason</LI>
<LI>Clinically significant response on depressive symptoms (at least 50% Montgomery-Asberg Depression Rating Scale (MADRS) improvement)</LI>
<LI>Clinically significant response on manic symptoms (at least 50% Bech-Rafaelsen improvement)</LI>
<LI>Clinically significant response on positive symptoms (at least 50% Manchester Scale (MS) improvement)</LI>
<LI>Adverse events - kidney dysfunction</LI>
<LI>Adverse events - thyroid dysfunction</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>BH assessed the risk of bias using the criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting. SL supervised BH in this process. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted the authors of the studies in order to obtain further information. We noted the level of risk of bias in both the text of the review (<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>) and in the tables (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that clinicians tend to interpret odds ratios as RRs (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). For statistically significant results, we had originally planned to calculate the number needed to treat to provide benefit/to induce harm statistic (NNTB/H) and its 95% confidence interval (CI) using Visual Rx (<A HREF="http://www.nntonline.net/visualrx/introduction/">www.nntonline.net/visualrx/introduction</A>), taking account of the event rate in the control group. However, 'Summary of findings' tables and calculations therein have superseded this.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes, we estimated the mean difference (MD) between groups. We would have prefered not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we would presume there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby, P values are spuriously low, confidence intervals unduly narrow, and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where primary studies did not account for clustering, we presented data in a table with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies to obtain intraclass correlation coefficients for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we presented these data as if from a non-cluster-randomised study, but adjusted for the clustering effect.</P>
<P>We sought statistical advice and were advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) (design effect = 1+(m-1)*ICC) (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported, we assumed it to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed, taking into account intraclass correlation coefficients, and relevant data documented in the reports, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g., pharmacological, physiological, or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase, the participants can differ systematically from their initial state despite a washout phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we only used data from the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added and combined these within a two-by-two table. If data were continuous, we combined data following the formula in section 7.7.3.8 (Combining groups) of the <I>Cochrane Handbook</I> <I>for Systematic Reviews of Interventions</I>. Where the additional treatment arms were not relevant, we did not reproduce these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Intention-to-treat</HEADING>
<P>For studies that did not specify the reasons for people leaving the study early, the reviewers assumed that these people had no change in the clinical outcome variables. <LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK> highlighted the problem of high dropout rates in randomised trials of drug treatments for schizophrenia. Since there is no evidence on the degree of attrition, which makes a reasonable analysis of the data possible, we included all trials in the main analysis. However, we used a sensitivity analysis to test whether the exclusion of trials with attrition rates higher than 50% significantly changed the results of the primary outcome parameters. When insufficient data were provided to identify the original group size (prior to attrition), we contacted the authors and allocated the trials to the '<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>' list.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous outcomes</HEADING>
<P>If standard deviations were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and confidence intervals were available for group means, and either P value or t value available for differences in mean, we calculated them according to the rules described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): When only the standard error (SE) is reported, standard deviations (SDs) are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formulas for estimating SDs from P, t, or F values; confidence intervals; ranges; or other statistics. If these formulas did not apply, we calculated the SDs according to a validated imputation method, which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially without seeing comparison data to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise. When such situations or participant groups arose, we discussed them fully.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially without seeing comparison data to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods that we had not predicted would arise. When such methodological outliers arose, we discussed them fully.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I² statistic</HEADING>
<P>We investigated heterogeneity between studies by considering the I² statistic method alongside the Chi² P value. The I² statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of the I² statistic depends on i) magnitude and direction of effects and ii) strength of evidence for heterogeneity (e.g., a P value from a Chi² test, or a confidence interval for an I² statistic). We interpreted I² statistic estimates greater than or equal to around 50% accompanied by a statistically significant Chi² statistic as evidence of substantial levels of heterogeneity (Section 9.5.2, <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When we found substantial levels of heterogeneity in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the nature and direction of results influence the dissemination of research findings (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). Section 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) describes this. We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-09-29 14:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for the use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us, and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is however a disadvantage to the random-effects model: it puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose random-effects model for all analyses. The reader is, however, able to choose to inspect the data using the fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>We reported if inconsistency was high. We first investigated whether data had been entered correctly. Second, if data were correct, we re-inspected outlier studies to find out whether methodological differences were likely to explain the differences. We also explored such reasons through subgroup analyses, of which we a priori defined the separate examination of studies in first-episode participants, treatment-resistant participants, and people with schizoaffective or prominent affective symptoms to be conducted in any case for the primary outcome of comparison three (lithium augmentation). Decisions as to whether we should nevertheless pool the studies, whether we should remove single outlier studies, or whether we would not pool studies at all depended on factors such as whether subgroup effects could explain heterogeneity or whether studies differed in the direction of effects, which is more problematic, or just in the degree of differences between intervention and control (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>We only performed sensitivity analyses for the primary outcome, response to treatment in comparison three (lithium augmentation).</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcomes, we included these studies, and if there was no substantive difference when we added the implied randomised studies to those with better description of randomisation, we employed all data from those studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Risk of bias</HEADING>
<P>We analysed the effects of excluding trials that we judged to be at a high risk of bias in terms of blinding, i.e., we excluded open RCTs. We also excluded studies with very high attrition (&gt; 50%) in a sensitivity analysis of the primary outcome. We excluded a priori studies with high risk randomisation methods or allocation concealment methods.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Cluster-randomised trials</HEADING>
<P>We also undertook a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster-randomised trials.</P>
<P>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Fixed and random effects</HEADING>
<P>We synthesised all data using a random-effects model; however, we also synthesised data for the primary outcome using a fixed-effect model to evaluate whether the greater weights assigned to larger trials with greater event rates in the fixed-effect model altered the significance of the results compared with the more evenly distributed weights in the random-effects model.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of the studies, please see the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables and the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' tables.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>The initial search in 2002 identified 91 citations, of which 65 appeared relevant and the full studies were inspected. The update search in 2006 yielded 56 further citations, of which four were potentially relevant. We contacted the authors of these studies; we had to exclude three because they were not appropriately randomised (<LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK>; <LINK REF="STD-Gao-2002" TYPE="STUDY">Gao 2002</LINK>; <LINK REF="STD-Wang-1995" TYPE="STUDY">Wang 1995</LINK>). We could obtain no information on the fourth study, <LINK REF="STD-Kamisada-1988" TYPE="STUDY">Kamisada 1988</LINK>, and therefore listed it among those studies awaiting assessment. The update search in 2012 identified four further potentially relevant studies. Eventually, we excluded two of them: the first, because of the intervention used (<LINK REF="STD-Zhou-2011" TYPE="STUDY">Zhou 2011</LINK>), and the second, because of a non-random allocation procedure (<LINK REF="STD-Sun-2008" TYPE="STUDY">Sun 2008</LINK>). We included the two remaining studies in our analysis (<LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK>; <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>). A further search was run in January 2015 and yielded 23 citations; initial scanning of this search found no new included studies, all were either studies to be excluded or additional references to studies already included in the review (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>We identified 22 studies for inclusion in this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Study design</HEADING>
<P>Most studies used a parallel group design, but <LINK REF="STD-Garver-1983" TYPE="STUDY">Garver 1983</LINK>; <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>; <LINK REF="STD-Small-1975" TYPE="STUDY">Small 1975</LINK>; <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK>; and <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK> were cross-over studies. Of the latter, we used only the results of the first phase, as described in the methods section.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Length of trials</HEADING>
<P>
<LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK> was the longest study, with a duration of one year. <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>; <LINK REF="STD-Small-1975" TYPE="STUDY">Small 1975</LINK>; <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK>; and <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK> were medium-term studies, with a duration of 13 to 19 weeks. All of the others were in the 'short-term' category, lasting between three and eight weeks within a single treatment phase.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<P>The 22 studies included a total of 763 people. The number of people in each study was rather low and ranged between 10 and 92. Fourteen out of 22 studies provided the mean age of the participants (median: 35 years, range: 26 to 72 years). Fifteen studies provided information about severity, out of which 11 described their participants as chronic or non-responsive to previous treatment. Only two studies, <LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK> and <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK>, were undertaken in the community; all others were carried out with people who were in hospital at the beginning of the trial.</P>
<P>Most participants had schizophrenia, but there were also some people with schizoaffective disorder (n = 196 - of these, 155 had schizomania), schizophreniform disorder (n = 22), atypical psychoses (n = 7), and delusional disorder (n = 5), and there were 29 participants where the diagnosis was not clearly indicated. Diagnostic criteria varied to a considerable extent, because the studies were carried out over a long period of time, but most of the studies used some sort of standard diagnostic criteria. Several studies examined specific groups of participants. <LINK REF="STD-Biederman-1979" TYPE="STUDY">Biederman 1979</LINK> studied participants with "motor hyperactivity" or elevated mood, <LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK> examined participants with "persistent distress and/or anxiety", <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK> analysed a chronic group with tardive dyskinesia, and <LINK REF="STD-Brockington-1978" TYPE="STUDY">Brockington 1978</LINK>; <LINK REF="STD-Collins-1991" TYPE="STUDY">Collins 1991</LINK>; <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK>; <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>; <LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Small-1975" TYPE="STUDY">Small 1975</LINK>; <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK>; <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK>; <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>; and <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> included only treatment-resistant participants according to a variety of criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Interventions</HEADING>
<P>Three studies compared lithium as a sole agent with placebo as a sole agent (<LINK REF="STD-Garver-1983" TYPE="STUDY">Garver 1983</LINK>; <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>; <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>); eight studies compared lithium as a sole agent with antipsychotics (<LINK REF="STD-Braden-1982" TYPE="STUDY">Braden 1982</LINK>; <LINK REF="STD-Brockington-1978" TYPE="STUDY">Brockington 1978</LINK>; <LINK REF="STD-Dube-1981" TYPE="STUDY">Dube 1981</LINK>; <LINK REF="STD-Johnson-1971" TYPE="STUDY">Johnson 1971</LINK>; <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>; <LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK>; <LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK>; <LINK REF="STD-Shopsin-1971" TYPE="STUDY">Shopsin 1971</LINK>); and 13 studies compared lithium added to antipsychotic drugs versus placebo added to antipsychotic drugs (<LINK REF="STD-Biederman-1979" TYPE="STUDY">Biederman 1979</LINK>; <LINK REF="STD-Collins-1991" TYPE="STUDY">Collins 1991</LINK>; <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK>; <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>; <LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Huang-1984" TYPE="STUDY">Huang 1984</LINK>; <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>; <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK>; <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>; <LINK REF="STD-Small-1975" TYPE="STUDY">Small 1975</LINK>; <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK>;<LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK>; <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK>). <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> provided data for all three comparisons.</P>
<P>The lithium dose was commonly adjusted to be within a therapeutic blood-level range. All but one study that compared lithium as a sole agent with antipsychotics used chlorpromazine as a comparator. The exception was the study by <LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK>, which used fluphenazine. The range of chlorpromazine or its equivalent daily doses in the other studies was 300 to 2000 mg.</P>
<P>Of the 13 studies that examined lithium as an adjunct to antipsychotics, three used haloperidol as an antipsychotic (<LINK REF="STD-Biederman-1979" TYPE="STUDY">Biederman 1979</LINK>; <LINK REF="STD-Huang-1984" TYPE="STUDY">Huang 1984</LINK>; <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK>); two, clozapine (<LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK>; <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK>); two, fluphenazine (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK>); one, pimozide (<LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>); and one, risperidone (<LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>). In the other four studies, the therapists could choose any antipsychotic drug that they preferred (<LINK REF="STD-Collins-1991" TYPE="STUDY">Collins 1991</LINK>; <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>; <LINK REF="STD-Small-1975" TYPE="STUDY">Small 1975</LINK>; <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Outcomes</HEADING>
<P>A variety of scales were used to assess clinical response and adverse events. The reporting on efficacy and on side effects was incomplete in the original publications. However, we were able to substantially improve this situation by contacting the authors, many of whom agreed to share their data with us.</P>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Outcome scales</HEADING>
<P>We present details of scales that provided usable data below. We have given reasons for exclusion of data provided by other instruments under 'outcomes' in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
<SUBSECTION>
<HEADING LEVEL="6">5.1.1 Global functioning</HEADING>
<UL>
<LI>Clinical Global Impression (CGI) Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)</LI>
</UL>
<P>A rating instrument commonly used in studies of schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used, with low scores indicating decreased severity or greater recovery or both.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.1.2 Mental state</HEADING>
<UL>
<LI>Brief Psychiatric Rating Scale (BPRS) (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)</LI>
</UL>
<P>A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 18 items, and each item can be defined on a seven-point scale varying from 'not present' (1) to 'extremely severe' (7). Scoring goes from 18 to 126.</P>
<UL>
<LI>Positive and Negative Syndrome Scale (PANSS) (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)</LI>
</UL>
<P>This scale was developed to evaluate the positive, negative, and general symptoms in schizophrenia. The scale has 30 items, and each item can be defined on a seven-point scoring system varying from one (absent) to seven (extreme). This scale can be divided into subscales for measuring the severity of general psychopathology, positive symptoms, negative symptoms, mania (excited component), and aggression (Supplemental Aggression Risk Profile). Higher scores indicate more pronounced symptomatology.</P>
<UL>
<LI>Bech-Rafaelsen Mania Scale (BRMS) (<LINK REF="REF-Bech-1978" TYPE="REFERENCE">Bech 1978</LINK>)</LI>
</UL>
<P>This rating scale has 11 items addressing symptoms of mania. The single items can all be defined on a five-point scale from zero (normal) to four (extreme). A total score is calculated, which goes from zero to 44.</P>
<UL>
<LI>New Haven Schizophrenia Index (NHSI) (<LINK REF="REF-Astrachan-1972" TYPE="REFERENCE">Astrachan 1972</LINK>)</LI>
</UL>
<P>A symptom checklist for the evaluation of schizophrenic pathology.</P>
<UL>
<LI>Manchester Scale (MS) (<LINK REF="REF-Krawiecka-1977" TYPE="REFERENCE">Krawiecka 1977</LINK>)</LI>
</UL>
<P>A brief rating scale used to assess the severity of symptoms associated with schizophrenia and comprising positive, negative, and depressive symptoms. Each item can be defined on a five-point scale varying from 'not present' (zero) to 'severe' (four).</P>
<UL>
<LI>Structured Clinical Interview (SCI) (<LINK REF="REF-Burdock-1968" TYPE="REFERENCE">Burdock 1968</LINK>)</LI>
</UL>
<P>A scale to assess the mental state of those with psychiatric disorders. Higher scores indicate more symptoms.</P>
<UL>
<LI>Hamilton Rating Scale for Depression (HRSD) (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>)</LI>
</UL>
<P>The instrument is designed to be used only on patients already diagnosed as suffering from affective disorder of depressive type. It is used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information. The scale contains 17 variables measured on either a five-point or a three-point rating scale, the latter being used where quantification of the variable is either difficult or impossible. Among the variables are depressed mood, suicide, work and loss of interest, retardation, agitation, gastrointestinal symptoms, general somatic symptoms, hypochondriasis, loss of insight, and loss of weight. It is useful to have two raters independently scoring a patient at the same interview. The scores of the patient are obtained by summing the scores of the two physicians.</P>
<UL>
<LI>Montgomery-Asberg Depression Rating Scale (MADRS) (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>)</LI>
</UL>
<P>A 10-item checklist to measure the overall severity of depression symptoms. Items are rated on a scale of zero to six with anchors at two-point intervals. Higher scores indicate more symptoms. Scoring ranges from zero to 60.</P>
<UL>
<LI>Scale for the Assessment of Negative Symptoms (SANS) (<LINK REF="REF-Andreasen-1989" TYPE="REFERENCE">Andreasen 1989</LINK>)</LI>
</UL>
<P>This six-point scale gives a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-asociality, and attention impairment. Higher scores indicate more symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.1.3 Adverse events</HEADING>
<UL>
<LI>Abnormal Involuntary Movement Scale (AIMS) (<LINK REF="REF-NIMH-1970" TYPE="REFERENCE">NIMH 1970</LINK>)</LI>
</UL>
<P>The Abnormal Involuntary Movement Scale has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder. However, using this scale in short-term trials may also be helpful to assess some rapidly occurring abnormal movement disorders, such as tremor.</P>
<UL>
<LI>Simpson-Angus Scale (SAS) (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)</LI>
</UL>
<P>This 10-item scale, with a scoring system of zero to four for each item, measures drug-induced parkinsonism, a short-term, drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
<UL>
<LI>Barnes Akathisia Scale (BAS) (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)</LI>
</UL>
<P>Akathisia is a drug-induced movement disorder. The scale comprises items rating the observable, restless movements that characterise akathisia, the subjective awareness of restlessness, and any distress associated with the condition. These items are rated from zero (normal) to three (severe). In addition, there is an item for rating the global severity, which starts from zero (absent) to five (severe). A low score indicates low levels of akathisia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.1.4 Missing outcomes</HEADING>
<P>No data were available for many important outcomes, such as length of hospital stay, ability to work, or quality of life.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 64 studies. The main reasons for exclusion were that studies did not (or did not adequately) randomise (n = 38), did not have a majority of participants with schizophrenia (n = 13), did not include a placebo or no-intervention group (n = six), or did not present any data that we could meta-analyse (n = seven). We contacted the authors of four studies, <LINK REF="STD-Carman-1981" TYPE="STUDY">Carman 1981</LINK>; <LINK REF="STD-Gerlach-1975" TYPE="STUDY">Gerlach 1975</LINK>; <LINK REF="STD-Growe-1979" TYPE="STUDY">Growe 1979</LINK>; <LINK REF="STD-Jus-1978" TYPE="STUDY">Jus 1978</LINK>, but were unable to obtain further data. After translation, we excluded <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK> as participants were people with periodic psychosis (according to the Chinese Classification of Mental Disorders (CCMD-3)), not people with schizophrenia.</P>
<SUBSECTION>
<HEADING LEVEL="3">Awaiting assessment</HEADING>
<P>Three studies are in awaiting assessment: one needs translation (<LINK REF="STD-Mosolov-1998" TYPE="STUDY">Mosolov 1998</LINK>), and we are seeking more information from the other studies (<LINK REF="STD-Kamisada-1988" TYPE="STUDY">Kamisada 1988</LINK>; <LINK REF="STD-McGorry-2002" TYPE="STUDY">McGorry 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing Studies</HEADING>
<P>There are currently no ongoing studies that we are aware of.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>For graphical representations of our judgements of risk of bias, please refer to <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. Full details of judgements can be seen in the 'Risk of bias' tables.<BR/>
</P>
<ALLOCATION MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>All included studies were stated to be randomised. <LINK REF="STD-Brockington-1978" TYPE="STUDY">Brockington 1978</LINK>; <LINK REF="STD-Collins-1991" TYPE="STUDY">Collins 1991</LINK>; <LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Johnson-1971" TYPE="STUDY">Johnson 1971</LINK>; <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>; <LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK>; <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK>; <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK>; and <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> used lists of random numbers for allocating the participants. <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK> used a coin-toss method. We classified these studies as having a low risk of selection bias. The other studies did not provide a specific method used in the randomisation procedure, and we thus classified these as having an unclear risk of selection bias.</P>
<P>Regarding the allocation concealment, we classified all but four studies as unclear in this respect.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>We rated separately objective and subjective outcomes. We also rated performance and detection bias separately, resulting in four independent assessments of blinding.</P>
<P>All but five studies were double-blind. 
<LINK REF="STD-Collins-1991" TYPE="STUDY">Collins 1991</LINK> was randomised but open. <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>
 only blinded the raters. <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> and <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> did not provide any information about blinding so we assumed an open-label design. <LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK>; <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK>; and <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> used identical capsules for blinding. In <LINK REF="STD-Shopsin-1971" TYPE="STUDY">Shopsin 1971</LINK> and <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK>, the raters and the participants, but not the therapists, were blind to medication. The other studies did not describe their blinding method; they were just said to be blind.<BR/>
</P>
<P>As for objective outcomes, for both performance and detection bias, we rated all studies as having a low risk of bias because we considered blinding to be less important for objective outcomes as it was for subjective outcomes.<BR/>
</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>Although all but two studies, <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK>; <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>, indicated the numbers of participants who left the study before its completion, the reasons for leaving the studies early were not consistently indicated. Thus, we could only analyse the specific reasons for leaving the studies early in only one study (<LINK REF="STD-Biederman-1979" TYPE="STUDY">Biederman 1979</LINK>).</P>
<P>We assessed only five studies as having a low risk of attrition bias, but only because there were no participants leaving early in these studies. We judged two studies as unclear and 15 studies as having a high risk of attrition bias. Many of these 15 studies often had a high attrition rate (more than 25%) that was not evenly distributed between groups. Moreover, none of these studies gave specific reasons for discontinuation.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>Selective reporting was a major problem within the included studies. We judged 19 out of 22 studies as having a high risk of reporting bias due to lack of information about predefined outcomes. Very often the studies did not report neither standard deviations nor means. The remaining three studies did not selectively report on any outcomes; thus, we judged these as having a low risk of bias in this respect.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-09-29 14:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>We did not identify any other potential sources of bias in 17 out of 22 of the included studies. We judged five studies as unclear in this respect (for various reasons).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison 1: lithium versus placebo as sole treatment</HEADING>
<P>Three studies fell into this category (<LINK REF="STD-Garver-1983" TYPE="STUDY">Garver 1983</LINK>; <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>; <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Clinically significant response as defined by the authors</HEADING>
<P>The studies by <LINK REF="STD-Garver-1983" TYPE="STUDY">Garver 1983</LINK> and <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> both provided data for the calculation of the clinically significant response defined as at least 50% improvement of the baseline score on the New Haven Schizophrenia Index or on the Manchester Scale. No significant difference between lithium and placebo as sole treatments was found (2 RCTs; n = 54, RR 0.83; 95% CI 0.44 to 1.55). No significant heterogeneity was found (Chi² = 0.08, P = 0.78; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Leaving the study early</HEADING>
<P>In the studies by <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK> and <LINK REF="STD-Garver-1983" TYPE="STUDY">Garver 1983</LINK> no participants left the studies before the end so that only the data from <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> had an impact on the statistical analysis. There was no significant difference between groups (3 RCTs; n = 65, RR 1.14; 95% CI 0.29 to 4.44)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1 General response/non-response according to two scores</HEADING>
<P>In <LINK REF="STD-Garver-1983" TYPE="STUDY">Garver 1983</LINK> no significant differences were found in outcomes in terms of improvement on the New Haven Schizophrenia Index (at least 20% improvement, 1 RTC; n = 15, RR 0.67, CI 0.13 to 3.53; at least 35% improvement, 1 RCT; n = 15, RR 0.67, CI 0.13 to 3.53; at least 50% improvement, 1 RCT; n = 15, RR 0.67, CI 0.13 to 3.53). The same applies to <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> for improvements in the Manchester Scale (at least 20% improvement, 1 RCT; n = 39, RR 0.92, CI 0.61 to 1.40; at least 35% improvement, 1 RCT; n = 39, RR 0.86, CI 0.47 to 1.58; at least 50% improvement, 1 RCT; n = 39, RR 0.86, CI 0.44 to 1.69).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.2 General - average global scores at endpoint</HEADING>
<P>In <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>, the mean Manchester Scale scores at endpoint were similar in both groups (1 RCT; n = 39, WMD 0.0, CI -2.9 to 2.9). The mean New Haven Schizophrenia Index scores in <LINK REF="STD-Garver-1983" TYPE="STUDY">Garver 1983</LINK> were skewed (see 'other data table').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.3 Specific - depression, mania, negative symptoms, positive symptoms</HEADING>
<P>Only <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> provided usable data on depression, manic symptoms, negative symptoms, and positive symptoms. No significant differences in terms of any level of improvement of these symptoms were found.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Adverse events - movement disorders</HEADING>
<P>
<LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> presented scale-derived data on extrapyramidal side effects in general and on tardive dyskinesia that were skewed; therefore, we only presented these in the 'other data table'. <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> reported no significant differences between groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Missing outcomes</HEADING>
<P>We could not extract information about any of the other outcomes that were listed in the methods section.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Publication bias</HEADING>
<P>We could not assess publication bias because there were fewer than 10 included studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Comparison 2: lithium versus antipsychotics as sole treatment</HEADING>
<P>Eight studies fell into this category (<LINK REF="STD-Braden-1982" TYPE="STUDY">Braden 1982</LINK>; <LINK REF="STD-Brockington-1978" TYPE="STUDY">Brockington 1978</LINK>; <LINK REF="STD-Dube-1981" TYPE="STUDY">Dube 1981</LINK>; <LINK REF="STD-Johnson-1971" TYPE="STUDY">Johnson 1971</LINK>; <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>; <LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK>; <LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK>; <LINK REF="STD-Shopsin-1971" TYPE="STUDY">Shopsin 1971</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Clinically significant response as defined by the authors</HEADING>
<P>Three studies provided dichotomised data on clinically significant response. <LINK REF="STD-Brockington-1978" TYPE="STUDY">Brockington 1978</LINK> and <LINK REF="STD-Johnson-1971" TYPE="STUDY">Johnson 1971</LINK> indicated the numbers of participants who were improved, and <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>, the number of participants with at least 50% Manchester Scale improvement. Data showed no difference between lithium and antipsychotic drugs (3 RTCs; n = 80, RR 0.72; 95% CI 0.28 to 1.84). No significant heterogeneity was found (Chi² = 3.02, P = 0.22; I² = 34%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Leaving the study early</HEADING>
<P>Significantly more participants who received lithium as a sole treatment left the studies early (8 RTCs; n = 270, RR 1.77, CI 1.01 to 3.11). Only four studies however reported the reasons (<LINK REF="STD-Dube-1981" TYPE="STUDY">Dube 1981</LINK>; <LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK>; <LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK>; <LINK REF="STD-Shopsin-1971" TYPE="STUDY">Shopsin 1971</LINK>). Combining the results of these studies, it appears that lack of efficacy (4 RCTs; n = 178, RR 2.89, CI 1.09 to 7.67; P = 0.03) rather than poor tolerability (n = 178, RR 1.24, CI 0.08 to 19.21; P = 0.88) led to the attrition.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1 Improved according to the Clinical Global Impression (CGI) Scale</HEADING>
<P>
<LINK REF="STD-Brockington-1978" TYPE="STUDY">Brockington 1978</LINK> and <LINK REF="STD-Johnson-1971" TYPE="STUDY">Johnson 1971</LINK> presented data on the number of participants with improvement of their global state according to the Global Clinical Impression (CGI) Scale. There was no significant difference between lithium and antipsychotic drugs (2 RCTs; n = 36, RR 0.62, CI 0.06 to 5.98).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2 Relapse</HEADING>
<P>Only <LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK> reported relapse at one year. More participants who were treated with lithium relapsed (six out of seven) compared with one out of seven participants taking an antipsychotic. This result did not reach statistical significance (1 RTC; n = 14, RR 6.0, CI 0.95 to 37.8; P = 0.06).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Mental state - general</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.4.1 At least 20%, 35%, or 50% improvement on the Manchester Scale</HEADING>
<P>
<LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> was the only study that allowed an analysis of dichotomised data derived from the Manchester Scale. More participants in the lithium group than in the pimozide group achieved at least 20% (1 RCT; n = 44, RR 0.73, CI 0.53 to 1.01; P = 0.06), 35% (1 RCT; n = 44, RR 0.61, CI 0.37 to 1.00; P = 0.05), or 50% improvement (1 RCT; n = 44, RR 0.58, CI 0.33 to 1.01; P = 0.05) on their initial score in this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.2 Mean BPRS at endpoint</HEADING>
<P>Homogeneous results of three trials, <LINK REF="STD-Dube-1981" TYPE="STUDY">Dube 1981</LINK>; <LINK REF="STD-Johnson-1971" TYPE="STUDY">Johnson 1971</LINK>; <LINK REF="STD-Shopsin-1971" TYPE="STUDY">Shopsin 1971</LINK>, showed a significant superiority of antipsychotic drugs in this regard (3 RCTs; n = 92, WMD 10.23, CI 6.32 to 14.15). We calculated the standard deviations from the study by <LINK REF="STD-Dube-1981" TYPE="STUDY">Dube 1981</LINK> and <LINK REF="STD-Johnson-1971" TYPE="STUDY">Johnson 1971</LINK> from exact P values in these publications. Although the data might be skewed according to the criteria stipulated in the methods section, our means of analysing it might justify us deviating from this. Furthermore, both studies used parametric tests in their analyses, and <LINK REF="STD-Dube-1981" TYPE="STUDY">Dube 1981</LINK> confirmed by e-mail that the data were normally distributed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.3 Mean MS at endpoint</HEADING>
<P>
<LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> used the Manchester Scale and also found a significant superiority of antipsychotic drugs (1 RCT; n = 44, WMD 3.00, CI 0.38 to 5.62). Original participant data were available for this analysis, and these appeared to be normally distributed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.4 Mean SCI at endpoint</HEADING>
<P>
<LINK REF="STD-Johnson-1971" TYPE="STUDY">Johnson 1971</LINK> also used the SCI for the evaluation of the mental state and found no significant difference between groups (1 RCT; n = 11, WMD -2.0, CI -81.29 to 77.29).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Mental state - specific</HEADING>
<P>Only <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> provided data for the analysis of specific aspects of the mental state, reporting on depressive, manic, negative, and positive symptoms.</P>
<SUBSECTION>
<HEADING LEVEL="5">2.5.1 Depressive symptoms</HEADING>
<P>No significant differences were found between lithium and pimozide in terms of an improvement on the Montgomery-Asberg Depression Rating Scale of at least 20% (1 RCT; n = 44, RR 0.79, CI 0.53 to 1.18), 35% (1 RCT; n = 44, RR 0.75, CI 0.44 to 1.14), and 50% (1 RCT; n = 44, RR 0.73, CI 0.43 to 1.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.2 Manic symptoms</HEADING>
<P>No significant differences were found between lithium and pimozide in terms of an improvement on the Bech-Rafaelsen Mania Scale of at least 20% (1 RCT; n = 44, RR 0.89, CI 0.58 to 1.37), 35% (1 RCT; n = 44, RR 0.67, CI 0.35 to 1.29) and 50% (1 RCT; n = 44, RR 0.51, 0.24 to 1.09; P = 0.08), although in this last comparison, statistical significance became borderline.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.3 Negative symptoms</HEADING>
<P>Lithium was significantly less effective than pimozide in terms of an improvement in the negative symptoms subscore of the Manchester Scale of at least 20% (1 RCT; n = 44, RR 0.40, CI 0.23 to 0.69), 35% (1 RCT; n = 44, RR 0.37, CI 0.20 to 0.68) and 50% (1 RCT; n = 44, RR 0.37, CI 0.20 to 0.68).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.4 Positive symptoms</HEADING>
<P>Lithium was significantly less effective than pimozide in terms of an improvement in the positive subscore of the Manchester Scale of at least 20% (1 RCT; n = 44, RR 0.55, CI 0.36 to 0.83), 35% (1 RCT; n = 44, RR 0.49, CI 0.29 to 0.83) and 50% (1 RCT; n = 44, RR 0.49, CI 0.29 to 0.83).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.6.1 Anticholinergic adverse events</HEADING>
<P>
<LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK> presented data on blurred vision, dry mouth, and constipation. No significant differences between groups were found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.2 Central nervous system</HEADING>
<P>Only two studies, <LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK>; <LINK REF="STD-Shopsin-1971" TYPE="STUDY">Shopsin 1971</LINK>, reported data on various adverse events relating to the central nervous system (ataxia, dizziness, hyperactive reflexes, muscle weakness, slurred speech, somnolence, and toxic confusion). Somnolence was significantly more frequent in the antipsychotics group (1 RCT; n = 83, RR 0.2, CI 0.04 to 0.73) and toxic confusion was more frequent in the lithium group (2 RCTs; n = 104, RR 8.83, CI 1.16 to 67.38). The other adverse events occurred with similar frequency in both groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.3 Dermatologic</HEADING>
<P>In the study by <LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK>, no significant difference in the occurrence of pruritus was found (1 RCT; n = 83, RR 0.41, CI 0.02 to 9.83).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.4 Gastrointestinal adverse events</HEADING>
<P>Again, only <LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK> presented data. There were no significant differences between groups in terms of dehydration (1 RCT; n = 83, RR 3.71, CI 0.16 to 88.51), nausea (1 RCT; n = 83, RR 0.62, CI 0.12 to 3.21) and vomiting (1 RCT; n = 83, RR 0.83, CI 0.15 to 4.70).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.5 Movement disorder</HEADING>
<P>In the two trials that presented dichotomous data on movement disorder, <LINK REF="STD-Prien-1972" TYPE="STUDY">Prien 1972</LINK>; <LINK REF="STD-Shopsin-1971" TYPE="STUDY">Shopsin 1971</LINK>, no significant differences were found in terms of parkinsonism (1 RCT; n = 83, RR 0.25, CI 0.01 to 5.00), tremor (1 RCT; n = 83, RR 2.18, CI 0.69 to 6.87)or use of antiparkinson medication (1 RCT; n = 21, RR 0.1, CI 0.01 to 1.68). <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> presented scale-derived data about tardive dyskinesia, which were skewed (see <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Laboratory abnormalities</HEADING>
<P>Only <LINK REF="STD-Shopsin-1971" TYPE="STUDY">Shopsin 1971</LINK> reported data on laboratory abnormalities. More participants in the antipsychotic group had a decreased white blood cell count, which was of borderline statistical significance (1 RCT; n = 21, RR 0.10, CI 0.00 to 1.11; P = 0.06), whereas more participants in the lithium group had an increased white blood cell count (one RCT; n = 21, RR 17.42, CI 1.14 to 265.34; P = 0.04). No significant differences in terms of increased uric acid blood level (1 RCT; n = 21, RR 6.42, CI 0.37 to 110.71) or proteinuria (1 RCT; n = 21, RR 4.58, CI 0.25 to 85.33) were found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Missing outcomes</HEADING>
<P>No data were found for 'service' outcomes, such as 'duration of hospital stay'. There were neither data on satisfaction with treatment or costs nor usable information about specific aspects of mental state, such as aggression, positive symptoms, negative symptoms, or mood.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.9 Publication bias</HEADING>
<P>We could not assess publication bias because there were fewer than 10 included studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Comparison 3: lithium versus placebo as an adjunct to antipsychotic drugs</HEADING>
<P>Twelve studies fell under this category (<LINK REF="STD-Biederman-1979" TYPE="STUDY">Biederman 1979</LINK>; <LINK REF="STD-Collins-1991" TYPE="STUDY">Collins 1991</LINK>; <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK>; <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>; <LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Huang-1984" TYPE="STUDY">Huang 1984</LINK>; <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>; <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK>; <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>; <LINK REF="STD-Small-1975" TYPE="STUDY">Small 1975</LINK>; <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK>; <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Clinically significant response as defined by the authors</HEADING>
<P>According to the data from 10 studies, there were more responders in the lithium augmentation group than in the group that received antipsychotic drugs alone (10 RCTs; n = 396, RR 1.81, CI 1.10 to 2.97; P = 0.02). As significant heterogeneity was found (Chi² = 17.71, P = 0.04; I² = 49%), we explored it in a subgroup analysis (see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> and <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Leaving the study early</HEADING>
<P>Although there was a trend showing that more participants treated with lithium augmentation left the studies early than participants who received antipsychotics alone, it did not reach conventional levels of significance (11 RCTs; n = 320, RR 1.89, CI 0.93 to 3.84; P = 0.08). Only <LINK REF="STD-Biederman-1979" TYPE="STUDY">Biederman 1979</LINK> reported on 'leaving early due to adverse events'. There was no significant difference between groups (1 RCT; n = 39, RR 4.32, CI 0.22 to 84.48).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3.1 Improved according to the Clinical Global Impression (CGI) Scale</HEADING>
<P>There was no statistically significant difference between participants who received lithium augmentation and those who received placebo in addition to antipsychotics in terms of improvement of their global state according to the Clinical Global Impression Scale (4 RCTs; n = 115, RR 1.52, CI 0.57 to 4.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.2 Relapse</HEADING>
<P>Only <LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK> reported relapse rates; no significant differences between groups were found (1 RCT; n = 29, RR 0.21, CI 0.01 to 4.76).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Mental state - general</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.4.1 At least 20%, 35%, or 50% improvement inf the BPRS total score</HEADING>
<P>No significant differences in terms of at least 20% BPRS improvement were found (5 RCTs; n = 131, RR 1.21, CI 0.83 to 1.76), but significantly more participants who received lithium augmentation had at least 35% (5 RCTs; n = 131, RR 1.77, CI 1.02 to 3.10) and at least 50% (5 RCTs; n = 131, RR 2.52, CI 1.17 to 5.42) improvement of this score.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.2 At least 20%, 35%, or 50% improvement in the MS total score</HEADING>
<P>
<LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> used the Manchester Scale for the evaluation of the general mental state. No significant differences between groups were found in terms of an improvement of the baseline MS score of at least 20% (1 RCT; n = 45, RR 0.90, CI 0.71 to 1.13), 35% (1 RCT; n = 45, RR 0.93, CI 0.67 to 1.30) or 50% (1 RCT; n = 45, RR 0.98, CI 0.69 to 1.40).</P>
<P>
<B>3.4.3 At least 50% improvement in the PANSS total score</B>
</P>
<P>
<LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> and <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> used the PANSS total score to evaluate general mental state. Significantly more participants who received lithium augmentation than those who received placebo in addition to antipsychotics had an improvement of at least 50% (2 RCTs; n = 152, RR 1.49, CI 1.16 to 1.90).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.4 Mean BPRS total score at endpoint</HEADING>
<P>Four studies presented usable data on the mean BPRS at endpoint. Although all studies showed a trend in favour of lithium augmentation, the pooled mean difference did not reveal a statistically significant superiority (4 RCTs; n = 102, WMD -3.26, CI -7.10 to 0.57). Individual participant data were available for <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK> and appeared to be normally distributed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.5 Mean MS total score at endpoint</HEADING>
<P>In <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>, the mean MS total score at endpoint was similar in both groups (1 RCT; n = 45, WMD 0.70, CI -1.53 to 2.93). Again individual participant data were available that seemed to be normally distributed.</P>
<P>
<B>3.4.5 Mean PANSS total score at endpoint</B>
</P>
<P>
<LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> and <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> showed a significant difference in mean PANSS total score at endpoint in favour of lithium (2 RCTs; n = 152, WMD -8.53, CI -11.44 to -5.62). No individual participant data were available.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Mental state - specific</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.5.1 Depressive symptoms</HEADING>
<P>
<LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> used the Montgomery-Asberg Depression Scale to monitor depression and found no significant differences in terms of participants who had an improvement of at least 20% (1 RCT; n = 45, RR 0.99, CI 0.72 to 1.35), 35% (1 RCT; n = 45, RR 0.98, CI 0.66 to 1.45) or 50% (1 RCT; n = 45, RR 1.05, CI 0.69 to 1.58) in their baseline score. <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> used the depression/anxiety subscore of the BPRS and found no significant differences in terms of participants who had an improvement of at least 20% (1 RCT; n = 22, RR 0.97, CI 0.48 to 1.95), 35% (1RCT; n = 22, RR 1.17, CI 0.53 to 2.55) or 50% (1 RCT; n = 22, RR 1.17, CI 0.53 to 2.55) in their baseline score. For <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>, it was possible to analyse the mean Montgomery-Asberg Depression Scale score at endpoint as well. There was no significant difference between groups (1 RCT; n = 45, WMD -0.34, CI -1.64 to 0.96). Using the Hamilton Depression Scale, <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK> found no significant differences in mean endpoint scores between groups (1 RTC; n = 16, WMD 3.40, CI -7.66 to 14.46).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.2 Manic symptoms</HEADING>
<P>
<LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> found no significant differences in terms of improvement of the Bech-Rafaelsen Mania Scale of at least 20% (1 RCT; n = 45, RR 1.05, CI 0.72 to 1.52), 35% (1 RCT; n = 45, RR 1.13, CI 0.70 to 1.82) or 50% (1 RCT; n = 45, RR 1.13, CI 0.70 to 1.82).</P>
<P>
<LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> provided endpoint data on the Excited Component of PANSS. A significant difference in favour of lithium was found (1 RCT; n = 60, WMD -2.47, CI -3.62 to -1.32).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.3 Negative symptoms</HEADING>
<P>Three studies, <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>; <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK>; <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK>, used the SANS and showed no significant differences in terms of an improvement in this scale of at least 20% (3 RCTs; n = 70, RR 1.43, CI 0.66 to 3.10), 35% (3 RCTs; n = 70, RR 1.14, CI 0.66 to 2.04) or 50% (3 RCTs; n = 70, RR 1.04, CI 0.50 to 2.17). <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> used the negative symptoms score of the Manchester Scale. Again, no significant differences were found in terms of an improvement in this scale of at least 20% (1 RCT; n = 45, RR 0.95, CI 0.81 to 1.11), 35% (1 RCT; n = 45, RR 1.00, CI 0.83 to 1.20) or 50% (1 RCT; n = 45, RR 1.00, CI 0.83 to 1.20). Finally, <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK> used the negative symptoms score of the PANSS and revealed no significant differences in terms of an improvement in this scale of at least 20% (1 RCT; n = 20, RR 0.50, CI 0.12 to 2.14), 35% (1 RCT; n = 20, RR 1.00, CI 0.07 to 13.87) or 50% (1 RCT; n = 20, RR 3.00, 0.14 to 65.90).</P>
<P>For several studies, it was possible to analyse mean scores of rating scales for negative symptoms as well. Two studies, <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK>; <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK>, used the negative symptom subscore of the BPRS and found no significant difference between groups (n = 61, WMD 0.6, CI -1.1 to 2.3). <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> provided data about the negative symptom subscore of the MS and found no significant difference (n = 45, RR 0.3, CI -0.3 to 0.9). <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> and <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK> used the negative symptoms subscore of the PANSS and found a similar result (n = 112, WMD -0.07, CI -2.85 to 2.72). Finally, <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK> and <LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK> used the SANS. On combining the results of both trials, we found a statistically significant superiority of lithium augmentation (n = 41, WMD -4.5, CI -8.8 to -0.2; P = 0.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.4 Positive symptoms</HEADING>
<P>Again, the trials used a variety of scales, and no significant differences between groups were found in almost all of them. <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK> and <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> used the positive symptoms subscore of the BPRS and showed no significant differences in terms of an improvement in this scale of at least 20% (2 RCTs; n = 49, RR 1.26, CI 0.87 to 1.82), 35% (2 RCTs; n = 49, RR 1.14, CI 0.66 to, 1.89) or 50% (2 RCTs; n = 49, RR 1.27, CI 0.71 to 2.28). <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> used the positive symptoms score of the Manchester Scale. Again, no significant differences were found in terms of an improvement of at least 20% (1 RCT; n = 45, RR 1.04, CI 0.93 to 1.18), 35% (1 RCT; n = 45, RR 0.94, CI 0.73 to 1.21) or 50% (1 RCT; n = 45, RR 0.84, CI 0.62 to 1.13). Finally, <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK> used the positive symptoms score of the PANSS and found no significant differences in terms of an improvement of at least 20% (1 RCT; n = 20, RR 1.00, CI 0.42 to 2.40), 35% (1 RCT; n = 20, RR 1.00, CI 0.34 to 2.93) or 50% (1 RCT; n = 20, RR 1.33, CI 0.40 to 4.49).</P>
<P>Concerning mean endpoint scores of scales, <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK> analysed the BPRS positive subscore at endpoint and found no significant difference between groups (1 RCT; n = 41, WMD 0.14, CI -3.45 to 3.73). <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> used the MS positive subscore and found no significant difference between groups (1 RCT; n = 45, WMD 0.23, CI -1.34 to 1.80). <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> and <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK> monitored the participants using the positive subscore of the PANSS and found a significant difference between groups in favour of lithium augmentation (2 RCTs; n = 112, WMD -3.15, CI -4.91 to -1.39).</P>
<P>
<B>3.5.5 Aggressive behaviour</B>
</P>
<P>
<LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> showed a statistical trend (P = 0.06) in favour of lithium in mean PANSS aggression scores at endpoint between groups (1 RCT; n = 60, WMD -1.34, CI -2.76 to 0.08).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 Medication use</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.6.1 Mean haloperidol dose</HEADING>
<P>The lithium augmentation group received a significantly lower mean haloperidol dose than the group that received haloperidol alone in the study by <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> (1 RCT; n = 21, WMD -6.90, CI -13.62 to -0.18). The data from other studies were skewed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.2 Number of participants using benzodiazepines</HEADING>
<P>In the study by <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK>, a similar number of participants in both groups received benzodiazepines during the study (1 RCT; n = 22, RR 0.83, CI 0.50 to 1.38).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7 Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.7.1 Central nervous system</HEADING>
<P>Two participants in the lithium augmentation groups of <LINK REF="STD-Biederman-1979" TYPE="STUDY">Biederman 1979</LINK> and <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> developed delirium, but this was not statistically significant (2 RCTs; n = 61, RR 2.56, CI 0.28 to 23.28).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7.2 Movement disorder</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.7.2.1 At least one extrapyramidal adverse event</HEADING>
<P>
<LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> and <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> found no significant difference between groups (2 RCTs; n = 113, RR 1.44, CI 0.22 to 9.40).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.7.2.2 Use of antiparkinson medication</HEADING>
<P>The pooled data of <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK> and <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> showed no significant differences between groups (2 RCTs; n = 49, RR 0.98, CI 0.58 to 1.63).</P>
<P>
<I>3.7.2.3. Atkathisia</I>
</P>
<P>
<LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> found no significant difference between groups (1 RCT; n = 92, RR 0.75, CI 0.28 to 1.99).</P>
<P>
<I>3.7.2.4 Tremor</I>
</P>
<P>
<LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> found no significant difference between groups (1 RCT; n = 92, RR 0.88, CI 0.35 to 2.21).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.7.2.5 Mean Simpson-Angus Scale score at endpoint</HEADING>
<P>The data from <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK> showed no significant differences between groups (1 RCT; n = 21, WMD 2.7, CI -0.53 to 5.93).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.7.2.6 Movement disorder - unable to use</HEADING>
<P>Some studies indicated other scale-derived data about movement disorder, but these were skewed (see <LINK REF="CMP-003.32" TYPE="ANALYSIS">Analysis 3.32</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7.3 Non-specific discomfort</HEADING>
<P>In the study by <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK>, one participant in the lithium group had 'non specific discomfort', but this did not lead to a statistically significant difference between groups (1 RCT; n = 21, RR 2.54, CI 0.11 to 56.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7.4 UKU Side Effect Rating Scale - unable to use</HEADING>
<P>
<LINK REF="STD-Terao-1995" TYPE="STUDY">Terao 1995</LINK> provided data about the UKU global score at endpoint, but these data were skewed (see <LINK REF="CMP-003.34" TYPE="ANALYSIS">Analysis 3.34</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7.5 Specific adverse events</HEADING>
<P>Only two studies reported on specific adverse events. <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> analysed abnormalities in electroencephalogram (EEG), liver functions, and QTC (corrected QT interval)/electrocardiogram (ECG). <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> provided data on constipation, dizziness, dry mouth, insomnia, lactation, nausea, somnolence, tachycardia, and weight gain. For each of these adverse events, no significant difference between groups was found.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.8 Missing outcomes</HEADING>
<P>No data were found for 'service' outcomes, such as 'duration of hospital stay'. Again, there were no data on satisfaction with treatment or costs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.9 Publication bias</HEADING>
<P>Funnel plots revealed no obvious publication bias in the primary outcome, but the small number of trials available for the plot hampered this.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Subgroup analyses</HEADING>
<P>We performed all subgroup analyses only on the primary outcome response to treatment in comparison three (adding lithium to antipsychotics versus monotherapy with antipsychotics). The preplanned subgroup analysis on participants with a first episode of schizophrenia did not apply, because we did not find relevant studies.</P>
<SUBSECTION>
<HEADING LEVEL="4">4.1. Participants with or without schizoaffective or prominent affective symptoms</HEADING>
<P>Lithium augmentation was not associated with statistically significantly more responders, neither when studies with an inclusion criterion of schizoaffective disorder or prominent affective symptoms were analysed separately (4 RCTs, n = 114, RR 1.32, CI 0.64 to 2.74), nor when the studies which did not have such a criterion were analysed separately (7 RCTs, n = 272, RR 1.64, CI 0.95 to 2.81; P = 0.07). The direction of the effect was the same, confidence intervals overlapped broadly, and the test for subgroup differences was not statistically significant (Chi² statistic = 0.22, df = 1 (P = 0.64); I² statistic = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2. Participants with or without treatment-resistant schizophrenia</HEADING>
<P>The effect of lithium augmentation for the primary outcome 'clinically significant response' was not statistically significant in neither studies on treatment-resistant participants (4 RCTs, n = 199, RR 1.90, CI 0.90 to 4.01) nor in studies without such an inclusion criterion (6 RCTs, n = 197, RR 1.36, CI 0.68, 2.71). The test for subgroup differences was not statistically significant (Chi² statistic = 0.40, df = one (P = 0.52); I² statistic = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Sensitivity analyses</HEADING>
<P>We performed all sensitivity analyses only on the primary outcome response to treatment in comparison three (adding lithium to antipsychotics versus monotherapy with antipsychotics). The preplanned sensitivity analyses excluding studies with 'implied randomisation' and excluding 'cluster randomised trials' did not apply.</P>
<SUBSECTION>
<HEADING LEVEL="4">5.1 Exclusion of participants with schizoaffective disorder</HEADING>
<P>We examined whether the exclusion of studies with an inclusion criterion of schizoaffective disorder or prominent affective symptoms led to any important change in terms of the primary outcome 'clinically significant response', and the superiority of lithium augmentation in terms of a clinically significant response no longer met conventional thresholds of statistical significance (7 RCTs, n = 272, RR 1.64, CI 0.95 to 2.81, p = 0.07).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.2 Exclusion of trials with attrition &gt; 50%</HEADING>
<P>In comparison three, only <LINK REF="STD-Schulz-1999" TYPE="STUDY">Schulz 1999</LINK> had an attrition rate of higher than 50%. When we excluded this trial from the analysis of the primary outcome 'clinically significant response', the overall result no longer met conventional thresholds of statistical significance (9 RTCs; n = 355, RR 1.67, CI 0.93 to 3.00; P = 0.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.3 Exclusion of non-double-blind studies</HEADING>
<P>When we excluded three non-double-blind studies from the analysis of the primary outcome 'clinically significant response' (<LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK>; <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK>; <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK>), the effect of lithium augmentation became statistically non-significant (7 RCTs; n = 224, RR 1.82, CI 0.84 to 3.96; P = 0.13).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.4 Fixed-effect model</HEADING>
<P>Where we changed the method of data synthesis from the random-effects model to the fixed-effect model, the results for our primary outcome remained statistically significant (10 RCTs; n = 396, RR 1.77 CI 1.33 to 2.37).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">General</HEADING>
<P>The use of lithium for schizophrenia and schizoaffective disorders has been of interest to researchers for a long period of time. The first randomised controlled trials were published in the early 1970s, with the most recent in 2010. The available studies are well distributed throughout the decades, with seven studies published in the 1970s, six in the 1980s, six in the 1990s, and three in the 21st century. Although we were able to include 22 studies in this review, they had rather small sample sizes, which lacked sufficient power to detect a small to moderate effect, and were incompletely reported in the original publications. However, we are indebted to a number of authors who shared their data with us and made a much better assessment of the available evidence possible (see <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Comparison 1: lithium versus placebo as the sole treatment for schizophrenia</HEADING>
<P>We found no difference between lithium and placebo as the sole treatments for schizophrenia in terms of any outcome parameter analysed. Although it should be noted that only three very small trials were relevant for this comparison, if lithium had a strong effect on the symptoms of schizophrenia, at least some difference compared with placebo might have been found. As lithium has a number of well-known side effects, its use as a treatment for those with schizophrenia is not justified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Comparison 2: lithium versus antipsychotics as the sole treatment for schizophrenia</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Clinically significant response as defined in the studies</HEADING>
<P>Only three trials reported on this simple measure, and no significant differences were found. Little can be concluded from this analysis including 80 participants. It is disappointing that more trials did not report this simple outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Leaving the study early</HEADING>
<P>More participants who received lithium salts than those who were on antipsychotics left the studies early. According to a subset of trials, this might reflect a lower efficacy of lithium when compared with antipsychotic agents.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.3.1 Improved according to the Clinical Global Impression Scale</HEADING>
<P>The data revealed no differences between groups, but again only two very small studies provided usable data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.3.2 Relapse</HEADING>
<P>It is surprising that there was only one long-term study (<LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK>), because the main indication for lithium salts in affective disorders is the prevention of relapse. A statistically borderline superiority of antipsychotics was found (P = 0.06), but given the very small number of participants included (n = 14), this cannot be considered robust.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Mental state - general</HEADING>
<P>Pimozide was superior to lithium salts according to several levels of response derived from the Manchester Scale (MS) global score, but only one study, <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>, provided data. However, the mean MS global score at endpoint in the same study and the mean Brief Psychiatric Rating Scale (BPRS) at endpoint in three other studies also showed a significant superiority of antipsychotic drugs. Thus, there is some evidence that lithium alone is not as effective as antipsychotic drugs alone for the treatment of schizophrenia, as was expected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Mental state - specific</HEADING>
<P>Only one study, <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>, provided data for the analysis of specific aspects of the mental state. No significant differences between groups in terms of depressive or manic symptoms were found, but lithium was less effective than pimozide in improving the negative and positive symptoms of schizophrenia. Thus, lithium does not seem to be a viable alternative to antipsychotic drugs for the treatment of the core symptoms of the disorder.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Adverse events</HEADING>
<P>Again, the fact that only one of two trials reported usable data on adverse events clearly hampered the analysis. There were no significant differences in terms of anticholinergic, dermatologic, gastrointestinal, or extrapyramidal adverse events. Lithium can lead to toxic confusion, especially when its plasma level is outside the therapeutic range, but it is also possible that it is less sedating than antipsychotic drugs. One trial reported a significant difference in terms of an increase of the white blood cell count, but the clinical meaning of this was unclear.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Comparison 3: lithium as an adjunct to antipsychotics for schizophrenia</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Clinically significant response</HEADING>
<P>Overall, more participants who received lithium in addition to antipsychotic drugs were classified as having had a clinically significant response. Thus, it is possible that lithium augmentation moderately improves the outcome compared with treatment with antipsychotic drugs alone. Importantly, however, this finding became non-significant when we excluded those with schizoaffective disorders, non-double-blind studies, and studies with a high attrition rate (see <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>, and <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>). The confidence interval was also quite large, meaning it was possible that the lithium effect was very small. Furthermore, it was not possible to show any effects of specific symptoms of schizophrenia, so lithium may act rather on general symptoms of the disorder. All in all, we do not think that lithium augmentation can be recommended on this basis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Leaving the study early</HEADING>
<P>The difference in the outcome 'leaving the studies early due to any reason' did not reach conventional levels of significance; thus, no difference between groups was identified. The reasons for discontinuing the studies were rarely specified; thus, we judged the vast majority (n = 15) of studies as having a high risk in terms of attrition bias. Based on these low quality results, one should not speculate about the tolerability of lithium augmentation for schizophrenia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Global state</HEADING>
<P>There were no significant differences between groups in terms of improvement of global state measured by Clinical Global Impression (CGI) of relapse rates, so any conclusions about the efficacy of lithium augmentation cannot be drawn based on these parameters.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 Mental state - general</HEADING>
<P>It is possible that augmentation with lithium somewhat improves the general mental state of those with schizophrenia. However, this effect was shown for an at least 50% or 35% improvement of the BPRS, but not for an at least 20% improvement. This effect is thus not consistent. Furthermore, one trial that used the Manchester Scale instead of the BPRS as an outcome measure did not find a superiority of lithium augmentation (<LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK>). The reasons for this difference in effect are unclear. Possible explanations are the fact that <LINK REF="STD-Johnstone-1988" TYPE="STUDY">Johnstone 1988</LINK> used a different scale, that it studied acutely ill participants whereas many of the other studies examined treatment-resistant participants, or that the study used pimozide as an antipsychotic in the study whereas most of the other studies used haloperidol. On the other hand, <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> and <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> found a significant effect of lithium augmentation, measured as at least 50% improvement on the Positive and Negative Syndrome Scale (PANSS) total score. However, it has to be noted that both these studies were not double-blind, which might have biased this result. To conclude, only limited evidence exists that lithium improves general mental state in schizophrenia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5 Mental state - specific</HEADING>
<P>Few studies reported responses to specific symptoms of the mental state (e.g., depressive, manic, negative, or positive symptoms). <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> found a significant difference in favour of lithium in the Excited Component of PANSS. <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> and <LINK REF="STD-Small-2001" TYPE="STUDY">Small 2001</LINK> showed the same effect for the PANSS positive symptoms scale. No other studies found any apparent differences for the remaining outcomes. The fact that the trials used a number of different scales hampered analysis. In addition, it should again be noted that <LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> and <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> were not double-blind studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6 Medication use</HEADING>
<P>Less haloperidol was given in the lithium augmentation group. As only one study provided usable data (<LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK>), the meaning of this result is unclear. In the same study, a similar number of participants in both groups used benzodiazepines at least once. Again, due to the small sample size, we cannot draw conclusions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7 Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.7.1 Delirium</HEADING>
<P>Based on data from two studies (<LINK REF="STD-Biederman-1979" TYPE="STUDY">Biederman 1979</LINK> and <LINK REF="STD-Wilson-1993" TYPE="STUDY">Wilson 1993</LINK>), two participants in the lithium augmentation group developed delirium, but this was not statistically significant (2 RCTs; n = 61, RR 2.56, CI 0.28 to 23.28).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.7.2 Movement disorder</HEADING>
<P>No significant differences between groups were found. This is not surprising, because lithium is not known to be frequently associated with movement disorders.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.7.3 Specific adverse events</HEADING>
<P>Only two studies reported on specific adverse events and found no differences between groups in terms of constipation, dizziness, dry mouth, electroencephalogram (EEG) abnormalities, insomnia, lactation, liver function abnormalities, nausea, QTC (corrected QT interval)/ECG (electrocardiogram) abnormalities, somnolence, tachycardia, and weight gain. Based on this scarce information, we cannot draw firm conclusions about the adverse events. The studies did not record thyroid dysfunction and kidney problems - two major side effects of lithium.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Missing outcomes</HEADING>
<P>It is surprising that although the main indication of lithium for affective disorders is relapse prevention, only one small study provided relevant data (<LINK REF="STD-Mattes-1984" TYPE="STUDY">Mattes 1984</LINK>). It is hoped that more data on long-term effects and on important 'service' outcomes, such as duration of hospital stay, satisfaction with treatment, or costs, will be available for future updates of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Subgroup analysis</HEADING>
<P>We performed all subgroup analyses for the primary outcome (clinically significant response) of lithium augmentation. We did not perform any separate subgroup analysis for people with a first episode of schizophrenia, because there were no studies on this subgroup.</P>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Studies on participants with versus without schizoaffective disorder or prominent affective symptoms</HEADING>
<P>When we analysed separately the studies with an inclusion criterion of prominent affective symptoms/schizoaffective disorder and the studies without such inclusion criteria, there was no significant effect in either subgroup. The direction of effect was the same in both subgroups. Although the subgroup test was far from ideal to address this question, there is no evidence that lithium works better for patients with affective symptoms based on this analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.2 Participants with treatment-resistant schizophrenia</HEADING>
<P>We found a statistically significant effect of lithium augmentation for participants with treatment-resistant schizophrenia. This effect was not significant for non-treatment-resistant participants. However, as we identified no significant difference between subgroups, one should not assume that lithium might be more helpful for patients that did not respond to previous antipsychotic treatment. It could be a spurious finding.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Sensitivity analysis</HEADING>
<P>We performed all sensitivity analyses for the primary outcome (clinically significant response) of lithium augmentation (comparison three).</P>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Exclusion of participants with schizoaffective disorder</HEADING>
<P>Excluding people with schizoaffective disorder from the overall analysis resulted in loss of statistical superiority of lithium augmentation over placebo or usual treatment. Therefore, the overall effect might have been in part driven by these participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Exclusion of trials with attrition higher than 50%</HEADING>
<P>Only two studies had an attrition rate that was higher than 50%. Nevertheless, exclusion of these two studies led to a reduction in statistical significance of the primary outcome, meaning it then did not meet conventional criteria of statistical significance anymore (P = 0.08). This finding shows that the superiority of lithium augmentation is not robust and may have been in part based on studies that are more prone to bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Exclusion of non-double-blind trials</HEADING>
<P>Excluding non-double-blind trials from the overall analysis resulted in a loss of statistical superiority of lithium augmentation over placebo. This result indicates that the lower quality non-double-blind studies in part drove the effect. The more carefully controlled double-blind studies did not show statistically significant effects, which needs to be interpreted as lithium augmentation is not proven as an efficacious treatment for schizophrenia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4 Application of random-effects model</HEADING>
<P>Application of the fixed-effect model instead of the random-effects model did not result in a loss of statistical superiority of lithium augmentation over placebo or usual treatment. As expected, the confidence interval got smaller, but the point estimate remained similar.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>Strengths in terms of completeness are that several studies were conducted in participants with treatment-resistant schizophrenia for which effective adjuncts are most needed. On the other hand, there are open questions. For example, as lithium is effective for bipolar disorder, more studies on participants with schizoaffective disorder or prominent affective symptoms would be useful. The data are also clearly not complete in terms of side effects and long-term effects. Moreover, the small number of included studies, together with a poor quality of all available data, makes any conclusive judgement about the potential applicability of the obtained results doubtful. Trials with small sample sizes lack sufficient power to detect a small to moderate effect; thus, results from such trials are often inconclusive, even when a real effect does exist. Moreover, it has been suggested that meta-analyses based on summation of small trials should be interpreted as inconclusive regardless of whether the combined estimate was significant (<LINK REF="REF-Davey-Smith-1998" TYPE="REFERENCE">Davey Smith 1998</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>First, as many as 31 out of 50 studies that we eventually excluded form the final analysis failed to randomise the trial sequence. Due to this low quality, we included only 22 studies in the meta-analysis.</P>
<P>Almost all studies were randomised and double-blind, but many of them did not present detailed descriptions. Therefore, it is unclear whether some these studies were really adequately randomised and whether treatment allocation was concealed and blinding assured throughout the whole procedure (<LINK REF="STD-Feng-2006" TYPE="STUDY">Feng 2006</LINK> and <LINK REF="STD-He-2010" TYPE="STUDY">He 2010</LINK> were especially problematic in that respect, as they did not provide any information about blinding).</P>
<P>Reporting bias is especially prevalent in this study pool, with high risk being a problem in a majority of reports often but not restricted to missing standard deviations. Without original study protocols and raw data sets, one cannot really use those trials to the full extent.</P>
<P>The threat of other biases was typically absent, although we emphasise that we focused on clear 'other biases' in this regard, because any study can be criticised for one aspect or another.</P>
<P>Overall, using the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and GRADE profiler to analyse the data (<LINK REF="REF-GRADE-Profiler" TYPE="REFERENCE">GRADE Profiler</LINK>), we found that the overall quality of the recommendations that we could derive from the preselected outcomes was low.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>We went to considerable lengths to obtain as many relevant studies as possible. However, one can never be certain whether some additional (unpublished) material exist that was not available for the analysis. Moreover, the change from RevMan 4 to the new requirements of RevMan 5 (<LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK>) was not without problems, because we had to re-examine the old studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>Some previous unsystematic reviews yielded conflicting results about the applicability and effectiveness of lithium for schizophrenia. One early review stated that there was a beneficial effect of lithium in schizophrenia (<LINK REF="REF-Delva-1982" TYPE="REFERENCE">Delva 1982</LINK>), whereas another from approximately the same period of time did not find any evidence to support such a claim (<LINK REF="REF-Atre_x002d_Vaidya-1989" TYPE="REFERENCE">Atre-Vaidya 1989</LINK>). A recent review of adjunctive lithium also emphasised this confusion by stressing that many positive early findings are denied by newer contradictory evidence and concluded that any firm conclusion could not be reached (<LINK REF="REF-Citrome--2009" TYPE="REFERENCE">Citrome 2009</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">For clinicians</HEADING>
<P>There is currently no evidence from randomised controlled trials to support the use of lithium alone as treatment for people with schizophrenia. Lithium is also associated with a wide range of side effects. Although there is some limited evidence to support the use of lithium as an augmentation of antipsychotics for people with schizophrenia, the data is of low quality and cannot be considered conclusive. While we lack evidence to predict which people with schizophrenia (if any) might most benefit from lithium augmentation, issues such as past response to lithium or prominent affective symptoms may warrant consideration by clinicians. For those currently caring for patients who have been receiving lithium as a treatment for schizophrenia, clinicians need to consider whether this treatment should continue to be used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Those with schizophrenia and schizoaffective disorder</HEADING>
<P>People with schizophrenia should be made aware of the lack of any empirical basis for the use of lithium as a sole agent for their illness. They should know that there is only very limited evidence that lithium is effective as an adjunct to antipsychotics. It should be kept in mind that the underlying evidence base was small and of low quality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">For managers and policymakers</HEADING>
<P>The data cannot support the use of lithium augmentation as a routine measure. Nevertheless, since some superiority was shown in certain efficacy outcomes, managers and policymakers should support further trials on the question.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<U>
<B>General (see </B>
</U>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>
<U>
<B>)</B>
</U>
</P>
<P>Any future studies should respect standards of measuring outcomes and of reporting data in order to enhance the comparability of study results (<LINK REF="REF-Schulz-2010" TYPE="REFERENCE">Schulz 2010</LINK>).</P>
<P>
<U>
<B>Specific</B>
</U>
</P>
<P>This review revealed some evidence that lithium augmentation for people with schizophrenia may be effective, but the results were not conclusive. Therefore, further studies are warranted. The following populations are of special research interest:</P>
<OL>
<LI>People with schizoaffective disorders, because lithium is frequently used in addition to antipsychotic drugs for this disorder in the clinical routine.</LI>
<LI>People with treatment-resistant schizophrenia. Here, drugs with additional effects on schizophrenic symptoms are most needed. Even small differences in outcome may be of great importance in this subgroup, and therefore, a large simple trial is justified.</LI>
<LI>People with aggressive behaviour. Lithium is used for those with aggressive or violent episodes, and its evaluation within trials in this subgroup of people with schizophrenia would be valuable.</LI>
<LI>Relapse prevention. Lithium is frequently used as a 'mood stabiliser' in bipolar disorder. It would be useful to assess its efficacy in relapse prevention for schizophrenia.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Schizophrenia Group (CSG) maintain a template for the methods section of their reviews; we have used and adapted this.</P>
<P>We would like to thank Profs. and Drs. Braden, Carman, Dube, Gershon, Hogarty, Johnstone, Kendell, Larkins, Lerner, Mattes, Prien, Schulz, Simhandl, Small, Wilson, and Terao for their replies to our letters or for sending us their original participant data. Without the contributions of these colleagues, this review would not have been possible. We thank Chunbo Li for contacting Chinese authors and Yijun Wang for translating Chinese studies. We also wish to thank Mark Fenton, Judy Wright, Samantha Roberts, and Farhad Shokraneh for the trial searches and the editorial base of the CSG for their continuous help.</P>
<P>Hong-ling Yang kindly peer-reviewed this version of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-10-13 14:17:41 +0100" MODIFIED_BY="[Empty name]">
<P>Stefan Leucht: in the last three years Stefan Leucht has received honoraria for lectures from EliLilly, Lundbeck (Institute), Pfizer, Janssen, BMS, Johnson and Johnson, Otsuka, Roche, SanofiAventis, ICON, Abbvie, AOP Orphan, Servier; for consulting/advisory boards from Roche, Janssen, Lundbeck, EliLilly, Otsuka, TEVA; for the preparation of educational material and publications from Lundbeck Institute and Roche. EliLilly has provided medication for a clinical trial led by SL as principal investigator.<BR/>John McGrath: John McGrath is a member of the following advisory boards: Eli Lilly Australia, Lundbeck Australia, and Pfizer Australia. In addition, JM has been a co-investigator on studies of neuroleptic medications produced by the following companies: Astra, Janssen-Cilag, Eli Lilly, Zeneca (ICI), Sandoz, and Pfizer. The same companies have provided travel and accommodation expenses for John McGrath to attend relevant investigator meetings and scientific symposia. No funds have been paid directly to Dr McGrath. Payments related to participation in drug trials and board attendances have been paid to a government-audited trust account to support schizophrenia research.<BR/>Werner Kissling: Werner Kissling has received honoraria or research support or both from Janssen-Cilag, Sanofi-Aventis, Johnson &amp; Johnson, Pfizer, Bristol-Myers Squibb, AstraZeneca, Lundbeck, Novartis, and Eli Lilly.<BR/>Markus Dold: nothing to declare.<BR/>Bartosz Helfer: nothing to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-10-14 11:24:47 +0100" MODIFIED_BY="[Empty name]">
<P>Stefan Leucht: protocol development, searching, data extraction, analysis, data interpretation, and writing the final report (all versions)<BR/>John McGrath: protocol development, data checking, and data interpretation (2008).<BR/>Werner Kissling: protocol development and data interpretation (2008).<BR/>Markus Dold: update searches (2012, 2015) data extraction, analysis, and data interpretation.<BR/>Bartosz Helfer: update of the review (2012, 2015), data extraction, analysis, data interpretation, and writing the final report.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-09-29 14:06:04 +0100" MODIFIED_BY="[Empty name]">
<P>We have updated the methods section to reflect changes in Cochrane methodology since publication of the original version of this review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-14 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-09-07 16:01:41 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-09-07 16:01:16 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Biederman-1979" NAME="Biederman 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective. Archives of General Psychiatry 1979 Mar;36:327-33.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biederman J, Lerner Y, Belmaker RH</AU>
<TI>Combination of lithium carbonate and haloperidol in schizo-affective patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1979 Mar</YR>
<VL>36</VL>
<PG>327-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braden-1982" NAME="Braden 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braden W, Fink EB, Qualls CB, Ho CK, Samuels WO</AU>
<TI>Lithium and chlorpromazine in psychotic inpatients</TI>
<SO>Psychiatry Research</SO>
<YR>1982</YR>
<VL>7</VL>
<PG>69-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brockington-1978" NAME="Brockington 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brockington I, Kendell R, Kellett J, Curry S, Wainwright S</AU>
<TI>Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1978 Aug</YR>
<VL>133</VL>
<PG>162-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-1991" NAME="Collins 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collins EJ, Larkins EP, Shubsacs AP</AU>
<TI>Lithium carbonate in chronic schizophrenia - a brief trial of lithium carbonated added to neuroleptics for treatment resistant schizophrenic patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1991</YR>
<VL>84</VL>
<PG>150-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dube-1981" NAME="Dube 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Dube S, Sethi BB. Efficacy of lithium in schizophrenia. Indian Journal of Psychiatry 1981 Jul;23:193-199.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dube S, Sethi BB</AU>
<TI>Efficacy of lithium in schizophrenia</TI>
<SO>Indian Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>23</VL>
<PG>193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feng-2006" MODIFIED="2013-04-16 09:50:59 +0100" MODIFIED_BY="[Empty name]" NAME="Feng 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-04-16 09:50:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng Z, Yang K-J ,Gao H, Wu D-H, Wu H-A</AU>
<TI>The effect of lithium carbonate combining clozapine for the resistant schizophrenics with agitation and aggressive behaviour</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>6</NO>
<PG>427-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garver-1983" NAME="Garver 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garver DL, Hirschowitz J, Fleishmann R, Djuric P</AU>
<TI>Lithium response and psychoses: a double-blind, placebo-controlled study</TI>
<SO>Psychiatry Research</SO>
<YR>1984 May</YR>
<VL>12</VL>
<PG>57-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2010" MODIFIED="2013-10-28 11:26:02 +0000" MODIFIED_BY="[Empty name]" NAME="He 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-10-28 11:26:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He Y-F, Xie W-C, Li X-Y</AU>
<TI>Risperidone combined with lithium in treatment of refractory schizophrenia</TI>
<SO>Guangzhou Medical Journal</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>6-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogarty-1995" NAME="Hogarty 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Archives of General Psychiatry 1995 Jan;52:29-41.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J</AU>
<TI>Pharmacotherapy of impaired affect in recovering schizophrenic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<PG>29-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-1984" NAME="Huang 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang LG BC</AU>
<TI>Platelet monoamine oxidase response to lithium treatment in psychiatric patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>326-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1971" NAME="Johnson 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Johnson G, Gershon S, Burdock EI, Floyd A, Hekimian L. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. British Journal of Psychiatry 1971 Sep;119:267-76.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson G, Gershon S, Burdock EI, Floyd A, Hekimian L</AU>
<TI>Comparative effects of lithium and chlorpromazine in the treatment of acute manic states</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1971</YR>
<VL>119</VL>
<PG>267-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Johnson G, Gershon S, Hekimian L. Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: an interim report. Comprehensive Psychiatry 1968;9:563-573.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson G, Gershon S, Hekimian L</AU>
<TI>Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: an interim report</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1968</YR>
<VL>9</VL>
<PG>563-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Johnson G. Differential response to lithium carbonate in manic depressive and schizo-affective disorders. Dis-Nerv-Syst 1970 Sep;31:613-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson G</AU>
<TI>Differential response to lithium carbonate in manic depressive and schizo-affective disorders</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1970</YR>
<VL>31</VL>
<PG>613-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnstone-1988" MODIFIED="2015-08-25 15:30:21 +0100" MODIFIED_BY="[Empty name]" NAME="Johnstone 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Johnstone EC, Crow TJ, Frith CD, Owens D. The Northwick Park &amp;quot;functional&amp;quot; psychosis study: diagnosis and treatment response. Lancet 1988 Jul 16;2:119-25.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnstone EC, Crow TJ, Frith CD, Owens D</AU>
<TI>The Northwick Park "functional" psychosis study: diagnosis and treatment response</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>2</VL>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Johnstone EC, Crow TJ, Owens D, Frith C. The Northwick Park 'Functional' Psychosis Study. Phase 2 - Maintenance treatment. Journal of Psychopharmacology 1991;5:388-395.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnstone EC, Crow TJ, Owens D, Frith C</AU>
<TI>The Northwick Park 'Functional' Psychosis Study. Phase 2 - Maintenance treatment</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>1991</YR>
<VL>5</VL>
<PG>388-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-25 15:30:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;04381&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 15:30:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Johnstone EC, Owens DGC, Crow TJ, Davis JM</AU>
<TI>Does a four week delay in the introduction of medication alter the course of functional psychosis?</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>3</NO>
<PG>238-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10512078"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Johnstone EC, Owens DGC. Does early treatment have an effect on outcome? 10th ECNP (European College of Neuropsychopharmacology) Congress, Vienna, Austria Sep 13 - 17, 1997;-:-.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Johnstone EC, Owens DGC</AU>
<TI>Does early treatment have an effect on outcome?</TI>
<SO>10th ECNP (European College of Neuropsychopharmacology) Congress, Vienna, Austria</SO>
<YR>Sep 13 - 17, 1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattes-1984" NAME="Mattes 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Mattes JA, Nayak D. Lithium   versus   fluphenazine for prophylaxis in mainly schizophrenic schizo affectives. Biological Psychiatry 1984 Mar;19:445-449.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattes JA, Nayak D</AU>
<TI>Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizoaffectives</TI>
<SO>Biological Psychiatry</SO>
<YR>1984</YR>
<VL>19</VL>
<PG>445-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prien-1972" NAME="Prien 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Pokorny AD, Prien RF. Lithium in treatment and prevention of effective disorder: A VA NIMH collaborative study. Diseases of the Nervous System 1974 Jul;35:327-333.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pokorny AD, Prien RF</AU>
<TI>Lithium in treatment and prevention of affective disorder: A VA NIMH collaborative study</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1974</YR>
<VL>35</VL>
<PG>327-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Prien R, Caffey EJ, Klett C. A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizo-affectives. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Archives of General Psychiatry 1972 Aug;27:182-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prien R, Caffey EJ, Klett C</AU>
<TI>A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizo-affectives. Report of the Veterans Administration and National Institute of Mental Health collaborative study group</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>27</VL>
<PG>182-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulz-1999" MODIFIED="2015-08-25 15:56:57 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-08-25 15:21:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;04016&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 15:21:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Schultz SC, Glick D, Group TSSCS</AU>
<TI>Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients</TI>
<SO>Schizophrenia Research</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1-2</NO>
<PG>151</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7841567"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schulz SC, Thompson PA, Jacobs M, Ninan PT, Robinson D, Weiden PJ, Yadalam K, Glick ID, Odbert CL</AU>
<TI>Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<PG>366-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shopsin-1971" NAME="Shopsin 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Shopsin B, Kim S, Gershon S. A controlled study of lithium vs. chlorpromazine in acute schizophrenics. British Journal of Psychiatry 1971 Oct;119:435-40.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shopsin B, Kim S, Gershon S</AU>
<TI>A controlled study of lithium vs. chlorpromazine in acute schizophrenics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1971</YR>
<VL>119</VL>
<PG>435-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simhandl-1996" NAME="Simhandl 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simhandl C, Meszaros K, Denk E, Thau K, Topitz A</AU>
<TI>Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia [2]</TI>
<SO>Canadian Journal of Psychiatry/ Revue Canadienne de Psychiatrie</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>5</NO>
<PG>317</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1976" NAME="Simpson 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Simpson-GM, Branchey-MH, Lee-JH, Voitashevsky-A, Zoubok-B. Lithium in tardive dyskinesia. Pharmakopsychiatr-Neuropsychopharmakol 1976;9:76-80.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Branchey MH, Lee JH, Voitashevsky A, Zoubok B</AU>
<TI>Lithium in tardive dyskinesia</TI>
<SO>Pharmakopsychiatrie-Neuropsychopharmakologie</SO>
<YR>1976</YR>
<VL>9</VL>
<PG>76-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Small-1975" MODIFIED="2015-08-25 15:56:57 +0100" MODIFIED_BY="[Empty name]" NAME="Small 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Kellams J, Small J, Milstein V, Perex H. Lithium combined with neuroleptics in the treatment of chronic schizophrenia. Psychopharmacol-Bull 1976 Apr;12:27-30.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kellams J, Small J, Milstein V, Perex H</AU>
<TI>Lithium combined with neuroleptics in the treatment of chronic schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1976</YR>
<VL>12</VL>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-25 15:56:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;08742&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 15:56:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Schulz SC, Kahn EM, Baker RW, Conley RR</AU>
<TI>Lithium and carbamazepine augmentation in treatment-refractory schizophrenia</TI>
<SO>The Neuroleptic-Nonresponsive Patient: Characterization and Treatment</SO>
<YR>1990</YR>
<PG>111-36</PG>
<ED>Angrist BSSC</ED>
<PB>American Psychiatric Press Inc</PB>
<CY>Washington, DC, USA</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7040529"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Small JG, Kellams JJ, Milstein V, Moore J. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. American Journal of Psychiatry 1975 Dec;132:1315-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Small JG, Kellams JJ, Milstein V, Moore J</AU>
<TI>A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1975</YR>
<VL>132</VL>
<PG>1315-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Small-2001" MODIFIED="2015-08-25 15:54:29 +0100" MODIFIED_BY="[Empty name]" NAME="Small 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Small JG, Klapper MH, Malloy FW, Steadman TM</AU>
<TI>Clozapine combined with lithium in schizophrenia and schizoaffective disorder</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49 (suppl)</VL>
<PG>246</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-25 15:54:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;07830&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 15:54:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Small JG, Klapper MH, Malloy FW, Steadman TM</AU>
<TI>Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder</TI>
<SO>Journal of clinical psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>223-8</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12826983"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terao-1995" MODIFIED="2015-08-25 16:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Terao 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Terao T, Oga T, Nozaki S, Ohta A, Ohtsubo Y, Yamamoto S, Zamami M, Okada M. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study. Acta-Psychiatr-Scand 1995 Sep;92:220-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terao T, Oga T, Nozaki S, Ohta A, Ohtsubo Y, Yamamoto S, Zamami M, Okada M</AU>
<TI>Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1995</YR>
<VL>92</VL>
<PG>220-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-25 16:54:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;06169&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:54:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Terao T, Oga T, Nozaki S, Ohta A, Ohtsubo Y, Yamoto S, et al</AU>
<TI>L'associazione di Litio alla terapia neurolettica nel trattamento della schizofrenia cronica: uno studio in doppio cieco crociato randomizzato, controllato con placebo</TI>
<SO>Rivista di Psichiatria</SO>
<YR>1995</YR>
<VL>30</VL>
<NO>6</NO>
<PG>42</PG>
<PB>Il Pensiero Scientifico Editore</PB>
<CY>Italy</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7040529"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1993" MODIFIED="2015-09-07 16:01:16 +0100" MODIFIED_BY="[Empty name]" NAME="Wilson 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-09-07 16:01:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wilson WH</AU>
<TI>Addition of lithium to haloperidol in non - affective, antipsychotic non - responsive schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1993</YR>
<VL>9</VL>
<PG>256</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7040529"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Wilson WH. Addition of lithium to haloperidol in non-affective, antipsychotic  non-responsive schizophrenia - A double blind, placebo controlled,   parallel design clinical trial. Psychopharmacology 1993;111:359-366.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson WH</AU>
<TI>Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia - A double blind, placebo controlled, parallel design clinical trial</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>111</VL>
<PG>359-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-09-07 16:01:41 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alexander-1979" NAME="Alexander 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Alexander PE, Van Kammen DP, Bunney WE Antipsychotic effects of lithium in schizophrenia. Am J Psychiatry 1979;136:283-287.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexander PE, Van Kammen DP, Bunney WE</AU>
<TI>Antipsychotic effects of lithium in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>136</VL>
<PG>283-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aronoff-1970" MODIFIED="2015-08-25 14:42:28 +0100" MODIFIED_BY="[Empty name]" NAME="Aronoff 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-08-25 14:42:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;02627&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 14:42:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Aronoff MS, Epstein RS</AU>
<TI>Factors associated with poor response to lithium carbonate: a clinical study</TI>
<SO>American journal of psychiatry</SO>
<YR>1970</YR>
<VL>127</VL>
<PG>472-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4918114"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baastrup-1967" NAME="Baastrup 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Baastrup PC, Schou G, Schou M. LIthium as a prophylactic agent. Arch Gen Psychiat 1967;16:162-172.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baastrup PC, Schou G, Schou M</AU>
<TI>Lithium as a prophylactic agent</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1967</YR>
<VL>16</VL>
<PG>162-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellaire-1990" MODIFIED="2015-08-25 16:32:50 +0100" MODIFIED_BY="[Empty name]" NAME="Bellaire 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-08-25 16:32:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;04145&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:32:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bellaire W, Demisch K, Stoll KD</AU>
<TI>Carbamazepine versus lithium. Application in the prophylaxis of recidivating affective and schizoaffective psychoses</TI>
<TO>Carbamazepin Vs. Lithium. Einsatz in der Prophylaxe Rezidivierender Affektiver und Schizoaffektiver Psychosen</TO>
<SO>Munchener Medizinische Wochenschriftenschrift</SO>
<YR>1990</YR>
<VL>132</VL>
<PG>82-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6938996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berger-2006" MODIFIED="2015-08-25 16:33:26 +0100" MODIFIED_BY="[Empty name]" NAME="Berger 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-08-25 16:33:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;09644&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:33:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Berger G</AU>
<TI>Lithium in patients at ultra high risk of developing a first psychotic episode</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bigelow-1981" NAME="Bigelow 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Bigelow LB, Weinberger DR, Wyatt R. Synergism of combined lithium-neuroleptic therapy - A double-blind,  placebo-controlled case study. American Journal of Psychiatry 1981;138:81-83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bigelow LB, Weinberger DR, Wyatt R</AU>
<TI>Synergism of combined lithium-neuroleptic therapy - A double-blind, placebo-controlled case study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>81-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowers-1983" NAME="Bowers 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Bowers MB, Heninger GR, Sternberg DE. Correlates of lithium response in psychotic-affective syndromes. Comprehensive psychiatry 1983;24:469-475.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowers MB, Heninger GR, Sternberg DE</AU>
<TI>Correlates of lithium response in psychotic-affective syndromes</TI>
<SO>Comprehensive psychiatry</SO>
<YR>1983</YR>
<VL>24</VL>
<PG>469-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braden-1980" MODIFIED="2015-08-25 16:34:17 +0100" MODIFIED_BY="[Empty name]" NAME="Braden 1980" YEAR="1980">
<REFERENCE MODIFIED="2015-08-25 16:34:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;03930&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:34:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Braden W</AU>
<TI>Lithium versus chlorpromazine in acute psychosis</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1980</YR>
<VL>16</VL>
<PG>70-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6938996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brewerton-1983" MODIFIED="2015-08-25 16:35:11 +0100" MODIFIED_BY="[Empty name]" NAME="Brewerton 1983" YEAR="1983">
<REFERENCE MODIFIED="2015-08-25 16:35:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;00834&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:35:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brewerton TD, Reus VI</AU>
<TI>Lithium carbonate and l-tryptophan in the treatment of bipolar and schizoaffective disorders</TI>
<SO>American journal of psychiatry</SO>
<YR>1983</YR>
<VL>140</VL>
<PG>757-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6405638"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabrera-1986" MODIFIED="2015-08-25 16:35:53 +0100" MODIFIED_BY="[Empty name]" NAME="Cabrera 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-08-25 16:35:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;03410&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:35:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cabrera JF, Muhlbauer HD, Schley J, Stoll KD, Muller-Oerlinghausen B</AU>
<TI>Long-term randomized clinical trial on oxcarbazepine vs lithium in bipolar and schizoaffective disorders - Preliminary results</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1986</YR>
<VL>19</VL>
<NO>4</NO>
<PG>282-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6938996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-1972" NAME="Campbell 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Campbell M, Fish B, Korein J, Shapiro T, Collins P, Koh C. Lithium and chlorpromazine: a controlled cross-over study of hyperactive severely disturbed young children. Journal of autism and childhood schizophrenia 1972;2:234-263.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell M, Fish B, Korein J, Shapiro T, Collins P, Koh C</AU>
<TI>Lithium and chlorpromazine: a controlled cross-over study of hyperactive severely disturbed young children</TI>
<SO>Journal of Autism and Childhood Schizophrenia</SO>
<YR>1972</YR>
<VL>2</VL>
<PG>234-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-1982" MODIFIED="2015-08-25 16:36:29 +0100" MODIFIED_BY="[Empty name]" NAME="Campbell 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-08-25 16:36:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;04871&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:36:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Campbell M, Cohen IL, Small AM</AU>
<TI>Drugs in aggressive behavior</TI>
<SO>Journal of the American Academy of Child Psychiatry</SO>
<YR>1982</YR>
<VL>21</VL>
<NO>2</NO>
<PG>107-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7040529"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carman-1981" NAME="Carman 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carman J, Bigelow LB, Wyatt RJ</AU>
<TI>Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1981</YR>
<VL>42</VL>
<PG>124-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2001" NAME="Chen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen L, Zhang X, Li J</AU>
<TI>A controlled study between clozapine and lithium carbonate in treatment-refractory schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2001</YR>
<VL>14</VL>
<PG>213-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dinsmore-1972" NAME="Dinsmore 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Dinsmore PR, Ryback R. Lithium in schizo-affective disorders. Diseases of the nervous system 1972; :771-776.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dinsmore PR, Ryback R</AU>
<TI>Lithium in schizo-affective disorders</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1972</YR>
<VL>33</VL>
<PG>771-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edelstein-1981" NAME="Edelstein 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Edelstein P, Schultz JR, Hirschowitz J, Kanter DR, Garver D. Physostigmine and lithium response in the schizophrenias. American Journal of Psychiatry 1981 Aug;138:1078-81.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edelstein P, Schultz JR, Hirschowitz J, Kanter DR, Garver D</AU>
<TI>Physostigmine and lithium response in the schizophrenias</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>1078-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-2002" NAME="Gao 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao S, Ma J, Xu F, Yang S</AU>
<TI>Clozapine combined with lithium carbonate treatment for patients with chronic schizophrenia: controlled clinical trial</TI>
<SO>Nervous Diseases and Mental Hygiene</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>338-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garver-1988" NAME="Garver 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychological Medicine 1988 Nov;18:873-85.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J</AU>
<TI>Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)</TI>
<SO>Psychological Medicine</SO>
<YR>1988</YR>
<VL>18</VL>
<PG>873-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1975" NAME="Gerlach 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Gerlach-J, Thorsen-K, Munkvad-I. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over  trial. Pharmakopsychiatr-Neuropsychopharmakol 1975;8:51-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Thorsen K, Munkvad I</AU>
<TI>Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial</TI>
<SO>Pharmakopsychiatrie Neuropsychopharmakologie</SO>
<YR>1975</YR>
<VL>8</VL>
<PG>51-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gram-1971" NAME="Gram 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gram LF, Rafaelsen OJ</AU>
<TI>Lithium treatment of psychotic children and adolescents. A controlled clinical trial</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1972</YR>
<VL>48</VL>
<PG>253-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greil-1997" NAME="Greil 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Greil W, Ludwig Mayerhofer W, Erazo N, Engel RR. Lithium vs cambamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. European-Archives-of-Psychiatry-and-Clinical-Neuroscience 1997;Vol 247:42-50.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greil W, Ludwig Mayerhofer W, Erazo N, Engel RR</AU>
<TI>Lithium vs cambamazepine in the maintenance treatment of schizoaffective disorder: A randomised study</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>1997</YR>
<VL>247</VL>
<PG>42-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Growe-1979" NAME="Growe 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Growe GA, Crayton JW, Klass DB, Evans H, Strizich M. Lithium in chronic schizophrenia. American Journal of Psychiatry 1979 Apr;136:454-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Growe GA, Crayton JW, Klass DB, Evans H, Strizich M</AU>
<TI>Lithium in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>136</VL>
<PG>454-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haastrup-1973" NAME="Haastrup 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Haastrup S, Rasmussen S, Kirk L. Lithium therapy of schizophrenics.  A controlled study. Acta. Psych. Scand. Suppl. 1973;243:68.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haastrup S, Rasmussen S, Kirk L</AU>
<TI>Lithium therapy of schizophrenics. A controlled study</TI>
<SO>Acta Psychiatrica Scandinavica Supplement</SO>
<YR>1973</YR>
<VL>243</VL>
<PG>68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-1980" NAME="Harrison 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Harrison GP, Lipinski JF, Cohen BM, Aselrod DT. &amp;quot;Schizoaffective disorder&amp;quot;: an invalid diagnosis? A comparison of schizoaffective disorder, schizophrenia, and affective disorder. Am J Psychiatry 1980;137:921-927&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrison GP, Lipinski JF, Cohen BM, Aselrod DT</AU>
<TI>"Schizoaffective disorder": an invalid diagnosis? A comparison of schizoaffective disorder, schizophrenia, and affective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>921-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofmann-1970" NAME="Hofmann 1970" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;Hofmann G, Kremser M, Katschnig H, Scheiber V. Prophylaktische Lithiumtherapie bei manisch-depressivem Krankheitsgeschehen und bei Legierungspsychosen. Int Pharmacopsychiat 1970;4:187-193.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofmann G, Kremser M, Katschnig H, Scheiber V</AU>
<TI>Prophylaktische Lithiumtherapie bei manisch-depressivem Krankheitsgeschehen und bei Legierungspsychosen</TI>
<SO>Internationale Pharmacopsychiatrie</SO>
<YR>1970</YR>
<VL>4</VL>
<PG>187-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hullin-1975" NAME="Hullin 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Hullin RP, McDonald R, Allsopp MNE. Further report on prophylactic lithium in recurrent affective disorders. Brit J Psychiat 1975;126:281-284.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hullin RP, McDonald R, Allsopp MNE</AU>
<TI>Further report on prophylactic lithium in recurrent affective disorders</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1975</YR>
<VL>126</VL>
<PG>281-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jus-1978" NAME="Jus 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Jus-A, Villeneuve-A, Gautier-J, Jus-K, Villeneuve-C, Pires-P, Villeneuve-R. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. Neuropsychobiology 1978;4:140-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jus A, Villeneuve A, Gautier J, Jus K, Villeneuve C, Pires P, Villeneuve R</AU>
<TI>Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study</TI>
<SO>Neuropsychobiology</SO>
<YR>1978</YR>
<VL>4</VL>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahn-1990" MODIFIED="2015-08-25 16:36:54 +0100" MODIFIED_BY="[Empty name]" NAME="Kahn 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-08-25 16:36:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;01856&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:36:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kahn EM, Schulz SC, Perel JM, Alexander JE</AU>
<TI>Change in haloperidol level due to carbamazepine - a complicating factor in combined medication for schizophrenia</TI>
<SO>Journal of clinical psychopharmacology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>54-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2106534"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenzi-1985" NAME="Lenzi 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Lenzi A, Lazzerini F, Grossi E, et a. Use of carbamazepine in acute psychosis - A controlled study. Journal of International Medical Research 1986;14:78-84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lenzi A, Lazzerini F, Grossi E</AU>
<TI>Use of carbamazepine in acute psychosis - A controlled study</TI>
<SO>Journal of International Medical Research</SO>
<YR>1986</YR>
<VL>14</VL>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lerner-1988" NAME="Lerner 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerner Y, Mintzer Y, Schestatzky M</AU>
<TI>Lithium combined with haloperidol in schizophrenic patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>153</VL>
<PG>359-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liebowitz-1976" NAME="Liebowitz 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Liebowitz JH, Rudy V, Gershon ES, Gillis A. A pharmacogenetic case report: Lithium-responsive postpsychotic antisocial behavior. Comprehensive-Psychiatry 1976 Sep-Oct;17:655-660.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liebowitz JH, Rudy V, Gershon ES, Gillis A</AU>
<TI>A pharmacogenetic case report: Lithium-responsive postpsychotic antisocial behavior</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1976</YR>
<VL>17</VL>
<PG>655-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2015-09-07 15:47:40 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-07 15:47:40 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11527&lt;/p&gt;" NOTES_MODIFIED="2015-09-07 15:47:40 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Liu N</AU>
<TI>The lithium compound norethisterone periodic relapse prevention control study</TI>
<TO>&#30899;&#37240;&#38146;&#19982;&#22797;&#26041;&#28820;&#35834;&#37230;&#39044;&#38450;&#21608;&#26399;&#24615;&#31934;&#31070;&#30149;&#22797;&#21457;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>5</NO>
<PG>199-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mackkay-1980" NAME="Mackkay 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;MacKay-AV, Sheppard-GP, Saha-BK, Motley-B, Johnson-AL, Marsden-CD. Failure of lithium treatment in established tardive dyskinesia. Psychological Medicine 1980 Aug;10:583-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacKay AV, Sheppard GP, Saha BK, Motley B, Johnson AL, Marsden CD</AU>
<TI>Failure of lithium treatment in established tardive dyskinesia</TI>
<SO>Psychological Medicine</SO>
<YR>1980</YR>
<VL>10</VL>
<PG>583-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marken-1994" MODIFIED="2015-08-25 16:38:13 +0100" MODIFIED_BY="[Empty name]" NAME="Marken 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-08-25 16:38:13 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;04136&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:38:13 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Marken PA, McCrary KE, Lacombe S, Sommi RW, Hornstra RK, Pierce CA, et al</AU>
<TI>Preliminary comparison of predictive and empiric lithium dosing: impact on patient outcome</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>10</NO>
<PG>1148-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7841567"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martorano-JT" NAME="Martorano JT" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Martorano JT. Target symptoms in lithium carbonate therapy. Comprehensive Psychiatry 1972;13:533-537.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martorano JT</AU>
<TI>Target symptoms in lithium carbonate therapy</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1972</YR>
<VL>13</VL>
<PG>533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1979" NAME="Miller 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Lithium carbonate in the treatment of schizophrenia and schizo-affective disorder: Review and hypothesis. Biological Psychiatry 14:705-710.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller V</AU>
<TI>Lithium carbonate in the treatment of schizophrenia and schizo-affective disorder: Review and hypothesis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1979</YR>
<VL>14</VL>
<PG>705-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nct-2005" MODIFIED="2015-08-25 16:38:58 +0100" MODIFIED_BY="[Empty name]" NAME="Nct 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-08-25 16:38:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10358&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:38:58 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nct</AU>
<TI>Divalproex extended release and placebo, lithium, or quetiapine for mania</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nemes-1986" NAME="Nemes 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Nemes ZC, Volavka J, Cooper TB, O'Donnell J, Jaeger J. Lithium and haloperidol. Biol Psychiatry 1986;21:568-569.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nemes ZC, Volavka J, Cooper TB, O'Donnell J, Jaeger J</AU>
<TI>Lithium and haloperidol</TI>
<SO>Biological Psychiatry</SO>
<YR>1986</YR>
<VL>21</VL>
<PG>568-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paykel-2000" MODIFIED="2015-09-07 15:50:19 +0100" MODIFIED_BY="[Empty name]" NAME="Paykel 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-09-07 15:50:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;05126&lt;/p&gt;" NOTES_MODIFIED="2015-09-07 15:50:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Paykel ES</AU>
<TI>Prophylaxis of puerperal psychosis</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Placidi-1986" MODIFIED="2015-08-25 15:44:48 +0100" MODIFIED_BY="[Empty name]" NAME="Placidi 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Placidi GF, Lenzi A, Lazzerini F, Cassano G, Et A. The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double blind 3 year trial in 83 patients. Journal of Clinical Psychiatry 1986 Oct;47:490-494.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Placidi GF, Lenzi A, Lazzerini F, Cassano G</AU>
<TI>The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double blind 3 year trial in 83 patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<PG>490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-25 15:44:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;05776&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 15:44:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Placidi GF, Lenzi A, Rampello E, Andreani MF, Cassano GB, Grossi E</AU>
<TI>Long term-double blind prospective study on carbamazepine versus lithium in bipolar and schizoaffective disorders. Preliminary results</TI>
<SO>Anticonvulsants in Affective Disorders</SO>
<YR>1984</YR>
<PG>188-97</PG>
<PB>Elsevier</PB>
<CY>Amsterdam, Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7040529"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prange-1973" NAME="Prange 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Prange A WJMCHC. Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia. Psychopharmacol Bull 1973;9:36-37.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prange A</AU>
<TI>Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1973</YR>
<VL>9</VL>
<PG>36-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prien-1972a" NAME="Prien 1972a" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Prien RF, Caffey EM, Klett J. Factors associated with treatment in lithium carbonate prophylaxis. Arch Gen Psychiat 1974;31:189-192.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prien RF, Caffey EM, Klett J</AU>
<TI>Factors associated with treatment in lithium carbonate prophylaxis</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1974</YR>
<VL>31</VL>
<PG>189-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Prien RF, Point P, Caffey EM, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiat 1972;26:146-153.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prien RF, Point P, Caffey EM, Klett CJ</AU>
<TI>Comparison of lithium carbonate and chlorpromazine in the treatment of mania</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<PG>146-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rice-1956" NAME="Rice 1956" YEAR="1956">
<REFERENCE NOTES="&lt;p&gt;Rice D. The use of lithium salts in the treatment of manic states.1956:604-611.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rice D</AU>
<TI>The use of lithium salts in the treatment of manic states</TI>
<SO>International Pharmacology</SO>
<YR>1956</YR>
<VL>3</VL>
<PG>604-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-1980" NAME="Rosenthal 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Rosenthal NE, Rosenthal LN, Stallone F, Dunner DL, Fieve RR. Toward the validation of RDC schizoaffective disorder. Arch Gen Psychiatry 1980;37:804-810.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal NE, Rosenthal LN, Stallone F, Dunner DL, Fieve RR</AU>
<TI>Toward the validation of RDC schizoaffective disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1980</YR>
<VL>37</VL>
<PG>804-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnexnayder-1995" NAME="Schnexnayder 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Schnexnayder LW, Hirschowitz J, Sautter FJ, Garver DL. Predictors of response to lithium in patients with psychoses. Am J Psychiatry 1995;152:1511-1513.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnexnayder LW, Hirschowitz J, Sautter FJ, Garver DL</AU>
<TI>Predictors of response to lithium in patients with psychoses</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>1511-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schou-1954" NAME="Schou 1954" YEAR="1954">
<REFERENCE NOTES="&lt;p&gt;Schou M, Juel-Nielsen N, Str&amp;#246;mgen E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiat 1954;17:250-260.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schou M, Juel-Nielsen N, Strömgen E, Voldby H</AU>
<TI>The treatment of manic psychoses by the administration of lithium salts</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1954</YR>
<VL>17</VL>
<PG>250-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shalif-1981" MODIFIED="2015-08-25 16:51:12 +0100" MODIFIED_BY="[Empty name]" NAME="Shalif 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-08-25 16:51:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;02875&lt;/p&gt;" NOTES_MODIFIED="2015-08-25 16:51:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Shalif I, Lerner Y, Dasberg H</AU>
<TI>A symptom profile analysis of antipsychotic drug treatment - nonparametric multidimensional technique</TI>
<SO>Psychiatry research</SO>
<YR>1981</YR>
<VL>4</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6938996"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-1974" NAME="Shaw 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Shaw-DM, Hewland-R, Johnson-AL, Hilary-Jones-P, Howlett-MR. Comparison of serum levels of two sustained-release preparations of lithium carbonate. Curr-Med-Res-Opin 1974;2:90-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw DM, Hewland R, Johnson AL, Hilary-Jones P, Howlett MR</AU>
<TI>Comparison of serum levels of two sustained-release preparations of lithium carbonate</TI>
<SO>Current Medical Research Opinion</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>90-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shopsin-1975" NAME="Shopsin 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. Arch Gen Psychiat 1975;32:34-42.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shopsin B, Gershon S, Thompson H, Collins P</AU>
<TI>Psychoactive drugs in mania</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1975</YR>
<VL>32</VL>
<PG>34-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smulevitch-1974" NAME="Smulevitch 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Smulevitch AB, Zavidovskaya GI, Igonin AL, Mikhailova NM. The effectiveness of lithium in affective and schizoaffective psychoses. Brit J Psychiat 1974;125:65-72.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smulevitch AB, Zavidovskaya GI, Igonin AL, Mikhailova NM</AU>
<TI>The effectiveness of lithium in affective and schizoaffective psychoses</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1974</YR>
<VL>125</VL>
<PG>65-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2008" MODIFIED="2013-10-25 09:52:32 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-25 09:52:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun H, Jiao Y-T, Zhang L-X</AU>
<TI>A comparative study of clozapine and clozapine unite lithium carbonate in the treatment of male patients with treatment-resistant schizophrenia</TI>
<SO>Journal of Sichuang Mental Health</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>2</NO>
<PG>83-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1974" NAME="Taylor 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Taylor MA, Abrams R. The phenomenology of mania. Arch Gen Psychiatry 1973;29:520-522.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor MA, Abrams R</AU>
<TI>The phenomenology of mania</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1973</YR>
<VL>29</VL>
<PG>520-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Taylor MA, Gaztanaga P, Abrams R. Manic-depressive illness and acute schizophrenia: a clinical, family history, and treatment-response study. Am J Psychiatry 1974;131:678-682.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Taylor MA, Gaztanaga P, Abrams R</AU>
<TI>Manic-depressive illness and acute schizophrenia: a clinical, family history, and treatment-response study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1974</YR>
<VL>131</VL>
<PG>678-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kammen-1978" NAME="Van Kammen 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Van Kammen DP, Et A. d Amphetamine raises serum prolactin in man: Evaluations after chronic placebo, lithium and pimozide treatment. Life Sciences 1978 Oct;23:1487-1492.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kammen DP, Alexander P</AU>
<TI>d Amphetamine raises serum prolactin in man: Evaluations after chronic placebo, lithium and pimozide treatment</TI>
<SO>Life Sciences</SO>
<YR>1978</YR>
<VL>23</VL>
<PG>1487-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kammen-1980" NAME="Van Kammen 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Van Kammen D, Alexander P, Bunney WJ. Lithium treatment in post-psychotic depression. British Journal of Psychiatry 1980 May;136:479-85.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kammen D, Alexander P, Bunney WJ</AU>
<TI>Lithium treatment in post-psychotic depression</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>136</VL>
<PG>479-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kammen-1985" NAME="Van Kammen 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Van Kammen DP, Docherty JP, Marder SR, et a. Lithium attenuates the activation-euphoria but not the psychosis  induced by d-amphetamine in schizophrenia. Psychopharmacology 1985;87:111-115.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kammen DP, Docherty JP, Marder SR</AU>
<TI>Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1985</YR>
<VL>87</VL>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Putten-1975" NAME="Van Putten 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Van Putten T, Sanders D. Lithium in treatment failures. Journal of Nervous and Mental disease 1975;161:255-264&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Putten T, Sanders D</AU>
<TI>Lithium in treatment failures</TI>
<SO>Journal of Nervous and Mental disease</SO>
<YR>1975</YR>
<VL>161</VL>
<PG>255-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vieweg-1989" NAME="Vieweg 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Vieweg V, Godleski L, Hundley P, Harrington D, Yank G. Antipsychotic drugs, lithium, carbamazepine, and abnormal diurnal weight gain in psychosis. Neuropsychopharmacology 1989 Mar;2:39-43.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vieweg V, Godleski L, Hundley P, Harrington D, Yank G</AU>
<TI>Antipsychotic drugs, lithium, carbamazepine, and abnormal diurnal weight gain in psychosis</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>39-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volavka-1986" NAME="Volavka 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, O'Donald J, Muragali R</AU>
<TI>Lithium and lecithin in tardive dyskinesia: An update</TI>
<SO>Psychiatry Research</SO>
<YR>1986</YR>
<VL>19</VL>
<PG>101-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1995" NAME="Wang 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Q, Yuan F, Ai L, Yin D, Xiao Y</AU>
<TI>Chlorpromazine combined with lithium carbonate treatment for patients with refractory schizophrenia: a randomized double-blind cross-over clinical trial</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>185</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1966" NAME="White 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;White RB, Schlagenhauf G, Tupin JP. The treatment of manic depressive states wtih lithium carbonate. Current psychiatric therapies 1966;230-242.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White RB, Schlagenhauf G, Tupin JP</AU>
<TI>The treatment of manic depressive states wtih lithium carbonate</TI>
<SO>Current Psychiatric Therapies</SO>
<YR>1966</YR>
<VL>11</VL>
<PG>230-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilner-1996" NAME="Wilner 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wilner KD, Anziano RJ, Tensfeldt TG, Pelletier SN, Apseloff G, Gerber N</AU>
<TI>The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium</TI>
<SO>American Psychiatric Association, 149th conference</SO>
<YR>May 4-9, 1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1994" MODIFIED="2015-09-07 15:59:05 +0100" MODIFIED_BY="[Empty name]" NAME="Wilson 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-09-07 15:59:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wilson WH</AU>
<TI>Open clozapine treatment following a controlled clinical trial of lithium augmentation of haloperidol for refractory schizophrenia</TI>
<SO>Lithium</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>2</NO>
<PG>113-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zemlan-1984" NAME="Zemlan 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Zemlan FP, Hirschowitz J, Sautter FJ, Garver DL. Impact of lithium therapy on core psychotic symptoms of schizophrenia. Brit J Psychiat 1984;144:64-69.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zemlan FP, Hirschowitz J, Sautter FJ, Garver DL</AU>
<TI>Impact of lithium therapy on core psychotic symptoms of schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>144</VL>
<PG>64-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2011" MODIFIED="2012-10-18 15:49:19 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-18 15:49:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Guangyu, Rong Min</AU>
<TI>Paroxetine combined with lithium in patients with refractory schizophrenia.</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>15</NO>
<PG>1899-1900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-10-18 15:46:56 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-09-07 15:50:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Kamisada-1988" NAME="Kamisada 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamisada M, Tateyama M, Nakano Y, Kawachi Y, FUjii Y, Tanoue A, Takamiya M, Nakajima S, Sakuma K, Oguchi E, Yagi G</AU>
<TI>Comparison of the clinical effects of lithium carbonate and carbamazepine on excited schizophrenics</TI>
<SO>Psychopharmacology</SO>
<YR>1988</YR>
<VL>96 (suppl)</VL>
<PG>348</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGorry-2002" MODIFIED="2015-01-28 16:18:11 +0000" MODIFIED_BY="[Empty name]" NAME="McGorry 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-01-28 16:18:11 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;06454&lt;/p&gt;" NOTES_MODIFIED="2015-01-28 16:18:11 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McGorry PD, Cocks J, Harrigan S, Elkins K, Lambert T, Owen S</AU>
<TI>Very low-dose risperidone treatment in first-episode psychosis: how effective is it?</TI>
<SO>Proceedings of the 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark</SO>
<YR>2002</YR>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mosolov-1998" MODIFIED="2015-01-28 16:18:11 +0000" MODIFIED_BY="[Empty name]" NAME="Mosolov 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-01-28 16:18:11 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;05596&lt;/p&gt;" NOTES_MODIFIED="2015-01-28 16:18:11 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mosolov SN, Kostiukova EG, Kuzavkova MV</AU>
<TI>The efficacy of lithium carbonate and contemnol in preventing affective and schizoaffective psychoses</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>3</NO>
<PG>15-8</PG>
<IDENTIFIERS MODIFIED="2015-01-28 16:18:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="9575624"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-14 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-14 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1989" MODIFIED="2015-01-20 11:57:48 +0000" MODIFIED_BY="[Empty name]" NAME="Andreasen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Scale for the assessment of negative symptoms</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>155</VL>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Astrachan-1972" NAME="Astrachan 1972" TYPE="JOURNAL_ARTICLE">
<AU>Astrachan BM, Harrow M, Adler D, Brauer L, Schwartz A, Tucker G</AU>
<TI>A scale for the diagnosis of schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1972</YR>
<VL>121</VL>
<PG>529</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atre_x002d_Vaidya-1989" MODIFIED="2012-10-18 19:49:55 +0100" MODIFIED_BY="[Empty name]" NAME="Atre-Vaidya 1989" TYPE="JOURNAL_ARTICLE">
<AU>Atre-Vaidya N and Taylor MA</AU>
<TI>Effectiveness of lithium in schizophrenia: Do we really have an answer?</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>50</VL>
<NO>5</NO>
<PG>170-173</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2015-01-20 11:57:53 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TRE</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Medicine</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bech-1978" MODIFIED="2015-01-20 11:57:59 +0000" MODIFIED_BY="[Empty name]" NAME="Bech 1978" TYPE="JOURNAL_ARTICLE">
<AU>Bech P, Rafaelsen OJ, Kramp P, Bolwig TG</AU>
<TI>The mania rating scale: scale construction and inter-observer agreement</TI>
<SO>Neuropharmacology</SO>
<YR>1978</YR>
<VL>17</VL>
<PG>430-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2013-05-15 11:48:01 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2011-02-09 13:41:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10667106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burdock-1968" NAME="Burdock 1968" TYPE="JOURNAL_ARTICLE">
<AU>Burdock EI, Hardesty, AS</AU>
<TI>A psychological test for psychopathology</TI>
<SO>Journal of Abnormal Psychology</SO>
<YR>1968</YR>
<VL>73</VL>
<PG>62-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheine-2001" MODIFIED="2015-01-20 11:58:07 +0000" MODIFIED_BY="[Empty name]" NAME="Cheine 2001" TYPE="COCHRANE_REVIEW">
<AU>Cheine M, Ahonen J, Wahlbeck K</AU>
<TI>Supplementing standard drug treatment of those with schizophrenia with beta-blocking medication</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-03 14:22:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:22:53 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000234"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Christison-1991" NAME="Christison 1991" TYPE="JOURNAL_ARTICLE">
<AU>Christison GW, Kirch DG, Wyatt RJ</AU>
<TI>When symptoms persist: choosing among alternative somatic treatments for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1991</YR>
<VL>17</VL>
<PG>217-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Citrome--2009" MODIFIED="2012-10-18 20:00:47 +0100" MODIFIED_BY="[Empty name]" NAME="Citrome  2009" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L</AU>
<TI>Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?</TI>
<SO>Expert Rev Neurother</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>1</NO>
<PG>55-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davey-Smith-1998" MODIFIED="2012-10-18 19:05:47 +0100" MODIFIED_BY="[Empty name]" NAME="Davey Smith 1998" TYPE="JOURNAL_ARTICLE">
<AU>Davey Smith G, Egger M.</AU>
<TI>Meta-analysis: Unresolved issues and future developments</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<ED>Cochrane Collaboration</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delva-1982" MODIFIED="2012-10-18 19:47:12 +0100" MODIFIED_BY="[Empty name]" NAME="Delva 1982" TYPE="JOURNAL_ARTICLE">
<AU>Delva, NJ and Letemendia, FJ</AU>
<TI>Lithium treatment in schizophrenia and schizo-affective disorders</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>141</VL>
<PG>387-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dold-2012" MODIFIED="2013-10-30 11:32:32 +0000" MODIFIED_BY="[Empty name]" NAME="Dold 2012" TYPE="JOURNAL_ARTICLE">
<AU>Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S</AU>
<TI>Benzodiazepines for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<VL>11</VL>
<PG>CD006391</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey mith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Essali-2009" MODIFIED="2013-10-30 11:32:14 +0000" MODIFIED_BY="[Empty name]" NAME="Essali 2009" TYPE="JOURNAL_ARTICLE">
<AU>Essali A, Al-Haj Haasan N, Li C, Rathbone J</AU>
<TI>Clozapine versus typical neuroleptic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<VL>1</VL>
<PG>CD000059</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-Profiler" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="GRADE Profiler" TYPE="COMPUTER_PROGRAM">
<TI>GRADE Profiler</TI>
<YR>2004</YR>
<EN>3.2</EN>
<PB>GRADE Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2015-01-20 11:58:17 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy U</AU>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville, Maryland, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale of depression</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-05-15 11:43:13 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<YR>[updated March 2011]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jope-1999" MODIFIED="2012-08-15 18:31:06 +0100" MODIFIED_BY="[Empty name]" NAME="Jope 1999" TYPE="JOURNAL_ARTICLE">
<AU>Jope RS</AU>
<TI>Anti-bipolar therapy: mechanism of action of lithium</TI>
<SO>Molecular Psychiatry</SO>
<YR>1999</YR>
<VL>4</VL>
<NO>2</NO>
<PG>117-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<TI>Positive and negative syndrome scale (PANSS) manual</TI>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" MODIFIED="2015-10-14 10:11:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A</AU>
<TI>The positive and negative syndrome scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>2</NO>
<PG>261-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krawiecka-1977" NAME="Krawiecka 1977" TYPE="JOURNAL_ARTICLE">
<AU>Krawiecka M, Goldberg D, Vaughan MA</AU>
<TI>Standardized assessment scale for rating chronic psychotic patients</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1977</YR>
<VL>55</VL>
<PG>299-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lenox-2003" MODIFIED="2012-08-15 18:32:12 +0100" MODIFIED_BY="[Empty name]" NAME="Lenox 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lenox RH, Wang L</AU>
<TI>Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks</TI>
<SO>Molecular Psychiatry</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>2</NO>
<PG>135-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2011-02-09 13:41:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2011-02-09 13:41:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2013" MODIFIED="2014-01-27 15:12:32 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2013" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM</AU>
<TI>Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis</TI>
<SO>The Lancet</SO>
<YR>2013</YR>
<VL>382</VL>
<NO>9896</NO>
<PG>951-962</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2014" MODIFIED="2015-01-20 11:57:26 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2014" TYPE="COCHRANE_REVIEW">
<AU>Leucht S, Helfer B, Dold M, Kissling W, McGrath J</AU>
<TI>Carbamazepine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2015-01-20 11:57:18 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-20 11:57:18 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001258.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2012-08-15 17:03:10 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marwaha S, Johnson S.</AU>
<TI>Schizophrenia and employment ? A review.</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIMH-1970" NAME="NIMH 1970" TYPE="BOOK_SECTION">
<AU>National Institute of Mental Health</AU>
<TI>Clinical global impression</TI>
<SO>Manual for the ECDEU Assessment Battery</SO>
<YR>1970</YR>
<ED>Guy W, Bonato RR</ED>
<PB>NIMH</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>790-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-_x0028_RevMan_x0029_" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager (RevMan)" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schooler-1993" NAME="Schooler 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Keith SJ</AU>
<TI>Clinical research for the treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<PG>431-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2010" MODIFIED="2014-03-12 09:45:00 +0000" MODIFIED_BY="[Empty name]" NAME="Schulz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D; CONSORT Group.</AU>
<TI>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c332</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwarz-2008" MODIFIED="2014-01-27 14:57:27 +0000" MODIFIED_BY="[Empty name]" NAME="Schwarz 2008" TYPE="COCHRANE_REVIEW">
<AU>Schwarz C, Volz A, Li C, Leucht S</AU>
<TI>Valproate for schizophrenia (Cochrane review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-11-03 14:26:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:26:23 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004028.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2015-01-20 11:58:27 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson M, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SPSS-2001" NAME="SPSS 2001" TYPE="COMPUTER_PROGRAM">
<AU>SPSS Inc.</AU>
<TI>SPSS for Windows version 11.0.1</TI>
<YR>2001</YR>
<PB>LEEDS technologies Inc.</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tharyan-2005" MODIFIED="2008-11-03 14:25:53 +0000" MODIFIED_BY="[Empty name]" NAME="Tharyan 2005" TYPE="COCHRANE_REVIEW">
<AU>Tharyan P, Adams CE</AU>
<TI>Electroconvulsive therapy for schizophrenia (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-03 14:25:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:25:53 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000076.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2012-08-15 17:06:50 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality.</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2011-02-09 13:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" NAME="Wahlbeck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Tuunainen A, Ahokas A, Leucht S</AU>
<TI>Drop-out rates in randomised antipsychotic drug trials</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>230-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alexander-1979" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Alexander 1979" TYPE="JOURNAL_ARTICLE">
<AU>Alexander PE, Van Kammen DP, Bunney WE</AU>
<TI>Antipsychotic effects of lithium in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>136</VL>
<NO>3</NO>
<PG>283-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anon-2005" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Anon 2005" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>Rational therapy of difficultly-treated bipolar and schizophrenic disorders - Bipolar disorders: Rapid Cycling and bipolar mixed conditions</TI>
<SO>Psychopharmakotherapie</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1996" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1996" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TRE, McEvedy CJB, Nelson HE</AU>
<TI>Management of treatment resistant schizophrenia unresponsive to clozapine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>169</VL>
<NO>Suppl. 31</NO>
<PG>31-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Citrome-2009" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Citrome 2009" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L</AU>
<TI>Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: Useful strategy or exercise in futility?</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2009</YR>
<VL>70</VL>
<NO>6</NO>
<PG>932-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feng-2006" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Feng 2006" TYPE="JOURNAL_ARTICLE">
<AU>Feng Z, Yang K-J, Gao H, ,</AU>
<TI>The effect of lithium carbonate combining clozapine for the resistant schizophrenics with agitation and aggressive behavior</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>12</NO>
<PG>427-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2006" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Liu N, ,</AU>
<TI>[ lithium carbonate and compound norethisterone periodic psychotic relapse prevention control study ] google translation</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>5</NO>
<PG>199-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meszaros-1991" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Meszaros 1991" TYPE="JOURNAL_ARTICLE">
<AU>Meszaros K, Simhandl C, Liechtenstein A, Dank E, Thau K, Topitz A</AU>
<TI>Lithium carbonate added to neuroleptics in treatment refractory schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>3</NO>
<PG>291-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCT00183443-2005" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00183443 2005" TYPE="OTHER">
<AU>NCT00183443</AU>
<TI>Divalproex extended release and PLACEBO, lithium, or quetiapine for mania</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCT00202293-2005" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00202293 2005" TYPE="OTHER">
<AU>NCT00202293</AU>
<TI>Comparison of combination olanzapine and lithium and combination chlorpromazine and lithium in the treatment of a first manic episode with psychotic features</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCT00283179-2006" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00283179 2006" TYPE="OTHER">
<AU>NCT00283179</AU>
<TI>Efficacy and safety of aripiprazole in the treatment of acutely relapsed patients with schizophrenia or schizoaffective disorder with risperidone as an active control</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCT01074073-2010" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01074073 2010" TYPE="JOURNAL_ARTICLE">
<AU>NCT01074073</AU>
<TI>Lithium drug-drug interaction study with lurasidone HCl</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Preskorn-2008" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Preskorn 2008" TYPE="JOURNAL_ARTICLE">
<AU>Preskorn SH</AU>
<TI>Deconstructing a medication regimen</TI>
<SO>Journal of Psychiatric Practice</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>2</NO>
<PG>114-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rifkin-1993" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Rifkin 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rifkin A</AU>
<TI>Pharmacological strategies in the treatment of schizophrenia</TI>
<SO>Psychiatric Clinics of North America</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>2</NO>
<PG>351-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruiz_x002d_Doblado-2010" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Ruiz-Doblado 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz-Doblado S, Baena-Baldomero A, Esparrago-Llorca G</AU>
<TI>Pharmacological augmentation strategies in clozapine-resistant schizophrenia: Overcoming the resistance</TI>
<SO>Psiquiatria Biologica</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>3</NO>
<PG>96-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Small-2001" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Small 2001" TYPE="CONFERENCE_PROC">
<AU>Small JG, Klapper MH, Malloy FW, Steadman TM</AU>
<TI>Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the 8th International Congress on Schizophrenia Research; 2001 Apr 28-May 2; Whistler, Canada</SO>
<YR>2001</YR>
<PG>223-8</PG>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Whistler, Canada</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smulevitch-1974" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Smulevitch 1974" TYPE="JOURNAL_ARTICLE">
<AU>Smulevitch AB, Zavidovskaya GI, Igonin AL, Mikhailova NM</AU>
<TI>The effectiveness of lithium in affective and schizo-affective psychoses</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1974</YR>
<VL>125</VL>
<PG>65-72</PG>
<CY>ENGLAND</CY>
<IDENTIFIERS MODIFIED="2011-01-31 10:32:03 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID 4854793"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sun-2008" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sun H, Jiao Y, Zhang L</AU>
<TI>A comparative study of clozapine and clozapine unite lithium carbonate in the treatment of male patients with treatment-resistant schizophrenia</TI>
<SO>Sichuan Mental Health []</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>2</NO>
<PG>83-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1994" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wilson WH</AU>
<TI>Open clozapine treatment following a controlled clinical trial of lithium augmentation of haloperidol for refractory schizophrenia</TI>
<SO>Lithium</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>2</NO>
<PG>113-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x4f55__x71d5__x98de__x002c_-2010" MODIFIED="2011-01-31 10:32:12 +0000" MODIFIED_BY="[Empty name]" NAME="&#20309;&#29141;&#39134;, 2010" TYPE="JOURNAL_ARTICLE">
<AU>, ,</AU>
<TI>[risperidone combined with lithium in treatment of refractory schizophrenia] Google Translate</TI>
<SO>Guangzhou Medical Journal</SO>
<YR>2010</YR>
<VL>2</VL>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-10-13 14:13:34 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-10-13 14:13:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-09-29 13:56:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biederman-1979">
<CHAR_METHODS MODIFIED="2015-09-16 21:31:06 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blinding: double (no further details were provided).<BR/>Duration: 5 weeks.<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-29 10:45:07 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, schizoaffective, and affective schizoaffective (RDC).<BR/>N = 36*.<BR/>Age: mean ~ 30 years.*<BR/>Sex: 25 M, 11 F.*<BR/>History: elevated mood or motor hyperactivity, acute admissions, number of previous admissions, and mean duration of the illness was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:39:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (flexible dose of haloperidol, which was started at admission) + flexible lithium dose, which was started at 1200 mg/day and then adjusted according to therapeutic effect and side effects. N = 21.</P>
<P>2. Adjunctive placebo (flexible dose of haloperidol, which was started at admission) + flexible placebo dose, which was adjusted according to therapeutic effect and side effects. N = 18.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:56:49 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Global state: CGI.</P>
<P>Adverse events: toxic symptoms.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Mental state: mean BPRS, mean mania scale (no SD was given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:56:57 +0100" MODIFIED_BY="[Empty name]">
<P>*The data of 3 participants who left before the end of week 3 were not considered in the description by the original authors. In total, there were 39 participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:57:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Braden-1982">
<CHAR_METHODS MODIFIED="2015-09-16 21:31:37 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 3 weeks.<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:43:59 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia (12)*, schizoaffective disorder, mania, and other psychotic disorders (RDC).<BR/>N = 78.<BR/>Age: this was not clearly indicated.<BR/>Sex: this was not clearly indicated.<BR/>History: drug-free, at least 2 manic symptoms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:40:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: target plasma level = 1.6 mEq/L (mean level of all participants: 1.16 mEq/l). N = 5*.</P>
<P>2. Chlorpromazine up to 2000 mg/day (mean of all participants: 796 mg/day). N = 7*.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:57:10 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Mental state: BPRS, GAS, structured interview, clinician's overall ratings (no SD was given, only P values).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Data could be extracted only for those with schizophrenia.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:57:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brockington-1978">
<CHAR_METHODS MODIFIED="2015-09-16 22:29:25 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (sealed envelopes were used; allocations were made within the trial, from a table of random numbers).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 4 weeks.<BR/>Design: parallel.<BR/>Setting: this was not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:32:06 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizomania (PSE).<BR/>N = 19.<BR/>Age: mean ~ 35 years.<BR/>Sex: 30 M, 12 F.<BR/>History: "chronic", non-response to &gt; 3 neuroleptics (2 different chemical classes) in the last 2 years, duration of the illness ~ 10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:51:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: flexible dose (maximum 2500 mg/day) to achieve therapeutic level (the range was not indicated). N = 8.</P>
<P>2. Chlorpromazine: flexible dose (400 to 1000 mg/day). N = 11.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:57:20 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Global state: judgement of rater.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Mental state: BPRS, PSE (no SD was given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:15:48 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:57:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collins-1991">
<CHAR_METHODS MODIFIED="2015-09-16 21:32:33 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further description was given).<BR/>Blinding: single (rater).<BR/>Duration: 4 weeks.<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:32:33 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia (DSM-III-R and PSE).<BR/>N = 44.<BR/>Age: mean ~ 39 years.<BR/>Sex: all male.<BR/>History: all persistent psychotic symptoms for a minimum period of 6 months prior to the study despite adequate neuroleptic treatment, current hospital stay of 1 to 19 years, number of previous hospitalisations and duration of illness was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:41:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (starting dose of 800 mg, which was then adjusted to keep plasma levels within 0.4 to 1.0 mml/L) + flexible dose of antipsychotics (mean chlorpromazine equivalent at week 4 = 1452 mg). N = 21.</P>
<P>2. No additional treatment + flexible dose of antipsychotics (mean chlorpromazine equivalent at week 4 = 1257 mg). N = 23.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:57:32 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Mental state: MS, SANS (no mean or SD was given).</P>
<P>Medication use: mean antipsychotic dose (no SD was given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:16:16 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:53:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dube-1981">
<CHAR_METHODS MODIFIED="2015-09-16 21:33:00 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 7 weeks (1 week of placebo, 4 weeks of CPZ or lithium, 2 weeks of placebo).<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:29:48 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia (ICD-9).<BR/>N = 60.<BR/>Age: this was not indicated.<BR/>Sex: this was not indicated.<BR/>History: no details.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:42:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: flexible dose, adjusted to achieve therapeutic serum levels (the range was not indicated), mean dose = 827 mg/day. N = 30.</P>
<P>2. Chlorpromazine: flexible dose, mean dose = 992 mg/day. N = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:53:16 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Global state: CGI (only a P value was given, not a SD).</P>
<P>Mental state: BPRS (only a P value was given, not a SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:16:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:53:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feng-2006">
<CHAR_METHODS MODIFIED="2015-09-16 21:33:36 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Blindness: open study.<BR/>Duration: 8 weeks.<BR/>Setting: inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:33:36 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia (CCMD-3) and treatment-resistant form of schizophrenia.<BR/>N = 60.<BR/>Age: 21.95 ± 9.26 years.<BR/>Sex: 34 M and 26 F.<BR/>History: duration of illness was 5.95 ± 4.15 years; number of previous hospitalisations: 4.93 ± 1.97, not all participants were in their first episode.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:16:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (mean dose: 1.0 to 1.5 g/day; the starting dose was 0.5 g/day, which increased to 1.0 g/day the next week) + dose of antipsychotics (mean clozapine dose: 425.66 ± 201.65 mg/day; the starting dose was 50 mg/day, which increased to 50 to 100 mg/day the next day; maximum: 300 to 600 mg/day). N = 30.</P>
<P>2. No additional treatment + dose of antipsychotics (clozapine mean dose: 438.70 ± 238.12 mg/day). N = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:53:39 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS total score, PANSS Excited Component,</P>
<P>PANSS Supplemental Aggression Risk profile.</P>
<P>Adverse events.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Leaving the study early: not reported.</P>
<P>Adverse events: TESS score (no means and SDs were reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:17:25 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:44:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garver-1983">
<CHAR_METHODS MODIFIED="2015-09-16 21:34:04 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (no further details were provided).<BR/>Duration: flexible according to response.<BR/>Design: cross-over.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:30:00 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: acute schizophrenia, schizophreniform disorder, schizoaffective disorder, major depressive episode (1*) (DSM-III and RDC).<BR/>N = 16.<BR/>Age: this was not indicated.<BR/>Sex: this was not indicated.<BR/>History: acute admissions, all had a red blood cell/lithium ratio &lt; 0.31 or &gt; 0.37.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:17:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: the dose was calculated so that the level was between 0.8 to 1.4 mEq/L, N = 9.</P>
<P>2. Placebo, N = 7.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:44:34 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving early.</P>
<P>Mental state: NH.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Global state: CGI (no individual numbers or means were given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 21:34:04 +0100" MODIFIED_BY="Laura E  Prescott">
<P>*This participant with a major depressive episode was excluded from all analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:45:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-2010">
<CHAR_METHODS MODIFIED="2015-09-16 21:34:43 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: random.<BR/>Blindness: open study.<BR/>Duration: 12 weeks.<BR/>Setting: outpatients and inpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:47:36 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: participants meeting CCMD-3 criteria for schizophrenia; specifically, they also met the criteria for treatment-resistant schizophrenia.<BR/>N = 92.<BR/>Age: 29.05 ± 4.6 years.<BR/>Sex: 54 M and 38 F.<BR/>History: the mean duration of illness was 4.4 ± 2.9 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:18:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (flexible dose, mean: 0.6 ± 0.15 g/d, maximum: 1.0 g/d) + dose of antipsychotics (risperidone, flexible dose, mean: 3.8 ± 1.4 mg/d, range: 4 to 6 mg/d). N = 46.</P>
<P>2. No additional treatment + dose of antipsychotics (risperidone, flexible dose, mean: 4.2 ± 1.6 mg/d, range: 6 to 8 mg/d, twice per day). N = 46.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:45:10 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS total, PANSS positive symptoms, PANSS negative symptoms, PANSS general pathology.</P>
<P>Adverse events.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Adverse events: TESS score (no means and SDs were reported).</P>
<P>Leaving the study early: this was not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:19:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:45:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hogarty-1995">
<CHAR_METHODS MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised - lithium:placebo 2:1 (no further details were provided).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 2 weeks (the intervention was withdrawn at week 6).<BR/>Design: parallel.<BR/>Setting: outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 23:41:53 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia or schizoaffective disorder (RDC).<BR/>N = 29.<BR/>Age: mean ~ 36 years.<BR/>Sex: M 15, F 14.<BR/>History: "persistent distress by anxiety for at least 3 months prior to the study". The participants had not sufficiently responded in 2 preceding trials of anticholinergic challenge and fluphenazine dose reduction. The mean duration of the illness was ~ 10 years*; the mean number of previous hospitalisations was ~ 4*.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:19:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (the dose was adjusted to maintain plasma levels between 0.4 to 0.8 mmol/L) + constant dose of fluphenazine decanoate (median biweekly dose: 10 mg). N = 18.</P>
<P>2. Placebo + constant dose of fluphenazine decanoate (median biweekly dose: 10 mg). N = 11.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:45:39 +0100" MODIFIED_BY="[Empty name]">
<P>Response: no overall improvement, relapse.<BR/>Leaving the study early<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Mental state: BPRS subscores, BDI, anxiety rating scale, personal comfort scale (no SD was given).</P>
<P>Adverse events: Barnes Akathisia Scale (no SD was given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott">
<P>*Data refer to the whole group of distressed participants who had entered the 2 previous trials.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:45:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-1984">
<CHAR_METHODS MODIFIED="2015-09-16 21:35:14 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 10 weeks (the intervention was withdrawn at week 6).<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:35:14 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia (10*), bipolar depression, mania (DSM-III-R).<BR/>N = 27.<BR/>Age: mean ~ 34 years*.<BR/>Sex: 9 M, 1 F*.<BR/>History of the schizophrenia participants: all had chronic paranoid type; the duration of the illness was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:22:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (the dose was adjusted to maintain levels between 0.6 to 1.2 mEq/L) + haloperidol (the dose was not indicated). N = 6*.</P>
<P>2. Adjunctive placebo + haloperidol (the dose was not indicated). N = 4*.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:45:59 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Mental state: GAS (no mean or SD was given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 21:35:14 +0100" MODIFIED_BY="Laura E  Prescott">
<P>*Only data of those 10 participants with schizophrenia were used for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:54:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1971">
<CHAR_METHODS MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (a table with random numbers was used).<BR/>Blindness: double (the participant and rater were blind, not the treating psychiatrist).<BR/>Duration: 3 weeks.<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:30:11 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: acute schizophrenia and acute schizoaffective disorder.<BR/>N = 17.<BR/>Age: mean ~ 39 years.<BR/>Sex: this was not indicated.<BR/>History: the duration of the illness was not indicated, but all participants were in an "excited" state at the time of the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:23:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: flexible dose, increased until response or toxic effect; all participants had levels higher than 1 mEq/L. N = 7.</P>
<P>2. Chlorpromazine: dosage increased until response or toxic effect. N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>Response: no improvement.<BR/>Leaving the study early.</P>
<P>Mental state: BPRS, SCI.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Adverse events and laboratory parameters (no clear numbers were given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:24:31 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:47:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnstone-1988">
<CHAR_METHODS MODIFIED="2015-09-16 21:55:18 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 8 weeks (this was for the initial study, then there was an open extension of up to 6 years for the responders).<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:55:31 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: "functional psychoses" (schizophrenia, schizophreniform disorder, schizoaffective disorder, atypical psychoses paranoid disorder, mania, or depression)* (DSM-III and PSE).<BR/>N = 120.<BR/>Age: the mean age was unclear.<BR/>Sex: 64 M, 56 F.<BR/>History: 38 were neuroleptic-naive, and 22 had no neuroleptics for at least 1 year; the duration of the illness was unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:25:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Pimozide alone: 16 mg/day. N = 23*.</P>
<P>2. Lithium alone, levels adjusted to 0.5 to 1.2 mmol/l. N = 21*.</P>
<P>3. Pimozide + lithium (same doses as in the monotherapy group). N = 22.*</P>
<P>4. Placebo. N = 18*.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:47:21 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: Krawiecka Scale, Montgomery-Asberg Depression Scale, Bech-Rafaelsen Mania Scale.</P>
<P>Adverse events: AIMS, TAKE.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Response: relapse rates and other long-term data (the numbers were unclear).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 21:35:56 +0100" MODIFIED_BY="Laura E  Prescott">
<P>*The data of only those with schizophrenia or similar psychoses are used in the analyses (schizophrenia, schizophreniform disorder, schizoaffective disorder, atypical psychosis, paranoid disorder).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:26:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mattes-1984">
<CHAR_METHODS MODIFIED="2015-09-16 21:56:20 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (a table with random numbers was used).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 1 year.<BR/>Design: parallel.<BR/>Setting: outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:30:19 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenic schizoaffective disorder (RDC).<BR/>N = 14.<BR/>Age: mean ~ 26 years.<BR/>Sex: this was not indicated.<BR/>History: 5 participants were chronic, 8 were subchronic, and 1 was subacute according to RDC criteria; on average, the participants had not worked 50% of the time they could have worked in the last 5 years; on average, each had 3.7 previous episodes; the mean duration of the illness was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:26:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: flexible dose, plasma levels &gt; 0.6. N = 7.</P>
<P>2. Fluphenazine: 5 to 20 mg/day orally or 12.5 to 50 mg biweekly. N = 7.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:26:52 +0100" MODIFIED_BY="[Empty name]">
<P>Response: relapse<BR/>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:26:55 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:47:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prien-1972">
<CHAR_METHODS MODIFIED="2015-09-16 21:57:47 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (identical capsules were used).<BR/>Duration: 3 weeks.<BR/>Design: parallel.<BR/>Setting: hospital, multicentre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:36:18 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizoaffective disorder, excited type (DSM-II).<BR/>N = 83.<BR/>Age: mean ~ 39 years.<BR/>Sex: 59 M, 24 F.<BR/>History: the duration of the illness was not indicated; the median number of previous hospitalisation was 3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:27:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium carbonate: the starting dose was 750 mg, which was then adjusted according to the participants's clinical condition and side effects (plasma levels &lt; 2.0 mEq/L). N = 37.</P>
<P>2. Chlorpromazine: the starting dose was 600 mg/day, which was then adjusted according to the participant's clinical condition and side effects. N = 46.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Adverse events.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Mental state: BPRS, IMPS, PIP (only P values were given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:27:36 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:55:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulz-1999">
<CHAR_METHODS MODIFIED="2015-09-16 22:00:30 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (stratified for gender and diagnoses).<BR/>Blindness: double (the participant and independent rater was blind, not the therapist).<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Setting: outpatients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:00:45 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia, schizophreniform, and schizoaffective disorder (DSM-III-R).<BR/>N = 41.<BR/>Age: mean ~ 29 years.<BR/>Sex: 34 M, 7 F.<BR/>History: severely ill (mean BPRS = 47) despite treatment with depot antipsychotics for 6 months before the trial. The mean duration of the illness and mean number of previous episodes was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (plasma levels were maintained between 0.8 to 1.0 mEq/L) + constant dose of fluphenazine. N = 21.</P>
<P>2. Placebo + constant dose of fluphenazine. N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:55:06 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: BPRS, HAMD.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Mental state: CGI, SAS (no mean or SD was given).</P>
<P>Adverse events: these were monitored but not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:29:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:55:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shopsin-1971">
<CHAR_METHODS MODIFIED="2015-09-16 22:04:51 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (identical capsules were used - the participant and rater were blinded, not the therapist).<BR/>Duration: 5 weeks (2-week placebo run-in, 3 weeks of lithium or chlorpromazine, and 2 weeks of placebo).<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:30:28 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: acute schizophrenia (undifferentiated type and paranoid type), schizoaffective disorder (clinical diagnose by at least 2 psychiatrists).<BR/>N = 21.<BR/>Age: 21 to 62 years.<BR/>Sex: this was not indicated.<BR/>History: included within 3 days of admission, having their first episode (N = 2) or exacerbation of chronic illness (N = 19); the mean duration of illness was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:29:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: the starting dose was 750 to 1000 mg/day, maximum dose = 3000 mg/day (plasma levels &lt; 1.5 mEq/L). N = 11.</P>
<P>2. Chlorpromazine: the starting dose was 300 to 400 mg/day, maximum dose = 1200 mg/day. N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:55:31 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Adverse events: use of antiparkinson medication, specific events.</P>
<P>Laboratory: white blood cell count, blood uric acid, proteinuria.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Global state: CGI (only a P value was given).</P>
<P>Mental state: BPRS, IMPS, SCI, SRSS (only P values were given).</P>
<P>Behaviour: NOSIE (only a P value was given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:32:39 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:33:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simhandl-1996">
<CHAR_METHODS MODIFIED="2015-09-16 22:05:44 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 8 weeks (the intervention was withdrawn at week 6).<BR/>Design: parallel.<BR/>Setting: this was not indicated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:37:12 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N = 42.<BR/>Age: mean ~ 35 years.<BR/>Sex: 30 M, 12 F.<BR/>History: "chronic", non-response to &gt; 3 neuroleptics of 2 different chemical classes in the last 2 years, the mean duration of illness was ~ 10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:33:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine (the dose increased during weeks 1 to 2 until plasma levels were 15 to 42 micromol/L) + constant dose of antipsychotics. N = 15.</P>
<P>2. Lithium (the dose increased during weeks 1 to 2 until plasma levels were 0.6 to 1.2 myml/L) + constant dose of antipsychotics. N = 13.</P>
<P>3. Placebo + constant dose of antipsychotics. N = 14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:33:10 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: BPRS, SANS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*The data of this group were not used in the analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:55:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-1976">
<CHAR_METHODS MODIFIED="2015-09-16 22:07:21 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (a coin toss was used).<BR/>Blindness: double (raters and participants were blind, not the therapists).<BR/>Duration: 18 weeks (6 weeks' baseline for withdrawal of antipsychotics, then 2 6-week cross-over phases).<BR/>Design: cross-over.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:07:41 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia.</P>
<P>N = 11.<BR/>Age: mean ~ 72 years.<BR/>Sex: 3 M, 8 F.<BR/>History: long-term hospitalised, all with tardive dyskinesia. The mean duration of hospitalisation was ~ 30 years; the mean duration of illness was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:33:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: flexible dose to maintain plasma levels between 0.6 to 1.0 MEq/L. N = 5.</P>
<P>2. Placebo. N = 6.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:55:50 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>
<BR/>Unable to use</P>
<P>Global state: CGI (only a P value was given).</P>
<P>Adverse events: Tardive dyskinesia rating scale (only a P value was given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:34:09 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:56:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Small-1975">
<CHAR_METHODS MODIFIED="2015-09-16 21:37:36 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (no further details were provided).<BR/>Blindness: double (no further details were provided).<BR/>Duration: 16 weeks (4 phases of 4 weeks).<BR/>Design: cross-over.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:10:56 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia, schizoaffective disorder (Feighner's criteria).<BR/>N = 22.<BR/>Age: mean ~ 36 years.<BR/>Sex: 4 M, 18 F.<BR/>History: "very chronically ill", all had failed to respond to various previous treatment approaches including at least 1 allocation of phenothiazine, haloperidol, and thiothixene; the mean duration of hospitalisation was ~ 9 years; the mean duration of illness was ~ 10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:34:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (flexible dose to maintain plasma levels between 0.6 to 1.2 MEq/L) + constant dose of antipsychotics. N = 12.</P>
<P>2. Placebo + constant dose of antipsychotics. N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:56:07 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Global state: CGI (there were no data for the first cross-over phase).</P>
<P>Mental state: BPRS (there were no data for the first cross-over phase).</P>
<P>Behaviour: NOSIE (there were no data for the first cross-over phase).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:35:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:36:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Small-2001">
<CHAR_METHODS MODIFIED="2015-09-16 22:11:43 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (a table with random numbers was used).<BR/>Blindness: double (lithium and placebo tablets had the same taste).<BR/>Duration: 16 weeks (4 phases of 4 weeks).<BR/>Design: cross-over.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:37:44 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia, schizoaffective disorder (DSM-IV).<BR/>N = 20.<BR/>Age: mean ~ 37 years.<BR/>Sex: 14 M, 6 F.<BR/>History: all had failed to respond satisfactorily to adequate treatment with at least 2 different antipsychotics; the mean duration of hospitalisation and mean duration of illness was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (flexible dose to maintain plasma levels &gt; 0.4 MEq/L) + constant dose of clozapine (mean dose: ~ 400 mg/day). N = 10.</P>
<P>2. Placebo + constant dose of clozapine (mean dose: ~ 400 mg/day). N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:36:26 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: BPRS.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Adverse events: there were no data from the first cross-over phase.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:36:28 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:37:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terao-1995">
<CHAR_METHODS MODIFIED="2015-09-16 22:14:02 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (a table with random numbers was used).<BR/>Blindness: double (identical capsules were used).<BR/>Duration: 19 weeks (the intervention was withdrawn between the 2 8-week cross-over phases).<BR/>Design: cross-over.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:13:41 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N = 21.<BR/>Age: mean ~ 47 years.<BR/>Sex: all male.<BR/>History: the mean duration of illness was ~ 21 years; the mean number of hospitalisations was ~ 2.6; the duration of current hospitalisation was ~ 6.7 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:36:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive lithium (the dose was calculated to reach a plasma level of at least 0.4 mEq/L) + constant dose of antipsychotics. N = 10.</P>
<P>2. Placebo + constant dose of antipsychotics. N = 11.</P>
<P>Mean daily antipsychotic dose in haloperidol equivalents 27.1 mg (both groups combined).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:37:15 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: BPRS, SANS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:37:18 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:49:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-1993">
<CHAR_METHODS MODIFIED="2015-09-16 22:16:12 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised (blocks of 6 participants, sealed envelopes were used derived from a table of random numbers).<BR/>Blinding: double (identical placebo capsules were prepared by a pharmacist).<BR/>Duration: 6 weeks' of baseline, followed by an 8-weeks experimental phase.<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:15:20 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenia without a concurrent major affective disorder (DSM-III-R).<BR/>N = 29*<BR/>Age: this was not indicated.<BR/>Sex: this was not indicated.<BR/>History: all with persistent psychosis for at least 8 weeks despite antipsychotic treatment with at least 800 mg chlorpromazine equivalent; the mean current hospital stay was ~ 20 months; the mean previous hospitalisations was ~ 10 times; the mean duration of illness was ~ 14 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>Baseline phase before randomisation (6 weeks):</P>
<P>All participants were put on haloperidol at "best clinical dose".</P>
<P>Experimental phase (8 weeks):</P>
<P>1. Lithium (flexible dose adjusted to reach plasma level of 1.0 mEq/L) + haloperidol (the dose was not indicated). N = 12.</P>
<P>2. Placebo + haloperidol (the dose was not indicated). N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:49:58 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state: BPRS, SANS.</P>
<P>Adverse events: number of participants with delirium.</P>
<P>medication use (mean haloperidol dose, use of benzodiazepines and anticholinergics).<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>Adverse events: EPS (AIMS and Barnes Akathisia Scale - data were skewed).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 21:38:31 +0100" MODIFIED_BY="Laura E  Prescott">
<P>*7 participants left the study during the baseline phase before randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<U>General abbreviations</U>
<BR/>CPZ = chlorpromazine.<BR/>EPS = extrapyramidal side effects.<BR/>F = females.<BR/>ICD-9 = Ninth Revision of the International Classification of Diseases.<BR/>L = litre.<BR/>M = males.<BR/>mg = milligram.<BR/>mEq = milliequivalents.<BR/>N = number.<BR/>SD = standard deviation.<BR/>TAKE = Scale for Targeting Abnormal Kinetic Effects<BR/>TRAM = Treatment response assessment method<BR/>
<BR/>
<U>Diagnostic tools</U>
<BR/>CCMD-3 = Chinese Classification of Mental Disorders.<BR/>DSM-II = Diagnostic and Statistical Manual of Mental disorders, second edition.<BR/>DSM-III = Diagnostic and Statistical Manual of Mental disorders, third edition.<BR/>DSM-III-R = Diagnostic and Statistical Manual of Mental disorders, third edition, revised.<BR/>DSM-IV = Diagnostic and Statistical Manual of Mental disorders, fourth edition.<BR/>RDC = Research Diagnostic Criteria.<BR/>
<BR/>
<U>Global effect scales</U>
<BR/>CGI = Clinical Global Impression.<BR/>
<BR/>
<U>Mental state scales</U>
<BR/>BDI = Beck Depression Inventory.<BR/>BPRS = Brief Psychiatric Rating Scale.<BR/>GAS = Global Assessment of Symptoms Scale.<BR/>HAMD = Hamilton Depression Scale.<BR/>IMPS = Inpatient Multidimensional Psychiatric Scale.<BR/>PANSS = Positive and Negative Syndrome Scale.<BR/>PIP = Psychotic Inpatient Profile.<BR/>PSE = Present State Examination.<BR/>MS = Manchester Scale.<BR/>MMSE = Mini-Mental State Examination.<BR/>MSRS = Manic State Rating Scale.<BR/>NHSI = (Modified) New Haven Schizophrenia Index.<BR/>NOSIE = Nurses' Observation Scale for Inpatient Evaluation.<BR/>SANS = Scale for the Assessment of Negative Symptoms.<BR/>SCI = Structured Clinical Interview.<BR/>SRSS = Self-Rating Symptom Scale.<BR/>TESS = Treatment Emergent Symptom Scale.<BR/>
<BR/>
<U>Side effect scales</U>
<BR/>AIMS = Abnormal Involuntary Movement Scale.<BR/>Barnes Akathisia Scale.<BR/>SAS = Simpson-Angus Scale.<BR/>SAFTEE = Systematic Assessment for Treatment Emergent Events.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-09-16 23:43:14 +0100" MODIFIED_BY="Laura E  Prescott" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:30 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Alexander-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:30 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised ("within patient cross-over").</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:30 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Aronoff-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:30 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.</P>
<P>Participants: the majority were those with manic depressive illness, not schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:27 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Baastrup-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:27 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was an observational study with no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 23:41:04 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Bellaire-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 23:41:04 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Participants: the majority were bipolar, not schizophrenic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 22:22:47 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Berger-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 22:22:47 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: placebo-controlled - it was unclear if the study was randomised.<BR/>Participants: people at high risk of a first episode.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 22:22:59 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Bigelow-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 22:22:59 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>The study was double-blind, with the cross-over of a single participant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:35 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Bowers-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:35 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised ("within patient cross-over").</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:35 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Braden-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:35 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Participants: newly admitted adult inpatients who manife<BR/>manic behavior with or without schizophrenic symptoms participated in this study.<BR/>Interventions: chlorpromazine versus lithium carbonate.<BR/>Outcomes: no useable data were presented.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 23:43:02 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Brewerton-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 23:43:02 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Participants: the majority of participants were bipolar, not schizophrenic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:38 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Cabrera-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:38 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Participants: the majority were not schizophrenic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:38 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Campbell-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:38 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised (matched groups).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:42 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Campbell-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:42 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not a RCT.</P>
<P>This was an overview of literature.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carman-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind, cross-over study.<BR/>Participants: those with schizophrenia or schizoaffective disorder.<BR/>Interventions: lithium versus placebo added to antipsychotic drugs.<BR/>Outcomes: no single outcome could be analysed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 22:23:48 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Chen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 22:23:48 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: alternate allocation by hospital ID number (not randomised).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:56 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Dinsmore-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:56 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was an observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:40:58 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Edelstein-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:40:58 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a controlled clinical study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gao-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: allocated according to odd or even number of date and ID of admission.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:00 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Garver-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:00 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised ("within patient cross-over").</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerlach-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind.<BR/>Participants: diagnostically mixed group, all showing tardive dyskinesia, most had schizophrenia.<BR/>Interventions: lithium or placebo added to ongoing treatment.<BR/>Outcomes: focus on tardive dyskinesia, but no data could be extracted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gram-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind.<BR/>Participants: unclear diagnosis ("psychotic" children and adolescents).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:06 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Greil-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:06 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Participants: those with schizoaffective disorder.<BR/>Interventions: lithium versus carbamazepine as sole agents, there was no placebo/no intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:09 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Growe-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:09 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: it was unclear whether the study was randomised (it was double-blind).<BR/>Participants: those with schizophrenia or schizoaffective disorder.<BR/>Interventions: lithium versus placebo added to antipsychotic drugs.<BR/>Outcomes: no single outcome could be used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:09 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Haastrup-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:09 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: this was a controlled clinical trial; it was unclear whether the study was randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: unclear.<BR/>Outcomes: not specified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:09 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Harrison-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:09 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a retrospective chart analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:13 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Hofmann-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:13 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:13 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Hullin-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:13 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:13 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Jus-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:13 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised, double-blind.<BR/>Participants: schizophrenia, all with tardive dyskinesia.<BR/>Interventions: lithium, deanol, or placebo as sole treatments.<BR/>Outcomes: focus on tardive dyskinesia, but no data could be extracted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:17 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Kahn-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:17 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia.<BR/>Interventions: haloperidol alone and, subsequently, haloperidol in combination with carbamazepine or lithium carbonate, measuring the change in haloperidol serum levels.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:17 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Lenzi-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:17 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised, double-blind.<BR/>Participants: mixed group, 8 out of 30 had schizophrenia-like disorders.<BR/>Interventions: placebo or carbamazepine added to antipsychotic drugs, no placebo, or no intervention control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lerner-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not adequately randomised (alternate allocation).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:23 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Liebowitz-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:23 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:23 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Liu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:23 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.</P>
<P>Participants: not people with schizophrenia (periodic psychosis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:21 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Mackkay-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:21 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised, pairs were matched then there was "within patient cross-over".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:29 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Marken-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:29 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Participants: the majority were bipolar, not schizophrenic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:30 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Martorano-JT">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:30 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a paper on case reports.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:32 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Miller-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:32 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a review with no original data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:36 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Nct-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:36 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Participants: mania, it was unclear if the majority were schizophrenic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:43 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Nemes-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:43 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised ("within patient cross-over").</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:51 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Paykel-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:51 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.</P>
<P>Participants: women with post-partum psychoses.</P>
<P>Interventions: lithium versus haloperidol versus placebo.</P>
<P>Notes: we contacted the authors who confirmed that the study was never undertaken.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:49 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Placidi-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:49 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised, double-blind.<BR/>Participants: mixed group with "major affective, schizoaffective or schizophreniform disorders".<BR/>Interventions: lithium versus carbamazepine as sole agents, no placebo, or no intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:49 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Prange-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:49 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:48 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Prien-1972a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:48 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised, double-blind.<BR/>Participants: those with mania; there were no participants with schizophrenia or schizoaffective disorder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:55 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Rice-1956">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:55 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:55 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Rosenthal-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:55 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:41:55 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Schnexnayder-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:41:55 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised, there was no control group.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schou-1954">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with mania.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 23:43:14 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Shalif-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 23:43:14 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>The authors used data from previous studies to assess a non-parametric statistical technique for multidimensional evaluation of ratings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 22:26:05 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Shaw-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 22:26:05 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised, controlled clinical trial.<BR/>Participants: those with chronic schizophrenia.<BR/>Interventions: 2 different sustained-release preparations of lithium carbonate, there was no placebo or intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shopsin-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind.<BR/>Participants: those with mania.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:02 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Smulevitch-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:02 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:02 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Sun-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:02 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised, allocation was according to the order of hospitalisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:02 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Taylor-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:02 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:08 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Van-Kammen-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:08 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: the allocation of drug intervention (lithium or pimozide) was not randomised, but participants were randomised to receive an additional amphetamine or placebo infusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:08 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Van-Kammen-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:08 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised, there was no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Kammen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind.<BR/>Participants: those with schizophrenia.<BR/>Interventions: amphetamine + placebo versus amphetamine + lithium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:08 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Van-Putten-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:08 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised ("within patient cross-over").</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:08 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Vieweg-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:08 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: non-randomised comparison of participants with healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 22:26:46 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Volavka-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 22:26:46 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.<BR/>Participants: chronic psychiatric inpatients with tardive dyskinesia.<BR/>Interventions: lithium versus lecithin, there was no placebo or intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:12 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Wang-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:12 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised cross-over study, no further details were provided.<BR/>Participants: people with schizophrenia.<BR/>Interventions: chlorpromazine + lithium versus chlorpromazine alone, but clozapine could be added to both groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:12 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-White-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:12 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilner-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-25 16:41:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-25 16:41:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, follow up of clozapine treatment on a cohort of participants in a previous lithium trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 22:27:00 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Zemlan-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 22:27:00 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: not randomised.</P>
<P>This was a case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-16 21:42:17 +0100" MODIFIED_BY="Laura E  Prescott" STUDY_ID="STD-Zhou-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-16 21:42:17 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia.</P>
<P>Interventions: paroxetine versus paroxetine + lithium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ID = identification.<BR/>RCT = randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-09-29 14:01:06 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-09-29 14:00:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kamisada-1988">
<CHAR_METHODS MODIFIED="2015-09-16 22:27:27 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Allocation: random (there were no details of the randomisation).<BR/>Blinding: double-blind.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 22:50:14 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: schizophrenic psychosis (ICD-9).<BR/>N = 30.<BR/>Age: 21 to 57 years.<BR/>Sex: this was not indicated.<BR/>History: participants were included if they were rated as moderate or more in "tention", "mannerisms and posturing" or "excitement" of BPRS. The number of previous admissions and mean duration of illness was not indicated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:59:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium: fixed-flexible method, the dose was started at 400 mgs/d, with an upper limit of 1200 mgs/d. N = unknown.</P>
<P>2. Carbamazepine: fixed-flexible method, the dose was started at 400 mgs/d, with an upper limit of 1200 mgs/d. N = unknown.</P>
<P>3. Placebo: N = unknown.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 14:00:30 +0100" MODIFIED_BY="[Empty name]">
<P>Adverse events.<BR/>
<BR/>
</P>
<P>Unable to use</P>
<P>General Improvement Rating (only a P value was provided).</P>
<P>Global Usefulness Rating (only a P value was provided).</P>
<P>Overall Safety Rating (only a P value was provided).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 21:38:57 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Insufficient data were provided to identify the original group size (prior to dropouts).</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-09-29 14:00:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGorry-2002">
<CHAR_METHODS MODIFIED="2015-08-25 15:49:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-16 21:39:03 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Diagnosis: first episode of psychosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 14:00:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone 2 mg versus risperidone 4 mg versus risperidone plus lithium.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 14:00:49 +0100" MODIFIED_BY="[Empty name]">
<P>No useable data were presented; this was a conference proceeding only.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 21:39:03 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Authors were contacted in an attempt to get further information.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-09-29 14:01:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mosolov-1998">
<CHAR_METHODS MODIFIED="2015-08-25 15:40:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-25 15:41:08 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: affective and schizoaffective disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 14:01:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lithium carbonate versus contemnol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 14:01:03 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-16 21:39:00 +0100" MODIFIED_BY="Laura E  Prescott">
<P>Translation of the paper is needed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-09-16 22:14:34 +0100" MODIFIED_BY="Laura E  Prescott">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-09-16 22:14:34 +0100" MODIFIED_BY="Laura E  Prescott" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:31:22 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>Quote (page 328): "Assignment (...) according to a prearranged random order."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:31:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>Quote (page 70): "Patients were assigned randomly to treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:32:21 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>Quote (letter): "Table of random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:46:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>Quote (page 150): "Randomized."</P>
<P>Quote (letter): "Random number list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>Quote (page 194): "Randomly administered."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:50 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>Quote: "Divided into two groups randomly" - no further details were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>Quote (page 58): "Design of random initial assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:47:50 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>Quote: "Randomly divided" - no further information was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>Quote (page 31): "Randomized."</P>
<P>Quote (letter): "Table of random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>The study was randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:34 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>Quote (letter): "Randomised (table with random numbers)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:00 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>Quote (letter): "The randomisation was done using computer generated lists of random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>Quote (letter): "Randomised (table with random numbers)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:24 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>Quote (page 182): "Randomly assigned."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:44 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>Quote (page 368): "Assignment to lithium of placebo was randomised, but stratified to account for gender differences and differences between schizophrenia and schizoaffective illness group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>Quote (page 435): "Subjects were assigned to either drug in random fashion."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 22:06:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>Quote: "Randomised."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>Quote (letter): "Randomized by toss of coin."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>Quote (page 1316): "Random assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 22:12:32 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>The trial was randomised using a table with random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 22:14:34 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>Quote (letter): "We used [a] random number list to allocate subjects randomly."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>Quote (letter): "Assigned randomly (...) based on a computer generated random number".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:31:22 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>Quote (page 328): "Assignment of code numbers to each sequential patient admitted to the study was done by the control psychiatrist."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:31:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:32:21 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>Quote (letter): "Sealed envelopes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:32:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:50 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:34:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:34 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:00 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:24 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:44 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:16 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:49 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>Allocation concealment was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>Quote (page 221): "Randomisation by a controller."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>Sealed envelopes were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-07-13 07:12:40 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-09-16 22:08:28 +0100" MODIFIED_BY="Laura E  Prescott" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:31:22 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>Quote (page 328): "Double blind design", "identical capsules", "neither the patient (...), nor the nursing staff were aware of [the manipulation]."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:31:22 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>Quote (page 328): "Double blind design", "identical capsules", "neither the patient (...), nor the nursing staff were aware of [the manipulation]."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:31:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>Quote (page 69): "Double-blind."</P>
<P>Quote (page 70): "Identical appearing capsules."</P>
<P>Quote (page 70): "The attending psychiatrist was informed of the identity of the drug; nursing stuff and raters were not."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:44:14 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>Quote (page 69): "Double-blind."</P>
<P>Quote (page 70): "Identical appearing capsules."</P>
<P>Quote (page 70): "The attending psychiatrist was informed of the identity of the drug; nursing stuff and raters were not."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:32:21 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>Quote (page 162): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:32:21 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>Quote (page 162): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:32:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>Quote (page 150): "Single-blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:32:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>Quote (page 150): "Single-blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:46:57 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>Quote (page 193): "Double blind."</P>
<P>Quote (page 194): "Identical capsules were used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:33:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>Quote (page 193): "Double blind."</P>
<P>Quote (page 194): "Identical capsules were used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:33:50 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>No information about blinding was provided. The study was open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:33:50 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>No information about blinding was provided. The study was open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>Quote (page 57): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>Quote (page 57): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:34:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>No information about blinding was provided. The study was open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:34:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>No information about blinding was provided. The study was open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:35:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>Quote (page 29): "Double blind."</P>
<P>Quote (page 35): "LI or placebo administration was (...) unknown to the treating clinicians."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:35:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>Quote (page 29): "Double blind."</P>
<P>Quote (page 35): "LI or placebo administration was (...) unknown to the treating clinicians."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:35:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>Quote (page 327): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:35:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>Quote (page 327): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:53:24 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>Quote (page 267): "Controlled double blind study."</P>
<P>Quote (page 268): "The raters were blind throughout", "identical capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:53:22 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>Quote (page 267): "Controlled double blind study."</P>
<P>Quote (page 268): "The raters were blind throughout", "identical capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:55:37 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>Quote (page 120): "Allocated (...) blindly", "to preserve blindness it was arranged for the clinical chemistry department to send false results in the case of patients on placebo lithium."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:55:39 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>Quote (page 120): "Allocated (...) blindly", "to preserve blindness it was arranged for the clinical chemistry department to send false results in the case of patients on placebo lithium."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:56:57 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>Quote (page 446): "Double blind", "lithium blood levels were (...) monitored monthly by nontreating psychiatrist."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:36:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>Quote (page 446): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:59:44 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>Quote (page 184): "Identically appearing capsules", "only the treating psychiatrist knew the identity of the patient's study medication. Other treatment personnel [were] the clinical raters [who] operated under double blind conditions."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:59:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>Quote (page 184): "Identically appearing capsules", "only the treating psychiatrist knew the identity of the patient's study medication. Other treatment personnel [were] the clinical raters [who] operated under double blind conditions."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 22:02:48 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>Quote (page 368): "Double blind", "a non-blinded physician assessed side effects and monitored lithium levels", "baseline assessment and weekly assessments of symptoms were performed by blinded psychiatrist and study nurse."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 22:02:38 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>Quote (page 368): "Double blind", "a non-blinded physician assessed side effects and monitored lithium levels", "baseline assessment and weekly assessments of symptoms were performed by blinded psychiatrist and study nurse."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 22:05:03 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>Quote (page 435): "Identical pink capsules", "a third psychiatrist, uninvolved in patient rating, assigned and regulated treatment, he was also charged with patient care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 22:05:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>Quote (page 435): "Identical pink capsules", "a third psychiatrist, uninvolved in patient rating, assigned and regulated treatment, he was also charged with patient care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:37:16 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>Quote (page 317): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:37:16 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>Quote (page 317): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 22:08:24 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>Quote (page 76): "Double blind."</P>
<P>Quote (page 78): "Placebo identical to the study medication", "the ward personnel (...) was blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 22:08:28 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>Quote (page 76): "Double blind."</P>
<P>Quote (page 78): "Placebo identical to the study medication", "the ward personnel (...) was blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>Quote (page 1315): "Double blind."</P>
<P>Quote (page 1316): "Double-blind conditions were maintained throughout the study for patients and for the psychiatrists, nurses and psychometrists who gathered the data. White capsules of identical appearance..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:37:41 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>Quote (page 1315): "Double blind."</P>
<P>Quote (page 1316): "Double-blind conditions were maintained throughout the study for patients and for the psychiatrists, nurses and psychometrists who gathered the data. White capsules of identical appearance..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:37:49 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>Quote (page 2): "Raters and patients were blinded; clinicians were not."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:37:48 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>Quote (page 2): "Raters and patients were blinded; clinicians were not."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:38:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>Quote (page 220): "Double blind."</P>
<P>Comment: Clinicians and raters were blind.</P>
<P>Quote (page 221): "Placebo capsules with appearance identical to that of the lithium capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:38:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>Quote (page 220): "Double blind."</P>
<P>Comment: Clinicians and raters were blind.</P>
<P>Quote (page 221): "Placebo capsules with appearance identical to that of the lithium capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>Quote (page 359): "Double blind."</P>
<P>Comment: Clinicians and raters were blind.</P>
<P>Quote (page 360): "Identical appearing placebo capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-09-16 21:38:35 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>Quote (page 359): "Double blind."</P>
<P>Comment: Clinicians and raters were blind.</P>
<P>Quote (page 360): "Identical appearing placebo capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-09-16 22:11:22 +0100" MODIFIED_BY="Laura E  Prescott" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:31:22 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>Quote (page 329): "The blood was submitted for serum lithium level determination to the control psychiatrist, who was physically removed from the study location and had no contact with the patients or nursing staff."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:31:22 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>Quote (page 328): "Clinical psychiatrist (clinical rater) [was not] aware of [the manipulation]."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:31:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>Quote (page 70): "Raters were not [informed about the identity of the drug]."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:31:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>Quote (page 70): "Raters were not [informed about the identity of the drug]."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:32:21 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>Quote (page 162): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:32:21 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>Quote (page 162): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:32:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>Quote (page 150): "Single-blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:32:47 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>Quote (page 150): "Single-blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:33:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>Quote (page 193): "Double blind."</P>
<P>Quote (page 194): "Identical capsules were used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:47:00 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>Quote (page 193): "Double blind."</P>
<P>Quote (page 194): "Identical capsules were used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:33:56 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>No information about blinding was provided. The study was open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:33:56 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>No information about blinding was provided. The study was open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>Quote (page 57): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>Quote (page 57): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:34:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>No information about blinding was provided. The study was open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:34:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>No information about blinding was provided. The study was open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:35:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>Quote (page 29): "Double blind."</P>
<P>Quote (page 35): "LI or placebo administration was (...) unknown to the treating clinicians."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:35:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>Quote (page 29): "Double blind."</P>
<P>Quote (page 35): "LI or placebo administration was (...) unknown to the treating clinicians."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:35:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>Quote (page 327): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:35:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>Quote (page 327): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:53:44 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>Quote (page 267): "Controlled double blind study."</P>
<P>Quote (page 268): "The raters were blind throughout", "identical capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:53:43 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>Quote (page 267): "Controlled double blind study."</P>
<P>Quote (page 268): "The raters were blind throughout", "identical capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:55:41 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>Quote (page 120): "Allocated (...) blindly", "to preserve blindness it was arranged for the clinical chemistry department to send false results in the case of patients on placebo lithium."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:55:43 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>Quote (page 120): "Allocated (...) blindly", "to preserve blindness it was arranged for the clinical chemistry department to send false results in the case of patients on placebo lithium."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:36:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>Quote (page 446): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:36:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>Quote (page 446): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:59:54 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>Quote (page 184): "Identically appearing capsules", "only the treating psychiatrist knew the identity of the patient's study medication. Other treatment personnel [were] the clinical raters [who] operated under double blind conditions."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:59:56 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>Quote (page 184): "Identically appearing capsules", "only the treating psychiatrist knew the identity of the patient's study medication. Other treatment personnel [were] the clinical raters [who] operated under double blind conditions."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 22:02:51 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>Quote (page 368): "Double blind", "a non-blinded physician assessed side effects and monitored lithium levels", "baseline assessment and weekly assessments of symptoms were performed by blinded psychiatrist and study nurse."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 22:02:54 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>Quote (page 368): "Double blind", "a non-blinded physician assessed side effects and monitored lithium levels", "baseline assessment and weekly assessments of symptoms were performed by blinded psychiatrist and study nurse."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 22:05:08 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>Quote (page 435): "Identical pink capsules", "a third psychiatrist, uninvolved in patient rating, assigned and regulated treatment, he was also charged with patient care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 22:05:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>Quote (page 435): "Identical pink capsules", "a third psychiatrist, uninvolved in patient rating, assigned and regulated treatment, he was also charged with patient care."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:37:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>Quote (page 317): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:37:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>Quote (page 317): "Double blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>Quote (page 76): "Double blind."</P>
<P>Quote (page 78): "Psychiatrist (...) responsible for the evaluation (...) was blind as to the design and the patients' medication (active or placebo)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>Quote (page 76): "Double blind."</P>
<P>Quote (page 78): "Psychiatrist (...) responsible for the evaluation (...) was blind as to the design and the patients' medication (active or placebo)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 22:11:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>Quote (page 1315): "Double blind", "blind psychiatric and nursing ratings."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 22:11:22 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>Quote (page 1315): "Double blind", "blind psychiatric and nursing ratings."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:37:49 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>Quote (page 2): "Raters and patients were blinded; clinicians were not."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:37:49 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>Quote (page 2): "Raters and patients were blinded; clinicians were not."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:38:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>Quote (page 220): "Double blind."</P>
<P>Comment: Clinicians and raters were blind.</P>
<P>Quote (page 221): "Placebo capsules with appearance identical to that of the lithium capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:38:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>Quote (page 220): "Double blind."</P>
<P>Comment: Clinicians and raters were blind.</P>
<P>Quote (page 221): "Placebo capsules with appearance identical to that of the lithium capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>Quote (page 359): "Double blind."</P>
<P>Comment: Clinicians and raters were blind.</P>
<P>Quote (page 360): "Identical appearing placebo capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>Quote (page 359): "Double blind."</P>
<P>Comment: Clinicians and raters were blind.</P>
<P>Quote (page 360): "Identical appearing placebo capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-09-16 22:12:57 +0100" MODIFIED_BY="Laura E  Prescott" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:43:33 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>Quote (page 329): "Three patients discontinued [and were excluded form analysis - Lithium]", "[another] seven patients discontinued [and] were included in all data analyses that used improvement scores to the end of treatment [from placebo]" - last observation carried forward was used; there was an attrition rate of more than 25%; the participants were not evenly distributed (3/18 to 7/21); reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:44:33 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>Quote (page 72): "[There was a] high rate of early terminations. There was no overall significant difference in frequency of participants leaving early, of number of days in the study between the lithium and chlorpromazine group" - the attrition rate was 50%; participants were not evenly distributed between groups (4/5 and 2/7); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:45:47 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>The was an attrition rate of over 40%; the participants were not evenly distributed (2/8 and 6/11); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:32:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>Quote (page 152): "Eleven patients [out of 21] in the treatment group failed to complete the treatment protocol" [as compared to 1 out of 23 in the control group] - the attrition rate was 27%; participants were not evenly distributed between groups (11/21 and 1/23); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:33:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>There was no attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:33:56 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>No information about attrition was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>There was no attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:34:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>No information about attrition was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:48:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>The attrition rate was 24%; participants were not evenly distributed (7/18 and 0/11); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:35:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>There were no dropouts.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:35:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>The attrition rate was 11%; the participants were evenly distributed (1/7 and 1/10); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:36:00 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>The attrition rate was 9%; participants were not evenly distributed (4/21 and 0/23); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:36:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>The attrition rate was 64%; participants were not evenly distributed (6/7 and 3/7); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 22:00:15 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>The attrition rate was 25.3%, and participant distribution was 13/37 and 8/46.</P>
<P>Quote (page 186): "Both early terminators and patients who completed the full three weeks of treatment were included into the analysis" - last observation carried forward analysis was used; no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 22:02:13 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>The attrition rate was 60%; participants were evenly distributed (14/21 and 11/20).</P>
<P>Quote (page 366): "Intent-to-treat analysis."</P>
<P>No reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:37:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>There was no attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:37:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>The attrition rate was 7%, but only in 1 group (0/13 and 2/14); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>There was no attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>The attrition rate was 9%; participants were evenly distributed (1/12 and 1/10); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 22:12:57 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>The attrition rate was 5% (1 participant from 1 group (0/10 and 1/10)); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:38:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>The attrition rate was 14%: 20% in 1 group and 9% in the second (2/10 and 1/11); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>The attrition rate was 9%; participants were unevenly distributed (2/12 and 0/10); no reasons for discontinuation were given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-09-16 22:11:30 +0100" MODIFIED_BY="Laura E  Prescott" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:31:31 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>The paper reported no SDs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:31:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>The paper provided no SD for the BPRS and other ratings.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:32:21 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>There was no SD given for the BPRS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:03 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>There was no SD given for the rating scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>There was no SD given for the BPRS and CGI.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:47:09 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>TESS: no means or SDs were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>CGI was used (there were no individual numbers or means given).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:34:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>The TESS score was measured, but no means and SDs were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:48:21 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>No SDs were given for various scales (BDI, BPRS subscores, etc.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>No mean and SD was given for the GAS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>No numerical results for CGI, TRAM, and NOSIE were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:00 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>No SDs were given for the scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>There was no selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:59:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>No SDs were given for BPRS, IMPS, and PIP.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:44 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>No SDs were given for CGI and SAS; adverse effects were monitored but not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>No SDs were given for BPRS, IMPS, SCI, SRSS, and NOSIE.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>No SD was given for BPRS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>No numerical values for CGI were given, and adverse effects were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 22:11:30 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>For CGI, BPRS, and NOSIE, there were no data for the first cross-over phase; no SD was given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:57 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="NO" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>There were no data from the first cross-over phase for the adverse effects reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:19 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>There was no selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>There was no selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:31:31 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Biederman-1979">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:32:00 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Braden-1982">
<DESCRIPTION>
<P>Quote (page 71): "Nonblind attending psychiatrist made an emergency decision based on serious worsening of patient's condition."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:32:36 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Brockington-1978">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:03 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Collins-1991">
<DESCRIPTION>
<P>We found no other risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:31 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Dube-1981">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:33:56 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Feng-2006">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:34:12 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Garver-1983">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:34:53 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-He-2010">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:05 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>Data refer to the whole group of distressed participants who had entered the 2 previous trials.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:20 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Huang-1984">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:35:52 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnson-1971">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:00 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Johnstone-1988">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Mattes-1984">
<DESCRIPTION>
<P>Quote (page 446): "Regardless of prior medication, eligible patients were openly changed to combined lithium (...) and fluphenazine."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:28 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Prien-1972">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:36:44 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Schulz-1999">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:06 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Shopsin-1971">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:17 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:30 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>Different washouts (gradual versus abrupt) (page 78).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:45 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Small-1975">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:37:57 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="UNKNOWN" STUDY_ID="STD-Small-2001">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:10 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Terao-1995">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-16 21:38:46 +0100" MODIFIED_BY="Laura E  Prescott" RESULT="YES" STUDY_ID="STD-Wilson-1993">
<DESCRIPTION>
<P>We found no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-09-16 23:44:06 +0100" MODIFIED_BY="Laura E  Prescott">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-09-16 22:32:00 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-09-15 22:48:29 +0100" MODIFIED_BY="Laura E  Prescott">Lithium as sole treatment compared with placebo as sole treatment for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Lithium as sole treatment compared with placebo as sole treatment for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Setting: </B>hospital<BR/>
<B>Intervention:</B> lithium as sole treatment<BR/>
<B>Comparison: </B>placebo as sole treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>P</B>lacebo as sole treatment</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>L</B>ithium as sole treatment</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Response to treatment</B>
<BR/>clinically relevant response as defined by the authors<BR/>Follow-up: mean 3 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>458 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>380 per 1000</B>
<BR/>(202 to 710)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.83 </B>
<BR/>(0.44 to 1.55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>54<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>, </SUP>²</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Acceptability of treatment</B>
<BR/>leaving early due to any reason<BR/>Follow-up: mean 3 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>114 per 1000</B>
<BR/>(29 to 444)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.14 </B>
<BR/>(0.29 to 4.44)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>65<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>²<SUP>, </SUP>³</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on depressive symptoms </B>
<BR/>at least 50% MADRS improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>333 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>477 per 1000</B>
<BR/>(217 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.43 </B>
<BR/>(0.65 to 3.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>²<SUP>, </SUP>&#8308;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on manic symptoms </B>
<BR/>at least 50% Bech-Rafaelsen improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>278 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>286 per 1000</B>
<BR/>(106 to 781)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.03 </B>
<BR/>(0.38 to 2.81)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>²<SUP>, </SUP>&#8308;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on positive symptoms</B>
<BR/>at least 50% MS improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>430 per 1000</B>
<BR/>(220 to 845)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.44 to 1.69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>²<SUP>, </SUP>&#8308;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Kidney dysfunction</B>
</P>
<P>outcome not available in any study</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Thyroid dysfunction</B>
</P>
<P>outcome not available in any study</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g., the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MADRS:</B> Montgomery-Asberg Depression Rating Scale; <B>MS:</B> Manchester Scale; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>¹Risk of bias: there was a high risk of selective reporting in both studies.<BR/>²Imprecision: the 95% confidence interval includes both benefit and harm. Moreover, the number of events was small.<BR/>³Indirectness: acceptability was measured by the number of participants leaving the studies for any reason, which is an indirect measure of acceptability.<BR/>&#8308;Risk of bias: there was an unclear risk of performance and detection bias. Selective reporting was present.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-09-16 23:44:06 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-09-16 23:44:02 +0100" MODIFIED_BY="Laura E  Prescott">Lithium compared with antipsychotics for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Lithium compared with antipsychotics for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Setting: </B>hospital<BR/>
<B>Intervention:</B> lithium<BR/>
<B>Comparison: </B>antipsychotics</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Antipsychotics</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Lithium</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Response to treatment</B>
<BR/>clinically relevant response as defined by the authors<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>360 per 1000</B>
<BR/>(140 to 920)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.72 </B>
<BR/>(0.28 to 1.84)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>80<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>, </SUP>²</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Acceptability of treatment</B>
<BR/>leaving early due to any reason<BR/>Follow-up: mean 10.6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>139 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>246 per 1000</B>
<BR/>(140 to 432)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.77 </B>
<BR/>(1.01 to 3.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>270<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>²<SUP>, </SUP>³<SUP>, </SUP>&#8308;<SUP>, </SUP>&#8309;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on depressive symptoms </B>
<BR/>at least 50% MADRS improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>652 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>476 per 1000</B>
<BR/>(280 to 815)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.73 </B>
<BR/>(0.43 to 1.25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>²<SUP>, </SUP>&#8310;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on manic symptoms </B>
<BR/>at least 50% Bech-Rafaelsen improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>565 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>288 per 1000</B>
<BR/>(136 to 616)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.51 </B>
<BR/>(0.24 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>²<SUP>, </SUP>&#8310;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on positive symptoms </B>
<BR/>at least 50% MS improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>870 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>426 per 1000</B>
<BR/>(252 to 722)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.49 </B>
<BR/>(0.29 to 0.83)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>&#8309;<SUP>, </SUP>&#8310;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Kidney dysfunction</B>
</P>
<P>outcome not available in any study</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Thyroid dysfunction</B>
</P>
<P>outcome not available in any study</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g., the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MADRS:</B> Montgomery-Asberg Depression Rating Scale; <B>MS:</B> Manchester Scale; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>¹Risk of bias: there was a high risk of selection bias.<BR/>²Imprecision: the 95% confidence interval includes both benefit and harm. Moreover, the number of events was small.<BR/>³Risk of bias: there was a high risk of selection bias in the majority of studies. Moreover, a high risk of attrition bias was also prevalent.<BR/>&#8308;Indirectness: acceptability was measured by the number of participants leaving the studies for any reason, which is an indirect measure of acceptability.<BR/>&#8309;Imprecision: the number of events was small.<BR/>&#8310;Risk of bias: there was an unclear risk of performance and detection bias. Selective reporting was present.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2015-09-16 22:34:31 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" READONLY="YES">
<TITLE MODIFIED="2015-09-15 22:48:54 +0100" MODIFIED_BY="Laura E  Prescott">Adjunctive lithium + antipsychotics compared with placebo/no adjunctive treatment + antipsychotics for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Adjunctive lithium</B> <B>+ antipsychotics compared with placebo/no adjunctive treatment + antipsychotics for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Setting: </B>hospital<BR/>
<B>Intervention:</B> adjunctive lithium + antipsychotics<BR/>
<B>Comparison:</B> placebo/no adjunctive treatment + antipsychotics</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Placebo/no adjunctive treatment<B> + </B>antipsychotics</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adjunctive lithium + </B>antipsychotics</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Response to treatment</B>
<BR/>clinically relevant response as defined by the authors<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>228 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>413 per 1000</B>
<BR/>(251 to 677)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.81 </B>
<BR/>(1.1 to 2.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>396<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>, </SUP>²</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Acceptability of treatment</B>
<BR/>leaving early due to any reason<BR/>Follow-up: mean 10.2 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>130 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>245 per 1000</B>
<BR/>(121 to 499)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.89 </B>
<BR/>(0.93 to 3.84)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>320<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>²<SUP>, </SUP>³<SUP>, </SUP>&#8308;<SUP>, </SUP>&#8309;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on depressive symptoms</B>
<BR/>at least 50% MADRS improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>652 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>685 per 1000</B>
<BR/>(450 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.05 </B>
<BR/>(0.69 to 1.58)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>45<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>, </SUP>&#8310;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on manic symptoms </B>
<BR/>at least 50% Bech-Rafaelsen improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>565 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>639 per 1000</B>
<BR/>(396 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.13 </B>
<BR/>(0.7 to 1.82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>45<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>, </SUP>&#8310;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response on positive symptoms </B>
<BR/>at least 50% MS improvement<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>870 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>730 per 1000</B>
<BR/>(539 to 983)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.84 </B>
<BR/>(0.62 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>45<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>¹<SUP>, </SUP>&#8310;</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Kidney dysfunction</B>
</P>
<P>outcome not available in any study</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Thyroid dysfunction</B>
</P>
<P>outcome not available in any study</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MADRS:</B> Montgomery-Asberg Depression Rating Scale; <B>MS:</B> Manchester Scale; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>¹Risk of bias: there was a high risk of reporting bias.<BR/>²Imprecision: there was a small number of events.<BR/>³Risk of bias: there was high reporting and attrition bias and some evidence of performance bias.<BR/>&#8308;Inconsistency: there were differences between studies (number of events, effects sizes).<BR/>&#8309;Indirectness: acceptability was measured by the number of participants leaving the studies for any reason, which is an indirect measure of acceptability.<BR/>&#8310;Imprecision: the 95% confidence interval includes both benefit and harm. Moreover, the number of events was small.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-09-16 22:36:15 +0100" MODIFIED_BY="Laura E  Prescott">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-09-16 22:36:15 +0100" MODIFIED_BY="Laura E  Prescott" NO="1">
<TITLE MODIFIED="2013-10-30 10:44:24 +0000" MODIFIED_BY="[Empty name]">Suggested study design</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH VALIGN="TOP">
<P>Methods</P>
</TH>
<TD>
<P>
<B>Allocation</B>: random (with details of the specific randomisation method).<BR/>
<B>Blinding</B>: double-blind (blind or independent raters).<BR/>
<B>Duration</B>: over 26 weeks.<BR/>
</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Participants</P>
</TH>
<TD>
<P>
<B>Diagnosis</B>: people with schizophrenia without prominent affective symptoms; people with schizoaffective disorders; and people with treatment-resistant schizophrenia.<BR/>
<B>Age</B>: adults.<BR/>
<B>Sex</B>: male and female.</P>
<P>
<B>N</B> = 750*.<BR/>
</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Interventions</P>
</TH>
<TD>
<OL>
<LI>Lithium alone: any dose.</LI>
<LI>Placebo (or no intervention).</LI>
<LI>Lithium in combination with any antipsychotic treatment: any dose.</LI>
<LI>Placebo (or no intervention) in combination with any antipsychotic treatment.</LI>
<LI>Antipsychotics alone: any dose.</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TD>
<P>Clinically significant response** (including relapse), leaving the study early**, service utilisation, behaviour, adverse events, and economic outcomes.<BR/>All outcomes grouped by time - short-term (up to 12 weeks), medium-term (13 to 26 weeks), and long-term (over 26 weeks).</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Notes</P>
</TH>
<TD>
<P>*150 in each arm.</P>
<P>**primary outcomes of interest.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-09-29 12:17:50 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-09-16 23:14:07 +0100" MODIFIED_BY="Laura E  Prescott" NO="1">
<NAME>Lithium as sole treatment versus placebo as sole treatment</NAME>
<DICH_OUTCOME CHI2="0.07596698824891507" CI_END="1.5478478783122296" CI_START="0.4420671058871735" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8271956430730818" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.18972827620739247" LOG_CI_START="-0.354511799645525" LOG_EFFECT_SIZE="-0.08239176171906623" METHOD="MH" MODIFIED="2015-09-15 22:12:19 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.7828391127462309" P_Q="1.0" P_Z="0.5528917196009059" Q="0.0" RANDOM="YES" SCALE="11.87" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.59343254110459">
<NAME>Clinically significant response</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.526070197838073" CI_START="0.1260452627168186" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5472909540864592" LOG_CI_START="-0.8994734721978217" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-03-07 13:13:40 +0000" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.8498365855987975" STUDY_ID="STD-Garver-1983" TOTAL_1="9" TOTAL_2="6" VAR="0.7222222222222222" WEIGHT="14.150943396226413"/>
<DICH_DATA CI_END="1.6855655438330195" CI_START="0.43587381116032275" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.22674564488520413" LOG_CI_START="-0.3606392241464306" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-03-07 13:13:10 +0000" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.3450327796711771" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.11904761904761904" WEIGHT="85.84905660377358"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.444461774072338" CI_START="0.2938764051474398" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.6478191752717338" LOG_CI_START="-0.5318352813163605" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" MODIFIED="2014-01-27 14:19:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8471907093730773" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.1927041038752425">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="108" O_E="0.0" SE="0.0" STUDY_ID="STD-Garver-1983" TOTAL_1="9" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.444461774072338" CI_START="0.2938764051474398" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6478191752717338" LOG_CI_START="-0.5318352813163605" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="109" O_E="0.0" SE="0.6929348671835831" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.48015873015873" WEIGHT="100.00000000000001"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="110" O_E="0.0" SE="0.0" STUDY_ID="STD-Simpson-1976" TOTAL_1="5" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.14973847140507568" CI_END="1.356542895805419" CI_START="0.6045080234809659" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9055611877231045" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.132433531320647" LOG_CI_START="-0.21859793048495582" LOG_EFFECT_SIZE="-0.04308219958215444" METHOD="MH" MODIFIED="2015-09-15 22:13:14 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="0.6987855642420515" P_Q="0.7102793180911875" P_Z="0.6304497161113995" Q="0.13799822752441745" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="24" WEIGHT="200.0" Z="0.4810939687369156">
<NAME>Mental state: 1. General - at least 20% MS or NH improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.400102612676391" CI_START="0.6085775415334511" DF="0" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.14615986602541753" LOG_CI_START="-0.21568407854384142" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2015-09-15 20:30:26 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.7064821387807334" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="99.99999999999999" Z="0.3765848638197609">
<NAME>At least 20% MS improvement</NAME>
<DICH_DATA CI_END="1.400102612676391" CI_START="0.6085775415334511" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.14615986602541753" LOG_CI_START="-0.21568407854384142" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2014-03-07 13:15:01 +0000" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.21254892419639573" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.04517704517704518" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.526070197838073" CI_START="0.12604526271681865" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.5472909540864592" LOG_CI_START="-0.8994734721978215" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-09-15 20:30:32 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.6332841521025252" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="100.0" Z="0.47710949961335497">
<NAME>At least 20% NH improvement</NAME>
<DICH_DATA CI_END="3.526070197838073" CI_START="0.1260452627168186" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5472909540864592" LOG_CI_START="-0.8994734721978217" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-03-07 13:15:07 +0000" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.8498365855987975" STUDY_ID="STD-Garver-1983" TOTAL_1="9" TOTAL_2="6" VAR="0.7222222222222222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07869731598899765" CI_END="1.4752609938592949" CI_START="0.4692800432486873" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8320520073897973" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.16886885974868202" LOG_CI_START="-0.32856791433909127" LOG_EFFECT_SIZE="-0.07984952729520459" METHOD="MH" MODIFIED="2015-09-15 20:30:46 +0100" MODIFIED_BY="Laura E  Prescott" NO="4" P_CHI2="0.7790705997843469" P_Q="0.7812490663973296" P_Z="0.529195528742649" Q="0.07711266157589139" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="24" WEIGHT="200.0" Z="0.6292345312352562">
<NAME>Mental state: 2. General - at least 35% MS or NH improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9890751884655055E-31" CI_END="1.5773196652330823" CI_START="0.46578629160909735" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="100.0" ID="CMP-001.04.01" LOG_CI_END="0.19791971791866744" LOG_CI_START="-0.3318132971798939" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2015-09-15 20:30:36 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.0" P_Z="0.6203219832758511" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.00000000000001" Z="0.4953940676405382">
<NAME>At least 35% MS improvement</NAME>
<DICH_DATA CI_END="1.5773196652330823" CI_START="0.46578629160909735" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.19791971791866744" LOG_CI_START="-0.3318132971798939" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-03-07 13:15:41 +0000" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.09682539682539684" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.526070197838073" CI_START="0.12604526271681865" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.5472909540864592" LOG_CI_START="-0.8994734721978215" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-09-15 20:30:46 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.6332841521025252" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="100.0" Z="0.47710949961335497">
<NAME>At least 35% NH improvement</NAME>
<DICH_DATA CI_END="3.526070197838073" CI_START="0.1260452627168186" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5472909540864592" LOG_CI_START="-0.8994734721978217" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-03-07 13:15:45 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.8498365855987975" STUDY_ID="STD-Garver-1983" TOTAL_1="9" TOTAL_2="6" VAR="0.7222222222222222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07596698824891507" CI_END="1.5478478783122296" CI_START="0.4420671058871735" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8271956430730818" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.18972827620739247" LOG_CI_START="-0.354511799645525" LOG_EFFECT_SIZE="-0.08239176171906623" METHOD="MH" MODIFIED="2015-09-15 22:14:32 +0100" MODIFIED_BY="Laura E  Prescott" NO="5" P_CHI2="0.7828391127462309" P_Q="0.7840850167521138" P_Z="0.5528917196009059" Q="0.07507572334558482" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="24" WEIGHT="200.0" Z="0.59343254110459">
<NAME>Mental state: 3. General - at least 50% MS or NH improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6855655438330195" CI_START="0.43587381116032275" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.22674564488520413" LOG_CI_START="-0.3606392241464306" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2015-09-15 20:30:53 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.6550403300289569" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.446771115411605">
<NAME>At least 50% MS improvement</NAME>
<DICH_DATA CI_END="1.6855655438330195" CI_START="0.43587381116032275" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.22674564488520413" LOG_CI_START="-0.3606392241464306" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-03-07 13:16:13 +0000" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.3450327796711771" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.11904761904761904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.526070197838073" CI_START="0.12604526271681865" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.5472909540864592" LOG_CI_START="-0.8994734721978215" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-09-15 20:30:57 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.6332841521025252" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="100.0" Z="0.47710949961335497">
<NAME>At least 50% NH improvement</NAME>
<DICH_DATA CI_END="3.526070197838073" CI_START="0.1260452627168186" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5472909540864592" LOG_CI_START="-0.8994734721978217" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-03-07 13:16:19 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.8498365855987975" STUDY_ID="STD-Garver-1983" TOTAL_1="9" TOTAL_2="6" VAR="0.7222222222222222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.884776979015369" CI_START="-2.884776979015369" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2015-09-16 22:58:02 +0100" MODIFIED_BY="Laura E  Prescott" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Mental state: 4. General - mean MS global score at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.884776979015369" CI_START="-2.884776979015369" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="6.7" ORDER="119" SD_1="4.86" SD_2="4.33" SE="1.471852034920091" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.07" MODIFIED="2015-09-16 23:14:07 +0100" MODIFIED_BY="Laura E  Prescott" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 5. General - unable to use (skewed data)</NAME>
<TR>
<TH>
<P>Mean + SD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-09-16 23:14:07 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="299" STUDY_ID="STD-Garver-1983">
<TR>
<TD>
<P>NH global score at endpoint - high = poor.<BR/>Lithium: mean = 13.8, SD = 7.2. N = 9.<BR/>Placebo: mean = 13.2, SD = 7.8. N = 6.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.3865043971843396" CI_END="1.741550979246444" CI_START="0.8304481933667834" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2026087744446912" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.2409361917895892" LOG_CI_START="-0.08068745536998102" LOG_EFFECT_SIZE="0.08012436820980409" METHOD="MH" MODIFIED="2015-09-15 22:15:30 +0100" MODIFIED_BY="Laura E  Prescott" NO="8" P_CHI2="0.8242741284838206" P_Q="0.8253529834004845" P_Z="0.32879171931530704" Q="0.3838883937881836" RANDOM="YES" SCALE="29.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="54" WEIGHT="300.0" Z="0.9765505575361371">
<NAME>Mental state: 6. Specific - depression - various degrees of MADRS improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.191365163185903" CI_START="0.6995090751399629" DF="0" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.34071475325332495" LOG_CI_START="-0.15520664677952745" LOG_EFFECT_SIZE="0.09275405323689871" MODIFIED="2015-09-15 20:31:04 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.4634615013439827" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.7331589391076461">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="2.191365163185903" CI_START="0.6995090751399629" EFFECT_SIZE="1.2380952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.34071475325332495" LOG_CI_START="-0.15520664677952745" LOG_EFFECT_SIZE="0.09275405323689871" MODIFIED="2014-03-07 13:17:26 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.291306685229819" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.08485958485958486" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9400761072506159" CI_START="0.5657023788049087" DF="0" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.2878187672037567" LOG_CI_START="-0.2474119950271827" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2015-09-15 20:31:14 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.8823698026036718" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.14796574447159488">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="1.9400761072506159" CI_START="0.5657023788049087" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.2878187672037567" LOG_CI_START="-0.2474119950271827" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2014-03-07 13:17:29 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.3143971991694564" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.09884559884559885" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.155571931675174" CI_START="0.6467342119649353" DF="0" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.49907808442318385" LOG_CI_START="-0.1892741644516975" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2015-09-15 20:31:21 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.37771566667040946" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="99.99999999999999" Z="0.8821130844068925">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="3.155571931675174" CI_START="0.6467342119649353" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.49907808442318385" LOG_CI_START="-0.1892741644516975" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2014-03-07 13:17:42 +0000" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.40434151838769106" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.1634920634920635" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.060394625778891715" CI_END="1.5476662089798312" CI_START="0.7017881495436813" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0421774344665309" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.18967730051388415" LOG_CI_START="-0.1537939695934537" LOG_EFFECT_SIZE="0.017941665460215247" METHOD="MH" MODIFIED="2015-09-16 22:58:12 +0100" MODIFIED_BY="Laura E  Prescott" NO="9" P_CHI2="0.9702540712299162" P_Q="0.9712924041402733" P_Z="0.8377576862822205" Q="0.05825543816482375" RANDOM="YES" SCALE="48.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="54" WEIGHT="300.0" Z="0.20476250088514686">
<NAME>Mental state: 7. Specific - mania - various degrees of Bech-Rafaelsen Mania Scale improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.667424369124828" CI_START="0.6154058363792154" DF="0" EFFECT_SIZE="1.0129870129870129" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.22204614434771586" LOG_CI_START="-0.21083838931171897" LOG_EFFECT_SIZE="0.0056038775179984845" MODIFIED="2015-09-15 20:31:26 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.959528588118257" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.050745162993934806">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="1.667424369124828" CI_START="0.6154058363792154" EFFECT_SIZE="1.0129870129870129" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.22204614434771586" LOG_CI_START="-0.21083838931171897" LOG_EFFECT_SIZE="0.0056038775179984845" MODIFIED="2014-03-07 13:18:03 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.25427851788455247" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.06465756465756467" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.676374127424099" CI_START="0.4880193824906988" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.42754682289202295" LOG_CI_START="-0.3115629289366495" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2015-09-15 20:31:30 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.7584133933171834" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.3075649514524864">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="2.676374127424099" CI_START="0.4880193824906988" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.42754682289202295" LOG_CI_START="-0.3115629289366495" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-07 13:18:08 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.4341567268764397" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.18849206349206346" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.812993893633129" CI_START="0.3760972201425789" DF="0" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.44916878941215616" LOG_CI_START="-0.424699876578133" LOG_EFFECT_SIZE="0.012234456417011586" MODIFIED="2015-09-15 20:31:35 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.9562338143766461" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.05488031527161801">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="2.812993893633129" CI_START="0.3760972201425789" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.44916878941215616" LOG_CI_START="-0.424699876578133" LOG_EFFECT_SIZE="0.012234456417011586" MODIFIED="2014-03-07 13:18:15 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.5133147801223569" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.26349206349206356" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06114127778359948" CI_END="1.7390467198863389" CI_START="0.6319999830713898" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0483689701286099" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.2403112495796414" LOG_CI_START="-0.19928293335052968" LOG_EFFECT_SIZE="0.020514158114555835" METHOD="MH" MODIFIED="2015-09-15 22:17:01 +0100" MODIFIED_BY="Laura E  Prescott" NO="10" P_CHI2="0.9698919177740337" P_Q="0.9698956419509264" P_Z="0.854854624469842" Q="0.06113359822712366" RANDOM="YES" SCALE="43.460925935436336" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="54" WEIGHT="300.0" Z="0.18292785773316936">
<NAME>Mental state: 8. Specific - negative symptoms - various degrees of MS-negative subscore improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.676374127424099" CI_START="0.4880193824906988" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.42754682289202295" LOG_CI_START="-0.3115629289366495" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2015-09-15 20:31:41 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.7584133933171834" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.3075649514524864">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="2.676374127424099" CI_START="0.4880193824906988" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.42754682289202295" LOG_CI_START="-0.3115629289366495" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-07 13:18:36 +0000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.4341567268764397" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.18849206349206346" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4359258116338616" CI_START="0.41052153362965704" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.38666405732345305" LOG_CI_START="-0.38666405732345305" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-15 20:31:51 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.0">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="2.4359258116338616" CI_START="0.41052153362965704" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.38666405732345305" LOG_CI_START="-0.38666405732345305" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 13:18:40 +0000" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.45425676257949793" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.20634920634920637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4359258116338616" CI_START="0.41052153362965704" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.38666405732345305" LOG_CI_START="-0.38666405732345305" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-15 20:31:56 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.0">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="2.4359258116338616" CI_START="0.41052153362965704" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.38666405732345305" LOG_CI_START="-0.38666405732345305" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 13:18:45 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.45425676257949793" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.20634920634920637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5070948509142882" CI_END="1.0645087601369256" CI_START="0.541880453968924" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7594975248128816" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.027149239718421616" LOG_CI_START="-0.26609651403011697" LOG_EFFECT_SIZE="-0.11947363715584772" METHOD="MH" MODIFIED="2015-09-16 22:58:20 +0100" MODIFIED_BY="Laura E  Prescott" NO="11" P_CHI2="0.7760429505716103" P_Q="0.7826960660189561" P_Z="0.11025462243638581" Q="0.4900216703971951" RANDOM="YES" SCALE="46.83" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="54" WEIGHT="300.0" Z="1.5970497300245046">
<NAME>Mental state: 9. Specific - positive symptoms - various degrees of MS-positive subscore improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.084824554419101" CI_START="0.4180961929702113" DF="0" EFFECT_SIZE="0.673469387755102" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.0353595066557645" LOG_CI_START="-0.3787237869570169" LOG_EFFECT_SIZE="-0.1716821401506262" MODIFIED="2015-09-15 20:32:03 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.10411302969982959" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="1.6252324915027627">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="1.084824554419101" CI_START="0.4180961929702113" EFFECT_SIZE="0.673469387755102" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.0353595066557645" LOG_CI_START="-0.3787237869570169" LOG_EFFECT_SIZE="-0.1716821401506262" MODIFIED="2014-03-07 13:19:08 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.24323457641350904" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.05916305916305917" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6855655438330195" CI_START="0.43587381116032275" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.22674564488520413" LOG_CI_START="-0.3606392241464306" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2015-09-15 20:32:06 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.6550403300289569" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.446771115411605">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="1.6855655438330195" CI_START="0.43587381116032275" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.22674564488520413" LOG_CI_START="-0.3606392241464306" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-03-07 13:19:15 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.3450327796711771" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.11904761904761904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6855655438330195" CI_START="0.43587381116032275" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="0.22674564488520413" LOG_CI_START="-0.3606392241464306" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2015-09-15 20:32:11 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.6550403300289569" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.446771115411605">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="1.6855655438330195" CI_START="0.43587381116032275" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.22674564488520413" LOG_CI_START="-0.3606392241464306" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2014-03-07 13:19:17 +0000" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.3450327796711771" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="18" VAR="0.11904761904761904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.12" MODIFIED="2015-09-16 23:05:49 +0100" MODIFIED_BY="Laura E  Prescott" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events: 1. Movement disorder - unable to use (skewed data)</NAME>
<TR>
<TH>
<P>Mean + SD</P>
</TH>
<TH>
<P>Mean + SD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-09-16 23:05:49 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="312" STUDY_ID="STD-Johnstone-1988">
<TR>
<TD>
<P>AIMS global score at endpoint - high = poor.<BR/>Placebo: mean = 2.1, SD = 2.2. N = 18.<BR/>Lithium: mean = 3.1, SD = 2.7. N = 21.</P>
</TD>
<TD>
<P>TAKE global score at endpoint - high = poor.<BR/>Placebo: mean = 2.5, SD = 1.9. N = 18.<BR/>Lithium: mean = 3.2, SD = 2.4. N = 21.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-09-29 12:15:53 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Lithium versus antipsychotics</NAME>
<DICH_OUTCOME CHI2="3.015415033958895" CI_END="1.8404219054625672" CI_START="0.2832722760554922" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7220391277920937" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="33.674138469282994" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.2649173937760339" LOG_CI_START="-0.5477959279338296" LOG_EFFECT_SIZE="-0.1414392670788978" METHOD="MH" MODIFIED="2015-09-15 22:18:10 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.2214170633316933" P_Q="1.0" P_Z="0.4951135021207642" Q="0.0" RANDOM="YES" SCALE="157.62" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.27345096429192245" TOTALS="YES" TOTAL_1="36" TOTAL_2="44" WEIGHT="100.00000000000001" Z="0.6821984138051249">
<NAME>Clinically significant response</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.621372781805979" CI_START="0.4421309044426735" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9832370417913192" LOG_CI_START="-0.3544491273473939" LOG_EFFECT_SIZE="0.31439395722196267" MODIFIED="2014-03-07 13:20:11 +0000" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.7857634774054101" STUDY_ID="STD-Brockington-1978" TOTAL_1="8" TOTAL_2="11" VAR="0.6174242424242423" WEIGHT="25.581917184769637"/>
<DICH_DATA CI_END="3.2946765817006547" CI_START="0.011711068663848304" EFFECT_SIZE="0.19642857142857142" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.5178127889826789" LOG_CI_START="-1.9314034726786298" LOG_EFFECT_SIZE="-0.7067953418479754" MODIFIED="2014-03-07 13:20:12 +0000" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="1.4386817559158782" STUDY_ID="STD-Johnson-1971" TOTAL_1="7" TOTAL_2="10" VAR="2.0698051948051948" WEIGHT="9.725908826356745"/>
<DICH_DATA CI_END="1.0053155099914903" CI_START="0.33442741798168957" EFFECT_SIZE="0.5798319327731093" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.002302382894889808" LOG_CI_START="-0.4756981242054406" LOG_EFFECT_SIZE="-0.2366978706552754" MODIFIED="2014-03-07 13:20:17 +0000" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.2807798640114048" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.07883733203426299" WEIGHT="64.69217398887363"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.880551700988648" CI_END="3.189538774391547" CI_START="1.2221516344816938" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.974360662686878" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5037278861233913" LOG_CI_START="0.08712509292223554" LOG_EFFECT_SIZE="0.2954264895228134" METHOD="MH" MODIFIED="2015-09-15 22:18:44 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="0.4452246560597555" P_Q="0.6570236567947055" P_Z="0.005440118577163091" Q="0.840070558098097" RANDOM="YES" SCALE="275.13" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="296" TOTAL_2="330" WEIGHT="300.0" Z="2.7797474668597957">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.154851265809983" CI_END="3.1113246515231503" CI_START="1.0102802276888523" DF="5" EFFECT_SIZE="1.7729381764051297" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" I2="18.763268451751994" ID="CMP-002.02.01" LOG_CI_END="0.4929453299800481" LOG_CI_START="0.004441853444877126" LOG_EFFECT_SIZE="0.24869359171246258" NO="1" P_CHI2="0.2914416262904559" P_Z="0.045976715079485156" STUDIES="8" TAU2="0.0929934089696605" TOTAL_1="126" TOTAL_2="144" WEIGHT="100.00000000000001" Z="1.9956070175776603">
<NAME>Overall</NAME>
<DICH_DATA CI_END="9.778912453978492" CI_START="0.8017251444776294" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9902905581108251" LOG_CI_START="-0.09597449542638684" LOG_EFFECT_SIZE="0.4471580313422192" ORDER="134" O_E="0.0" SE="0.6380774695464941" STUDY_ID="STD-Braden-1982" TOTAL_1="5" TOTAL_2="7" VAR="0.4071428571428572" WEIGHT="16.463500234992644"/>
<DICH_DATA CI_END="1.7086977117497668" CI_START="0.12294125695839199" EFFECT_SIZE="0.4583333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.23266523783425758" LOG_CI_START="-0.9103023509410194" LOG_EFFECT_SIZE="-0.338818556553381" ORDER="135" O_E="0.0" SE="0.6713848194274098" STUDY_ID="STD-Brockington-1978" TOTAL_1="8" TOTAL_2="11" VAR="0.4507575757575757" WEIGHT="15.142949191719126"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Dube-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="19.196915244833633" CI_START="0.1063095971671723" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.283231447465077" LOG_CI_START="-0.9734275274935905" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="137" O_E="0.0" SE="1.325572652532805" STUDY_ID="STD-Johnson-1971" TOTAL_1="7" TOTAL_2="10" VAR="1.7571428571428571" WEIGHT="4.450479505476069"/>
<DICH_DATA CI_END="172.109750484579" CI_START="0.5600885129602998" EFFECT_SIZE="9.818181818181818" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.235805474985875" LOG_CI_START="-0.2517433343284256" LOG_EFFECT_SIZE="0.9920310703287246" ORDER="138" O_E="0.0" SE="1.461198484156417" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="2.1351010101010104" WEIGHT="3.6955316903069773"/>
<DICH_DATA CI_END="4.955183529843845" CI_START="0.8072354890407164" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.695059744496845" LOG_CI_START="-0.0929997531688827" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="139" O_E="0.0" SE="0.46291004988627577" STUDY_ID="STD-Mattes-1984" TOTAL_1="7" TOTAL_2="7" VAR="0.2142857142857143" WEIGHT="26.79646260194721"/>
<DICH_DATA CI_END="4.350402875946654" CI_START="0.9381871245774615" EFFECT_SIZE="2.02027027027027" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.638529477345151" LOG_CI_START="-0.02771053148620657" LOG_EFFECT_SIZE="0.30540947292947224" ORDER="140" O_E="0.0" SE="0.39135267912877164" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.1531569194612673" WEIGHT="33.45107677555798"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="141" O_E="0.0" SE="0.0" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.21190210481675" CI_START="0.08045292722382011" DF="0" EFFECT_SIZE="1.2432432432432432" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="1.2835703650038697" LOG_CI_START="-1.0944581497747115" LOG_EFFECT_SIZE="0.09455610761457907" NO="2" P_CHI2="1.0" P_Z="0.8761388651311312" STUDIES="4" TAU2="0.0" TOTAL_1="85" TOTAL_2="93" WEIGHT="100.0" Z="0.15586572178687635">
<NAME>Due to adverse events</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="142" O_E="0.0" SE="0.0" STUDY_ID="STD-Dube-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="143" O_E="0.0" SE="0.0" STUDY_ID="STD-Mattes-1984" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="19.21190210481675" CI_START="0.08045292722382011" EFFECT_SIZE="1.2432432432432432" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2835703650038697" LOG_CI_START="-1.0944581497747115" LOG_EFFECT_SIZE="0.09455610761457907" ORDER="144" O_E="0.0" SE="1.396865721011934" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="1.9512338425381903" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="145" O_E="0.0" SE="0.0" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8467140064414738" CI_END="7.669310756582739" CI_START="1.0912390755847514" DF="1" EFFECT_SIZE="2.89293131276661" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.8847563355183355" LOG_CI_START="0.03791990900502719" LOG_EFFECT_SIZE="0.4613381222616814" NO="3" P_CHI2="0.3574836723771042" P_Z="0.03272086276409996" STUDIES="4" TAU2="0.0" TOTAL_1="85" TOTAL_2="93" WEIGHT="100.0" Z="2.135491757366018">
<NAME>Due to inefficacy of treatment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="146" O_E="0.0" SE="0.0" STUDY_ID="STD-Dube-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="37.764265975213235" CI_START="0.9532821324695883" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5770810477247645" LOG_CI_START="-0.02077854695747745" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="147" O_E="0.0" SE="0.938590635448906" STUDY_ID="STD-Mattes-1984" TOTAL_1="7" TOTAL_2="7" VAR="0.8809523809523812" WEIGHT="28.088065683845105"/>
<DICH_DATA CI_END="6.869146207798808" CI_START="0.689105239942718" EFFECT_SIZE="2.175675675675676" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8369027603077874" LOG_CI_START="-0.1617144477060403" LOG_EFFECT_SIZE="0.3375941563008736" ORDER="148" O_E="0.0" SE="0.5865926912222256" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.3440909853953332" WEIGHT="71.9119343161549"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="149" O_E="0.0" SE="0.0" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.887542415216901" CI_END="5.9759604169229" CI_START="0.06407591583462205" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6188013709630779" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="85.48103315065381" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.7764077121726546" LOG_CI_START="-1.1933051777448853" LOG_EFFECT_SIZE="-0.2084487327861154" METHOD="MH" MODIFIED="2015-09-16 22:58:28 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="0.008679917490904354" P_Q="1.0" P_Z="0.6782633766772691" Q="0.0" RANDOM="YES" SCALE="75.67" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.2963964139006183" TOTALS="YES" TOTAL_1="15" TOTAL_2="21" WEIGHT="99.99999999999999" Z="0.41483407147820756">
<NAME>Global state: 1. Improved CGI</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.436587603566429" CI_START="0.6658499338828099" EFFECT_SIZE="1.71875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6470490613919536" LOG_CI_START="-0.1766236390432778" LOG_EFFECT_SIZE="0.23521271117433787" MODIFIED="2014-03-07 13:20:44 +0000" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.483829421481279" STUDY_ID="STD-Brockington-1978" TOTAL_1="8" TOTAL_2="11" VAR="0.2340909090909091" WEIGHT="52.90258479882184"/>
<DICH_DATA CI_END="0.8359309703246265" CI_START="0.046157141011877505" EFFECT_SIZE="0.19642857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.0778295843371591" LOG_CI_START="-1.3357610993587918" LOG_EFFECT_SIZE="-0.7067953418479754" MODIFIED="2014-03-07 13:20:52 +0000" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.7389151987851319" STUDY_ID="STD-Johnson-1971" TOTAL_1="7" TOTAL_2="10" VAR="0.5459956709956709" WEIGHT="47.097415201178144"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="37.764265975213235" CI_START="0.9532821324695883" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.5770810477247645" LOG_CI_START="-0.02077854695747745" LOG_EFFECT_SIZE="0.7781512503836436" METHOD="MH" MODIFIED="2015-09-29 12:14:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.05626347349915768" Q="0.0" RANDOM="YES" SCALE="86.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="7" TOTAL_2="7" WEIGHT="0.0" Z="1.908989288361159">
<NAME>Global state: 2. Relapse</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotic</GRAPH_LABEL_2>
<DICH_DATA CI_END="37.764265975213235" CI_START="0.9532821324695883" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5770810477247645" LOG_CI_START="-0.02077854695747745" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="155" O_E="0.0" SE="0.938590635448906" STUDY_ID="STD-Mattes-1984" TOTAL_1="7" TOTAL_2="7" VAR="0.8809523809523812" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7441377908251703" CI_END="0.8526812947136235" CI_START="0.52233185124057" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.667369911807517" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.06921326403881646" LOG_CI_START="-0.2820534905400741" LOG_EFFECT_SIZE="-0.17563337728944528" METHOD="MH" MODIFIED="2015-09-16 22:58:38 +0100" MODIFIED_BY="Laura E  Prescott" NO="5" P_CHI2="0.6893068923673291" P_Q="0.7144426244074689" P_Z="0.0012177880380015256" Q="0.6725053744389304" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="69" WEIGHT="300.0" Z="3.2346807709153964">
<NAME>Mental state: 1. General - various degrees of MS global score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0132674801077586" CI_START="0.5261510723410486" DF="0" EFFECT_SIZE="0.7301587301587301" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.005724104591239424" LOG_CI_START="-0.2788895401352547" LOG_EFFECT_SIZE="-0.13658271777200764" MODIFIED="2015-09-15 20:32:18 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.059954643132800564" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="99.99999999999999" Z="1.8811270134359401">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="1.0132674801077586" CI_START="0.5261510723410486" EFFECT_SIZE="0.7301587301587301" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.005724104591239424" LOG_CI_START="-0.2788895401352547" LOG_EFFECT_SIZE="-0.13658271777200764" MODIFIED="2014-03-07 13:21:11 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.16718346377260584" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.02795031055900621" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0007934078873804" CI_START="0.3699368858423629" DF="0" EFFECT_SIZE="0.6084656084656085" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="3.444360463111502E-4" LOG_CI_START="-0.4318723636855761" LOG_EFFECT_SIZE="-0.21576396381963245" MODIFIED="2015-09-16 22:58:38 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.05036626244190408" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.9568401714621453">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="1.0007934078873804" CI_START="0.3699368858423629" EFFECT_SIZE="0.6084656084656085" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="3.444360463111502E-4" LOG_CI_START="-0.4318723636855761" LOG_EFFECT_SIZE="-0.21576396381963245" MODIFIED="2014-03-07 13:21:18 +0000" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.25388628767017474" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.06445824706694273" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0053155099914903" CI_START="0.33442741798168957" DF="0" EFFECT_SIZE="0.5798319327731093" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="0.002302382894889808" LOG_CI_START="-0.4756981242054406" LOG_EFFECT_SIZE="-0.2366978706552754" MODIFIED="2015-09-15 20:32:27 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.05224822465525806" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.9410828851036563">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="1.0053155099914903" CI_START="0.33442741798168957" EFFECT_SIZE="0.5798319327731093" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.002302382894889808" LOG_CI_START="-0.4756981242054406" LOG_EFFECT_SIZE="-0.2366978706552754" MODIFIED="2014-03-07 13:21:29 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.2807798640114048" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.07883733203426299" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="12.237204807949723" CI_END="7.416651708899018" CI_START="3.059028438187497" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="5.237840073543257" ESTIMABLE="YES" I2="67.3127968128681" I2_Q="77.97621914000581" ID="CMP-002.06" MODIFIED="2015-09-16 22:58:43 +0100" MODIFIED_BY="Laura E  Prescott" NO="6" P_CHI2="0.015671856954954544" P_Q="0.010667592189488428" P_Z="2.4561948714787926E-6" Q="9.081092900052258" RANDOM="YES" SCALE="129.05" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="19.326641308946062" TOTALS="SUB" TOTAL_1="74" TOTAL_2="73" UNITS="" WEIGHT="300.0" Z="4.71173264101335">
<NAME>Mental state: 2. General - BPRS/MS global score at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1494386607721325" CI_END="14.14551469225233" CI_START="6.318465424715902" DF="2" EFFECT_SIZE="10.231990058484117" ESTIMABLE="YES" I2="6.95245058625913" ID="CMP-002.06.01" NO="1" P_CHI2="0.3413937747869824" P_Z="2.9854080594247835E-7" STUDIES="3" TAU2="0.9677886095076583" TOTAL_1="47" TOTAL_2="45" WEIGHT="100.0" Z="5.124365854697851">
<NAME>Mean BPRS at endpoint</NAME>
<CONT_DATA CI_END="18.220301818814697" CI_START="3.139698181185304" EFFECT_SIZE="10.68" ESTIMABLE="YES" MEAN_1="32.28" MEAN_2="21.6" ORDER="159" SD_1="14.9" SD_2="14.9" SE="3.847163457232701" STUDY_ID="STD-Dube-1981" TOTAL_1="30" TOTAL_2="30" WEIGHT="25.2842928018139"/>
<CONT_DATA CI_END="13.384537042897643" CI_START="-5.6045370428976415" EFFECT_SIZE="3.8900000000000006" ESTIMABLE="YES" MEAN_1="34.5" MEAN_2="30.61" ORDER="160" SD_1="8.0" SD_2="8.0" SE="4.844240566555987" STUDY_ID="STD-Johnson-1971" TOTAL_1="6" TOTAL_2="5" WEIGHT="16.316886778477105"/>
<CONT_DATA CI_END="16.554289264105307" CI_START="7.065710735894699" EFFECT_SIZE="11.810000000000002" ESTIMABLE="YES" MEAN_1="66.47" MEAN_2="54.66" ORDER="161" SD_1="5.54" SD_2="5.54" SE="2.420600226089689" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" WEIGHT="58.39882041970899"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.624337765929676" CI_START="0.3756622340703246" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" NO="2" P_CHI2="1.0" P_Z="0.02505691940787746" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="2.240524078095261">
<NAME>Mean MS at endpoint</NAME>
<CONT_DATA CI_END="5.624337765929676" CI_START="0.3756622340703246" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="3.7" ORDER="162" SD_1="4.86" SD_2="3.92" SE="1.338972443692903" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="77.29452495632633" CI_START="-81.29452495632633" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.03" NO="3" P_CHI2="1.0" P_Z="0.9605726048447643" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="5" WEIGHT="100.0" Z="0.04943503944615493">
<NAME>Mean SCI at endpoint</NAME>
<CONT_DATA CI_END="77.29452495632633" CI_START="-81.29452495632633" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="143.0" MEAN_2="145.0" ORDER="163" SD_1="63.7" SD_2="69.3" SE="40.457133693165495" STUDY_ID="STD-Johnson-1971" TOTAL_1="6" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.13493362346194898" CI_END="0.9775404479897661" CI_START="0.5746885338497296" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7495207047400669" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.009865263624851985" LOG_CI_START="-0.24056746779664512" LOG_EFFECT_SIZE="-0.12521636571074854" METHOD="MH" MODIFIED="2015-09-16 22:59:06 +0100" MODIFIED_BY="Laura E  Prescott" NO="7" P_CHI2="0.934758754138029" P_Q="0.9357918073732305" P_Z="0.03337129653358929" Q="0.13272453222164343" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="69" WEIGHT="300.0" Z="2.12758753605415">
<NAME>Mental state: 3. Specific - depression - various degrees of MADRS improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1785125499123223" CI_START="0.5309144738805832" DF="0" EFFECT_SIZE="0.791005291005291" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.07133421166191202" LOG_CI_START="-0.27497543468750335" LOG_EFFECT_SIZE="-0.10182061151279567" MODIFIED="2015-09-15 20:32:43 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.2491066820046116" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.00000000000001" Z="1.1525219326265572">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="1.1785125499123223" CI_START="0.5309144738805832" EFFECT_SIZE="0.791005291005291" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.07133421166191202" LOG_CI_START="-0.27497543468750335" LOG_EFFECT_SIZE="-0.10182061151279567" MODIFIED="2014-03-07 13:22:19 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.20342400052604326" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.04138132399001965" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.139117319661196" CI_START="0.44089599621273345" DF="0" EFFECT_SIZE="0.7086834733893558" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="0.056568455121774455" LOG_CI_START="-0.35566384499452497" LOG_EFFECT_SIZE="-0.14954769493637526" MODIFIED="2015-09-16 22:59:06 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.15501085635031858" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.422053031572667">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="1.139117319661196" CI_START="0.44089599621273345" EFFECT_SIZE="0.7086834733893558" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.056568455121774455" LOG_CI_START="-0.35566384499452497" LOG_EFFECT_SIZE="-0.14954769493637526" MODIFIED="2014-03-07 13:22:28 +0000" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.24214729367110996" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.05863531183224277" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6699254655348217E-31" CI_END="1.2514444520214385" CI_START="0.4260131325572221" DF="0" EFFECT_SIZE="0.7301587301587301" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="100.0" ID="CMP-002.07.03" LOG_CI_END="0.09741157730344036" LOG_CI_START="-0.37057701284745564" LOG_EFFECT_SIZE="-0.13658271777200764" MODIFIED="2015-09-15 20:32:53 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="0.0" P_Z="0.2526099489313507" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.144033052846091">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="1.2514444520214385" CI_START="0.4260131325572221" EFFECT_SIZE="0.7301587301587301" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.09741157730344036" LOG_CI_START="-0.37057701284745564" LOG_EFFECT_SIZE="-0.13658271777200764" MODIFIED="2014-03-07 13:22:36 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.2748988144355189" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.07556935817805385" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8721651548917344" CI_END="1.0381034605224946" CI_START="0.5414763955851795" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7497389679403239" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.016240638767635443" LOG_CI_START="-0.2664204706924781" LOG_EFFECT_SIZE="-0.1250899159624213" METHOD="MH" MODIFIED="2015-09-16 22:59:13 +0100" MODIFIED_BY="Laura E  Prescott" NO="8" P_CHI2="0.39216115187193623" P_Q="0.42126945284564876" P_Z="0.08278691353692656" Q="1.7289668645935035" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="69" WEIGHT="300.0" Z="1.7347397424694826">
<NAME>Mental state: 4. Specific - mania - various degrees of Bech-Rafaelsen Mania Scale improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3691549180022713" CI_START="0.5783772887920322" DF="0" EFFECT_SIZE="0.8898809523809523" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.13645259073959157" LOG_CI_START="-0.23778876887042036" LOG_EFFECT_SIZE="-0.05066808906541442" MODIFIED="2015-09-15 20:32:57 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.5956167434396841" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.00000000000001" Z="0.5307143488211251">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="1.3691549180022713" CI_START="0.5783772887920322" EFFECT_SIZE="0.8898809523809523" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.13645259073959157" LOG_CI_START="-0.23778876887042036" LOG_EFFECT_SIZE="-0.05066808906541442" MODIFIED="2014-03-07 13:23:00 +0000" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.21983122715952821" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.048325768434464095" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2942687440737386" CI_START="0.3509828439231118" DF="0" EFFECT_SIZE="0.673992673992674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="0.11202446331110531" LOG_CI_START="-0.45471411137354445" LOG_EFFECT_SIZE="-0.17134482403121953" MODIFIED="2015-09-16 22:59:13 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.23596573682190514" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.1851308488235837">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="1.2942687440737386" CI_START="0.3509828439231118" EFFECT_SIZE="0.673992673992674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.11202446331110531" LOG_CI_START="-0.45471411137354445" LOG_EFFECT_SIZE="-0.17134482403121953" MODIFIED="2014-03-07 13:23:07 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.3329050441709529" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.1108257684344641" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0867083985549026" CI_START="0.23513639484605953" DF="0" EFFECT_SIZE="0.5054945054945055" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="0.0361130234900962" LOG_CI_START="-0.6286801447691354" LOG_EFFECT_SIZE="-0.29628356063951955" MODIFIED="2015-09-15 20:33:26 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.08063301956236972" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="1.7470248967369217">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="1.0867083985549026" CI_START="0.23513639484605953" EFFECT_SIZE="0.5054945054945055" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.0361130234900962" LOG_CI_START="-0.6286801447691354" LOG_EFFECT_SIZE="-0.29628356063951955" MODIFIED="2014-03-07 13:23:15 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.3905027978147285" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.15249243510113075" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.058912814363421405" CI_END="0.5317792632384097" CI_START="0.2680057773997455" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37751809870425274" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.27426860201144865" LOG_CI_START="-0.5718558437854471" LOG_EFFECT_SIZE="-0.42306222289844786" METHOD="MH" MODIFIED="2015-09-16 22:59:36 +0100" MODIFIED_BY="Laura E  Prescott" NO="9" P_CHI2="0.9709732043574015" P_Q="0.9710918052656611" P_Z="2.507776417977477E-8" Q="0.058668536419004755" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="69" WEIGHT="300.0" Z="5.572730303607151">
<NAME>Mental state: 5. Specific - negative symptoms - various degrees of MS-negative subscore improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6917718222105591" CI_START="0.22929196010385633" DF="0" EFFECT_SIZE="0.39826839826839827" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="-0.16003713198296968" LOG_CI_START="-0.6396111731102083" LOG_EFFECT_SIZE="-0.39982415254658904" MODIFIED="2015-09-15 20:34:07 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.0010828330788368065" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="3.2680707124956774">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="0.6917718222105591" CI_START="0.22929196010385633" EFFECT_SIZE="0.39826839826839827" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" LOG_CI_END="-0.16003713198296968" LOG_CI_START="-0.6396111731102083" LOG_EFFECT_SIZE="-0.39982415254658904" MODIFIED="2014-03-07 13:23:38 +0000" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.28170416568792983" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.07935723696593264" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6772103768751846" CI_START="0.19681172551098908" DF="0" EFFECT_SIZE="0.365079365079365" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="-0.16927639583022508" LOG_CI_START="-0.7059490310417527" LOG_EFFECT_SIZE="-0.4376127134359889" MODIFIED="2015-09-16 22:59:36 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.0013916312700981899" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="99.99999999999999" Z="3.1963811874750214">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="0.6772103768751846" CI_START="0.19681172551098908" EFFECT_SIZE="0.36507936507936506" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.16927639583022508" LOG_CI_START="-0.7059490310417527" LOG_EFFECT_SIZE="-0.43761271343598884" MODIFIED="2014-03-07 13:23:43 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.31524416249564025" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.09937888198757763" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6772103768751846" CI_START="0.19681172551098908" DF="0" EFFECT_SIZE="0.365079365079365" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="-0.16927639583022508" LOG_CI_START="-0.7059490310417527" LOG_EFFECT_SIZE="-0.4376127134359889" MODIFIED="2015-09-15 20:34:03 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.0013916312700981899" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="99.99999999999999" Z="3.1963811874750214">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="0.6772103768751846" CI_START="0.19681172551098908" EFFECT_SIZE="0.36507936507936506" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.16927639583022508" LOG_CI_START="-0.7059490310417527" LOG_EFFECT_SIZE="-0.43761271343598884" MODIFIED="2014-03-07 13:23:48 +0000" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.31524416249564025" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.09937888198757763" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.14097163481723277" CI_END="0.6796265450069963" CI_START="0.39181510136157455" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5160309521917585" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-0.16772966669981487" LOG_CI_START="-0.40691882941424934" LOG_EFFECT_SIZE="-0.28732424805703205" METHOD="MH" MODIFIED="2015-09-16 22:59:43 +0100" MODIFIED_BY="Laura E  Prescott" NO="10" P_CHI2="0.9319409704420838" P_Q="0.9331922221068594" P_Z="2.4919767699776407E-6" Q="0.1382881736814619" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="69" WEIGHT="300.0" Z="4.708785061045335">
<NAME>Mental state: 6. Specific - positive symptoms - various degrees of MS-positive subscore improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8309582544523995" CI_START="0.36089252343105704" DF="0" EFFECT_SIZE="0.5476190476190477" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="-0.08042079368443515" LOG_CI_START="-0.4426221150761799" LOG_EFFECT_SIZE="-0.26152145438030755" MODIFIED="2015-09-15 20:34:12 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.0046501621466166826" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="2.830318949695693">
<NAME>At least 20% improvement</NAME>
<DICH_DATA CI_END="0.8309582544523995" CI_START="0.36089252343105704" EFFECT_SIZE="0.5476190476190477" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.08042079368443515" LOG_CI_START="-0.4426221150761799" LOG_EFFECT_SIZE="-0.26152145438030755" MODIFIED="2014-03-07 13:24:04 +0000" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.2127588491109677" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.04526632787502352" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7605030983015745E-31" CI_END="0.8278468812961589" CI_START="0.29342160821453495" DF="0" EFFECT_SIZE="0.4928571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" I2="100.0" ID="CMP-002.10.02" LOG_CI_END="-0.082049982970642" LOG_CI_START="-0.5325079069113233" LOG_EFFECT_SIZE="-0.3072789449409827" MODIFIED="2015-09-16 22:59:43 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="0.0" P_Z="0.007495898027057824" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="2.673970789649603">
<NAME>At least 35% improvement</NAME>
<DICH_DATA CI_END="0.8278468812961589" CI_START="0.29342160821453495" EFFECT_SIZE="0.4928571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.082049982970642" LOG_CI_START="-0.5325079069113233" LOG_EFFECT_SIZE="-0.3072789449409827" MODIFIED="2014-03-07 13:24:08 +0000" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.26460121432544154" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.07001380262249826" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7605030983015745E-31" CI_END="0.8278468812961589" CI_START="0.29342160821453495" DF="0" EFFECT_SIZE="0.4928571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" I2="100.0" ID="CMP-002.10.03" LOG_CI_END="-0.082049982970642" LOG_CI_START="-0.5325079069113233" LOG_EFFECT_SIZE="-0.3072789449409827" MODIFIED="2015-09-15 20:34:25 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="0.0" P_Z="0.007495898027057824" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="2.673970789649603">
<NAME>At least 50% improvement</NAME>
<DICH_DATA CI_END="0.8278468812961589" CI_START="0.29342160821453495" EFFECT_SIZE="0.4928571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.082049982970642" LOG_CI_START="-0.5325079069113233" LOG_EFFECT_SIZE="-0.3072789449409827" MODIFIED="2014-03-07 13:24:15 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.26460121432544154" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" VAR="0.07001380262249826" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8055808191236822" CI_END="1.1283945842402923" CI_START="0.2809961965767046" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.563093763426016" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.05246099308045673" LOG_CI_START="-0.5512995584469788" LOG_EFFECT_SIZE="-0.24941928268326097" METHOD="MH" MODIFIED="2015-09-15 22:23:05 +0100" MODIFIED_BY="Laura E  Prescott" NO="11" P_CHI2="0.6684524259870102" P_Q="0.6729071841333825" P_Z="0.10536985093921518" Q="0.7922963839824875" RANDOM="YES" SCALE="33.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="111" TOTAL_2="138" WEIGHT="300.0" Z="1.619359893163846">
<NAME>Adverse events: 1. Anticholinergic</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2086310730291476" CI_START="0.12042937678799459" DF="0" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.506319784980049" LOG_CI_START="-0.9192675610788532" LOG_EFFECT_SIZE="-0.20647388804940214" MODIFIED="2015-09-15 20:34:32 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.5702116201908787" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="99.99999999999999" Z="0.5677398658784991">
<NAME>Blurred vision</NAME>
<DICH_DATA CI_END="3.2086310730291476" CI_START="0.12042937678799459" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.506319784980049" LOG_CI_START="-0.9192675610788532" LOG_EFFECT_SIZE="-0.20647388804940214" ORDER="176" O_E="0.0" SE="0.8373970638461723" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.7012338425381904" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6606460756835997" CI_START="0.2769186859771411" DF="0" EFFECT_SIZE="0.6781326781326781" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.22027708353154962" LOG_CI_START="-0.5576477378515543" LOG_EFFECT_SIZE="-0.16868532716000237" MODIFIED="2015-09-15 20:34:37 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.3953263571232918" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="0.8499977295136136">
<NAME>Dry mouth</NAME>
<DICH_DATA CI_END="1.6606460756835997" CI_START="0.2769186859771411" EFFECT_SIZE="0.6781326781326781" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.22027708353154962" LOG_CI_START="-0.5576477378515543" LOG_EFFECT_SIZE="-0.16868532716000237" ORDER="177" O_E="0.0" SE="0.4569568908704058" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.20880960011394795" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3760803289074244" CI_START="0.07020183203517953" DF="0" EFFECT_SIZE="0.3108108108108108" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-002.11.03" LOG_CI_END="0.13864378664873836" LOG_CI_START="-1.153651554075505" LOG_EFFECT_SIZE="-0.5075038837133833" MODIFIED="2015-09-15 20:34:41 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.12370304529696853" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="1.5394148732827275">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="1.3760803289074244" CI_START="0.07020183203517953" EFFECT_SIZE="0.3108108108108108" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.13864378664873836" LOG_CI_START="-1.153651554075505" LOG_EFFECT_SIZE="-0.5075038837133833" ORDER="178" O_E="0.0" SE="0.7591006801065261" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.5762338425381904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.870379335588918" CI_END="1.607807939926007" CI_START="0.41804487580121275" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8198389296432387" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" I2="45.61154867717272" I2_Q="52.436636837413104" ID="CMP-002.12" LOG_CI_END="0.20623416903182115" LOG_CI_START="-0.37877709557725653" LOG_EFFECT_SIZE="-0.0862714632727177" METHOD="MH" MODIFIED="2015-09-15 22:23:30 +0100" MODIFIED_BY="Laura E  Prescott" NO="12" P_CHI2="0.07533030832349719" P_Q="0.049578449653059575" P_Z="0.5632163321971276" Q="12.614751357026767" RANDOM="YES" SCALE="700.21" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.8200758515886293" TOTALS="SUB" TOTAL_1="270" TOTAL_2="332" WEIGHT="700.0" Z="0.5780707864525895">
<NAME>Adverse events: 2. Central nervous system/neurologic</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2086310730291476" CI_START="0.12042937678799459" DF="0" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="0.506319784980049" LOG_CI_START="-0.9192675610788532" LOG_EFFECT_SIZE="-0.20647388804940214" MODIFIED="2015-09-15 20:34:46 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.5702116201908787" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="99.99999999999999" Z="0.5677398658784991">
<NAME>Ataxia</NAME>
<DICH_DATA CI_END="3.2086310730291476" CI_START="0.12042937678799459" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.506319784980049" LOG_CI_START="-0.9192675610788532" LOG_EFFECT_SIZE="-0.20647388804940214" ORDER="179" O_E="0.0" SE="0.8373970638461723" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.7012338425381904" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2086310730291476" CI_START="0.12042937678799459" DF="0" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="0.506319784980049" LOG_CI_START="-0.9192675610788532" LOG_EFFECT_SIZE="-0.20647388804940214" MODIFIED="2015-09-15 20:34:50 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.5702116201908787" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="99.99999999999999" Z="0.5677398658784991">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="3.2086310730291476" CI_START="0.12042937678799459" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.506319784980049" LOG_CI_START="-0.9192675610788532" LOG_EFFECT_SIZE="-0.20647388804940214" ORDER="180" O_E="0.0" SE="0.8373970638461723" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.7012338425381904" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="162.49497579952444" CI_START="0.46130128581155566" DF="0" EFFECT_SIZE="8.657894736842106" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.12.03" LOG_CI_END="2.210839937522434" LOG_CI_START="-0.33601533485610546" LOG_EFFECT_SIZE="0.9374123013331642" MODIFIED="2015-09-15 20:34:57 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.14907837790733894" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="1.442794468302817">
<NAME>Hyperactive reflexes</NAME>
<DICH_DATA CI_END="162.49497579952444" CI_START="0.46130128581155566" EFFECT_SIZE="8.657894736842104" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.210839937522434" LOG_CI_START="-0.33601533485610546" LOG_EFFECT_SIZE="0.9374123013331641" ORDER="181" O_E="0.0" SE="1.4960353941320774" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="2.2381219004959205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.408980352653936" CI_START="0.1838098909794882" DF="0" EFFECT_SIZE="1.2432432432432432" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.12.04" LOG_CI_END="0.924743337764293" LOG_CI_START="-0.7356311225351349" LOG_EFFECT_SIZE="0.09455610761457907" MODIFIED="2015-09-15 20:35:05 +0100" MODIFIED_BY="Laura E  Prescott" NO="4" P_CHI2="1.0" P_Z="0.8233528765795086" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="0.22323466166716058">
<NAME>Muscle weakness</NAME>
<DICH_DATA CI_END="8.408980352653936" CI_START="0.18380989097948813" EFFECT_SIZE="1.2432432432432432" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.924743337764293" LOG_CI_START="-0.735631122535135" LOG_EFFECT_SIZE="0.09455610761457907" ORDER="182" O_E="0.0" SE="0.9753121769660166" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.9512338425381904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.70352435191257" CI_START="0.14605159367750142" DF="0" EFFECT_SIZE="0.8288288288288288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.12.05" LOG_CI_END="0.6724233968724609" LOG_CI_START="-0.8354936997546654" LOG_EFFECT_SIZE="-0.08153515144110218" MODIFIED="2015-09-15 20:35:10 +0100" MODIFIED_BY="Laura E  Prescott" NO="5" P_CHI2="1.0" P_Z="0.8321414418895057" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="0.2119558968540507">
<NAME>Slurred speech</NAME>
<DICH_DATA CI_END="4.70352435191257" CI_START="0.14605159367750142" EFFECT_SIZE="0.8288288288288288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6724233968724609" LOG_CI_START="-0.8354936997546654" LOG_EFFECT_SIZE="-0.08153515144110218" ORDER="183" O_E="0.0" SE="0.885757966868785" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.7845671758715237" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7325505278050042" CI_START="0.04306044856509026" DF="0" EFFECT_SIZE="0.1776061776061776" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" I2="0.0" ID="CMP-002.12.06" LOG_CI_END="-0.1351624144003584" LOG_CI_START="-1.3659214503989972" LOG_EFFECT_SIZE="-0.7505419323996777" MODIFIED="2015-09-15 20:35:13 +0100" MODIFIED_BY="Laura E  Prescott" NO="6" P_CHI2="1.0" P_Z="0.01682765184192493" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="2.390451929848097">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="0.7325505278050042" CI_START="0.04306044856509026" EFFECT_SIZE="0.1776061776061776" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="-0.1351624144003584" LOG_CI_START="-1.3659214503989972" LOG_EFFECT_SIZE="-0.7505419323996777" ORDER="184" O_E="0.0" SE="0.7229539501010848" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.5226624139667618" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10152987295871171" CI_END="67.3774281518066" CI_START="1.157284115939429" DF="1" EFFECT_SIZE="8.830335631952835" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-002.12.07" LOG_CI_END="1.8285144296074696" LOG_CI_START="0.06343999234605477" LOG_EFFECT_SIZE="0.9459772109767621" MODIFIED="2015-09-15 20:35:18 +0100" MODIFIED_BY="Laura E  Prescott" NO="7" P_CHI2="0.7500014213404897" P_Z="0.035653842404086915" STUDIES="2" TAU2="0.0" TOTAL_1="48" TOTAL_2="56" WEIGHT="100.0" Z="2.1008533403121348">
<NAME>Toxic confusion</NAME>
<DICH_DATA CI_END="124.97403173142621" CI_START="0.30601925299156363" EFFECT_SIZE="6.184210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0968197806290476" LOG_CI_START="-0.5142512493191955" LOG_EFFECT_SIZE="0.7912842656549262" ORDER="185" O_E="0.0" SE="1.5337560480016483" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="2.352407614781635" WEIGHT="45.697104006189996"/>
<DICH_DATA CI_END="187.83722728790315" CI_START="0.7560106507896145" EFFECT_SIZE="11.916666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.2737816688858175" LOG_CI_START="-0.12147208605094371" LOG_EFFECT_SIZE="1.076154791417437" ORDER="186" O_E="0.0" SE="1.406983912347163" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="1.9796037296037294" WEIGHT="54.30289599381"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.83421370893586" CI_START="0.017284084124045508" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.412280701754386" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.9927396417824025" LOG_CI_START="-1.7623536285839128" LOG_EFFECT_SIZE="-0.3848069934007551" METHOD="MH" MODIFIED="2015-09-29 12:15:53 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.584034741753439" Q="0.0" RANDOM="YES" SCALE="149.45" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="37" TOTAL_2="46" WEIGHT="0.0" Z="0.547500773332689">
<NAME>Adverse events: 3. Dermatologic - pruritus</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.83421370893586" CI_START="0.017284084124045508" EFFECT_SIZE="0.41228070175438597" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9927396417824025" LOG_CI_START="-1.7623536285839128" LOG_EFFECT_SIZE="-0.38480699340075514" ORDER="187" O_E="0.0" SE="1.6183554249448115" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="2.6190742814483015" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.972758489966813" CI_END="2.6676003980871363" CI_START="0.2860709613796909" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.873569121740022" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.4261207735565696" LOG_CI_START="-0.5435262245177646" LOG_EFFECT_SIZE="-0.058702725480597434" METHOD="MH" MODIFIED="2015-09-15 22:24:38 +0100" MODIFIED_BY="Laura E  Prescott" NO="14" P_CHI2="0.6148486353212095" P_Q="0.6165159649124314" P_Z="0.8124134838471452" Q="0.9673422782847116" RANDOM="YES" SCALE="177.31" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="111" TOTAL_2="138" WEIGHT="300.0" Z="0.23731363674575623">
<NAME>Adverse events: 4. Gastrointestinal</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="88.50792338042271" CI_START="0.15555675711640954" DF="0" EFFECT_SIZE="3.710526315789474" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="1.9469821512217274" LOG_CI_START="-0.8081111191445879" LOG_EFFECT_SIZE="0.5694355160385698" MODIFIED="2015-09-15 20:35:25 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.4178315777131014" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="0.8101889797764886">
<NAME>Dehydration</NAME>
<DICH_DATA CI_END="88.50792338042271" CI_START="0.15555675711640954" EFFECT_SIZE="3.710526315789474" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9469821512217274" LOG_CI_START="-0.8081111191445879" LOG_EFFECT_SIZE="0.5694355160385698" ORDER="188" O_E="0.0" SE="1.6183554249448115" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="2.6190742814483015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2086310730291476" CI_START="0.12042937678799459" DF="0" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="0.506319784980049" LOG_CI_START="-0.9192675610788532" LOG_EFFECT_SIZE="-0.20647388804940214" MODIFIED="2015-09-15 20:35:30 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.5702116201908787" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="99.99999999999999" Z="0.5677398658784991">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="3.2086310730291476" CI_START="0.12042937678799459" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.506319784980049" LOG_CI_START="-0.9192675610788532" LOG_EFFECT_SIZE="-0.20647388804940214" ORDER="189" O_E="0.0" SE="0.8373970638461723" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.7012338425381904" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.70352435191257" CI_START="0.14605159367750142" DF="0" EFFECT_SIZE="0.8288288288288288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.14.03" LOG_CI_END="0.6724233968724609" LOG_CI_START="-0.8354936997546654" LOG_EFFECT_SIZE="-0.08153515144110218" MODIFIED="2015-09-15 20:35:36 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.8321414418895057" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="0.2119558968540507">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="4.70352435191257" CI_START="0.14605159367750142" EFFECT_SIZE="0.8288288288288288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6724233968724609" LOG_CI_START="-0.8354936997546654" LOG_EFFECT_SIZE="-0.08153515144110218" ORDER="190" O_E="0.0" SE="0.885757966868785" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.7845671758715237" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.448808015716451" CI_END="3.1482220018861393" CI_START="0.42363659681954263" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1548601884693452" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="63.29472438318191" I2_Q="60.428452375608664" ID="CMP-002.15" LOG_CI_END="0.49806534973360966" LOG_CI_START="-0.37300652941853807" LOG_EFFECT_SIZE="0.06252941015753576" METHOD="MH" MODIFIED="2015-09-15 22:25:04 +0100" MODIFIED_BY="Laura E  Prescott" NO="15" P_CHI2="0.065585483284891" P_Q="0.07989298579597703" P_Z="0.7784114040652679" Q="5.054136418883017" RANDOM="YES" SCALE="410.36" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.301329997722362" TOTALS="SUB" TOTAL_1="85" TOTAL_2="102" WEIGHT="300.0" Z="0.2813898481089566">
<NAME>Adverse events: 5. Movement disorder</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.998961269257048" CI_START="0.012240770119662544" DF="0" EFFECT_SIZE="0.2473684210526316" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="0.6988797719570102" LOG_CI_START="-1.9121912579912332" LOG_EFFECT_SIZE="-0.6066557430171114" MODIFIED="2015-09-15 20:35:41 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.3624243227340139" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.0" Z="0.910755313578347">
<NAME>Parkinsonism</NAME>
<DICH_DATA CI_END="4.998961269257048" CI_START="0.012240770119662544" EFFECT_SIZE="0.24736842105263157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6988797719570102" LOG_CI_START="-1.9121912579912332" LOG_EFFECT_SIZE="-0.6066557430171116" ORDER="191" O_E="0.0" SE="1.5337560480016483" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="2.352407614781635" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.869146207798808" CI_START="0.689105239942718" DF="0" EFFECT_SIZE="2.1756756756756763" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="0.8369027603077874" LOG_CI_START="-0.1617144477060403" LOG_EFFECT_SIZE="0.33759415630087364" MODIFIED="2015-09-15 20:35:51 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.18511237904659375" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="46" WEIGHT="100.00000000000001" Z="1.3251772199217622">
<NAME>Tremor</NAME>
<DICH_DATA CI_END="6.869146207798808" CI_START="0.689105239942718" EFFECT_SIZE="2.175675675675676" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8369027603077874" LOG_CI_START="-0.1617144477060403" LOG_EFFECT_SIZE="0.3375941563008736" ORDER="192" O_E="0.0" SE="0.5865926912222256" STUDY_ID="STD-Prien-1972" TOTAL_1="37" TOTAL_2="46" VAR="0.3440909853953332" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.683074771076131" CI_START="0.0061636000395982" DF="0" EFFECT_SIZE="0.10185185185185183" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-002.15.03" LOG_CI_END="0.22610341006046747" LOG_CI_START="-2.210165550717917" LOG_EFFECT_SIZE="-0.9920310703287247" MODIFIED="2015-09-15 20:35:45 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.11045167621584336" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="1.5961662695631165">
<NAME>Use of antiparkinson medication</NAME>
<DICH_DATA CI_END="1.683074771076131" CI_START="0.0061636000395982" EFFECT_SIZE="0.10185185185185185" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.22610341006046747" LOG_CI_START="-2.210165550717917" LOG_EFFECT_SIZE="-0.9920310703287247" ORDER="193" O_E="0.0" SE="1.4310764472870756" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="2.047979797979798" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-002.16" MODIFIED="2015-09-16 23:07:08 +0100" MODIFIED_BY="Laura E  Prescott" NO="16" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events: 6. Unable to use (skewed data)</NAME>
<TR>
<TH>
<P>Mean + SD</P>
</TH>
<TH>
<P>Mean + SD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-09-16 23:07:08 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="373" STUDY_ID="STD-Johnstone-1988">
<TR>
<TD>
<P>AIMS global score at endpoint - high = poor.<BR/>Pimozide: mean = 3.6, SD = 3.2. N = 23.<BR/>Lithium: mean = 3.1, SD = 2.7. N = 21.</P>
</TD>
<TD>
<P>TAKE global score at endpoint - high = poor.<BR/>Pimozide: mean = 5.5, SD = 4.0. N = 23.<BR/>Lithium: mean = 3.2, SD = 2.4. N = 21.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="9.10745841157682" CI_END="9.786233032417522" CI_START="0.5891366181287224" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4011306155513594" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" I2="67.05996487245451" I2_Q="66.5395474478293" ID="CMP-002.17" LOG_CI_END="0.9906155530842575" LOG_CI_START="-0.22978398259926416" LOG_EFFECT_SIZE="0.38041578524249664" METHOD="MH" MODIFIED="2015-09-16 23:21:35 +0100" MODIFIED_BY="Laura E  Prescott" NO="17" P_CHI2="0.027895802905137157" P_Q="0.02974898545674831" P_Z="0.2217466200202497" Q="8.965808203946066" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="4.189088950120166" TOTALS="SUB" TOTAL_1="44" TOTAL_2="40" WEIGHT="400.0" Z="1.2218969549316008">
<NAME>Laboratory abnormalities</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1114628833603748" CI_START="0.004473435803488841" DF="0" EFFECT_SIZE="0.07051282051282051" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-002.17.01" LOG_CI_END="0.04589496427214443" LOG_CI_START="-2.3493587906646174" LOG_EFFECT_SIZE="-1.1517319131962365" MODIFIED="2015-09-15 20:36:19 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.059449410050740094" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="1.884855051417826">
<NAME>Decreased white blood cell count</NAME>
<DICH_DATA CI_END="1.1114628833603741" CI_START="0.004473435803488841" EFFECT_SIZE="0.07051282051282051" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.04589496427214417" LOG_CI_START="-2.3493587906646174" LOG_EFFECT_SIZE="-1.1517319131962365" ORDER="195" O_E="0.0" SE="1.406983912347163" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="1.9796037296037294" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="265.34119517185064" CI_START="1.1432083796159758" DF="0" EFFECT_SIZE="17.416666666666664" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-002.17.02" LOG_CI_END="2.423804680992264" LOG_CI_START="0.0581253991345943" LOG_EFFECT_SIZE="1.2409650400634291" MODIFIED="2015-09-15 20:36:04 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.03975575584118619" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="2.056277706999813">
<NAME>Increased white blood cell count</NAME>
<DICH_DATA CI_END="265.34119517185064" CI_START="1.1432083796159758" EFFECT_SIZE="17.416666666666668" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.423804680992264" LOG_CI_START="0.0581253991345943" LOG_EFFECT_SIZE="1.2409650400634291" ORDER="196" O_E="0.0" SE="1.3896117204645018" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="1.9310207336523124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="110.70884355637304" CI_START="0.3719089621792091" DF="0" EFFECT_SIZE="6.416666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.17.03" LOG_CI_END="2.0441823142330944" LOG_CI_START="-0.42956335598338025" LOG_EFFECT_SIZE="0.8073094791248571" MODIFIED="2015-09-15 20:36:14 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="1.0" P_Z="0.20080111051128657" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="1.279272580454114">
<NAME>Increased blood uric acid level</NAME>
<DICH_DATA CI_END="110.70884355637304" CI_START="0.3719089621792091" EFFECT_SIZE="6.416666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0441823142330944" LOG_CI_START="-0.42956335598338025" LOG_EFFECT_SIZE="0.8073094791248571" ORDER="197" O_E="0.0" SE="1.4530904519237133" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="2.1114718614718613" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="85.32705053303664" CI_START="0.24619325657238147" DF="0" EFFECT_SIZE="4.583333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.17.04" LOG_CI_END="1.9310867338036768" LOG_CI_START="-0.6087238469104388" LOG_EFFECT_SIZE="0.661181443446619" MODIFIED="2015-09-15 20:36:08 +0100" MODIFIED_BY="Laura E  Prescott" NO="4" P_CHI2="1.0" P_Z="0.30750877305953317" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="1.0204633575762296">
<NAME>Proteinuria</NAME>
<DICH_DATA CI_END="85.32705053303664" CI_START="0.24619325657238147" EFFECT_SIZE="4.583333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9310867338036768" LOG_CI_START="-0.6087238469104388" LOG_EFFECT_SIZE="0.661181443446619" ORDER="198" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" VAR="2.2257575757575756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.573512276382004" CI_END="1.2861646479260513" CI_START="0.2906991003805043" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.7884318741532779" ESTIMABLE="YES" I2="46.17397699628962" I2_Q="0.0" ID="CMP-002.18" MODIFIED="2015-09-16 23:22:06 +0100" MODIFIED_BY="Laura E  Prescott" NO="18" P_CHI2="0.1343074017373339" P_Q="0.5117952889171655" P_Z="0.0019048875052091355" Q="0.4303948428248102" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1315107883809626" TOTALS="SUB" TOTAL_1="68" TOTAL_2="68" UNITS="" WEIGHT="200.0" Z="3.1046741525389385">
<NAME>Mental state: 2. General - BPRS/MS global score at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antipsychotics</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.253661313246279" CI_END="1.8864498854642586" CI_START="0.16181614042916692" DF="2" EFFECT_SIZE="1.0241330129467128" ESTIMABLE="YES" I2="61.93131074214252" ID="CMP-002.18.01" NO="1" P_CHI2="0.07230739517713924" P_Z="0.019925029989655656" STUDIES="3" TAU2="0.3587233498686793" TOTAL_1="47" TOTAL_2="45" WEIGHT="100.0" Z="2.3277566341637455">
<NAME>Mean BPRS at endpoint</NAME>
<CONT_DATA CI_END="1.2301989527532782" CI_START="0.18474047023983597" EFFECT_SIZE="0.7074697114965571" ESTIMABLE="YES" MEAN_1="32.28" MEAN_2="21.6" ORDER="199" SD_1="14.9" SD_2="14.9" SE="0.2667034932171931" STUDY_ID="STD-Dube-1981" TOTAL_1="30" TOTAL_2="30" WEIGHT="45.031509888285036"/>
<CONT_DATA CI_END="1.653829657278931" CI_START="-0.7646868001360738" EFFECT_SIZE="0.4445714285714286" ESTIMABLE="YES" MEAN_1="34.5" MEAN_2="30.61" ORDER="200" SD_1="8.0" SD_2="8.0" SE="0.6169798211834385" STUDY_ID="STD-Johnson-1971" TOTAL_1="6" TOTAL_2="5" WEIGHT="26.17975096432673"/>
<CONT_DATA CI_END="3.1441775752356573" CI_START="0.9488188146560406" EFFECT_SIZE="2.046498194945849" ESTIMABLE="YES" MEAN_1="66.47" MEAN_2="54.66" ORDER="201" SD_1="5.54" SD_2="5.54" SE="0.560050791212575" STUDY_ID="STD-Shopsin-1971" TOTAL_1="11" TOTAL_2="10" WEIGHT="28.788739147388245"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2801893062502567" CI_START="0.06115234033922312" DF="0" EFFECT_SIZE="0.6706708232947399" ESTIMABLE="YES" I2="0.0" ID="CMP-002.18.02" NO="2" P_CHI2="1.0" P_Z="0.031036448076673384" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.00000000000001" Z="2.1566050840093225">
<NAME>Mean MS at endpoint</NAME>
<CONT_DATA CI_END="1.2801893062502567" CI_START="0.06115234033922312" EFFECT_SIZE="0.6706708232947399" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="3.7" ORDER="202" SD_1="4.86" SD_2="3.92" SE="0.310984532248205" STUDY_ID="STD-Johnstone-1988" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-09-29 12:17:50 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Adjunctive lithium + antipsychotics versus placebo/no adjunctive treatment + antipsychotics</NAME>
<DICH_OUTCOME CHI2="17.70834317306902" CI_END="2.9657522126358065" CI_START="1.103175383461459" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8087965154837555" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="44" I2="49.1764988286015" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.4721348630847007" LOG_CI_START="0.04264456231742176" LOG_EFFECT_SIZE="0.2573897127010612" METHOD="MH" MODIFIED="2015-09-15 22:26:24 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.03871210734712205" P_Q="1.0" P_Z="0.018814913652654773" Q="0.0" RANDOM="YES" SCALE="657.09" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23404496914775688" TOTALS="YES" TOTAL_1="203" TOTAL_2="193" WEIGHT="100.00000000000004" Z="2.3491779254802934">
<NAME>Clinically significant response</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.444461774072338" CI_START="0.2938764051474398" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6478191752717338" LOG_CI_START="-0.5318352813163605" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.6929348671835831" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="0.48015873015873" WEIGHT="8.911685053989796"/>
<DICH_DATA CI_END="3.375390052295833" CI_START="1.0695060256945985" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.5283239661364544" LOG_CI_START="0.02918323576920342" LOG_EFFECT_SIZE="0.2787536009528289" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.2931977358041869" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.08596491228070177" WEIGHT="19.889255932357035"/>
<DICH_DATA CI_END="4.868921183833246" CI_START="1.1584958529887723" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6874327444158161" LOG_CI_START="0.0638944835059546" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.36626946102262364" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.13415331807780323" WEIGHT="17.286224986469747"/>
<DICH_DATA CI_END="132.89880114989023" CI_START="0.5072486869632472" EFFECT_SIZE="8.210526315789474" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.123521063287836" LOG_CI_START="-0.2947790684845707" LOG_EFFECT_SIZE="0.9143709974016326" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.4205214681818263" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="2.0178812415654517" WEIGHT="2.826361895134235"/>
<DICH_DATA CI_END="1.282357944877448" CI_START="0.5780418365006762" EFFECT_SIZE="0.8609625668449198" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.10800926682647895" LOG_CI_START="-0.23804072783577748" LOG_EFFECT_SIZE="-0.06501573050464926" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.20327147983970956" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.041319294516225444" WEIGHT="23.11395948016167"/>
<DICH_DATA CI_END="4.32212374238197" CI_START="0.4721790601501604" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6356971965741458" LOG_CI_START="-0.32589327660265943" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.319047619047619" WEIGHT="11.507582217618758"/>
<DICH_DATA CI_END="16.669089271039443" CI_START="1.1132109688794265" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2219118724514737" LOG_CI_START="0.046577476947253414" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.6903972419182682" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.47664835164835173" WEIGHT="8.955703179374375"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="2.3409370541015098"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="2.5875078655383676"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2014-03-07 14:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="2.5807823352545216"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.533682658040334" CI_END="3.938415863564332" CI_START="0.9925287863945542" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.977116869934746" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="20" I2="26.110281638242643" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.5953215720650693" LOG_CI_START="-0.0032568885033742103" LOG_EFFECT_SIZE="0.2960323417808476" METHOD="MH" MODIFIED="2015-09-15 22:26:45 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="0.19534361774461095" P_Q="0.5965974039067654" P_Z="0.052545737023305304" Q="0.28015851134669933" RANDOM="YES" SCALE="459.44" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2865919364157182" TOTALS="SUB" TOTAL_1="187" TOTAL_2="172" WEIGHT="200.0" Z="1.9386355051884452">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.938676596654112" CI_END="3.8409822576316497" CI_START="0.9313483457040143" DF="9" EFFECT_SIZE="1.8913731708797465" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="20" I2="30.44110861904252" ID="CMP-003.02.01" LOG_CI_END="0.5844423010650807" LOG_CI_START="-0.03088785250785517" LOG_EFFECT_SIZE="0.27677722427861273" MODIFIED="2013-10-24 11:51:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16540082060837347" P_Z="0.07786768008457445" STUDIES="11" TAU2="0.3367130405831734" TOTAL_1="166" TOTAL_2="154" WEIGHT="100.00000000000001" Z="1.7631945653147518">
<NAME>Overall</NAME>
<DICH_DATA CI_END="6.620664101453002" CI_START="0.6041689985634735" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8209015545652094" LOG_CI_START="-0.21884156323724713" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="203" O_E="0.0" SE="0.6107502542086028" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="0.373015873015873" WEIGHT="18.40768191907674"/>
<DICH_DATA CI_END="85.51113291732983" CI_START="1.697382782390174" EFFECT_SIZE="12.047619047619047" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.9320226603400072" LOG_CI_START="0.2297797925437902" LOG_EFFECT_SIZE="1.0809012264418987" ORDER="204" O_E="0.0" SE="0.9999058867815901" STUDY_ID="STD-Collins-1991" TOTAL_1="21" TOTAL_2="23" VAR="0.999811782420478" WEIGHT="9.774950577380674"/>
<DICH_DATA CI_END="151.1845630812874" CI_START="0.5936498455369373" EFFECT_SIZE="9.473684210526315" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.1795074491620645" LOG_CI_START="-0.2264696408611102" LOG_EFFECT_SIZE="0.976518904150477" ORDER="205" O_E="0.0" SE="1.4132828524582868" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="1.9973684210526315" WEIGHT="5.597261408840082"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="206" O_E="0.0" SE="0.0" STUDY_ID="STD-Huang-1984" TOTAL_1="6" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="102.92635130735574" CI_START="0.2644723307192462" EFFECT_SIZE="5.217391304347826" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0125265775055743" LOG_CI_START="-0.5776197574455103" LOG_EFFECT_SIZE="0.7174534100300319" ORDER="207" O_E="0.0" SE="1.5214647785814064" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="2.314855072463768" WEIGHT="4.9270709004305555"/>
<DICH_DATA CI_END="1.99567803423578" CI_START="0.7362098533277803" EFFECT_SIZE="1.2121212121212122" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3000904772151379" LOG_CI_START="-0.13299837431498804" LOG_EFFECT_SIZE="0.08354605145007492" ORDER="208" O_E="0.0" SE="0.25439853521318617" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.06471861471861472" WEIGHT="32.54467832259403"/>
<DICH_DATA CI_END="4.084781791910898" CI_START="0.011241326877697851" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6111688615783089" LOG_CI_START="-1.94918242349546" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="209" O_E="0.0" SE="1.5039630187955957" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="2.2619047619047614" WEIGHT="5.027466554641139"/>
<DICH_DATA CI_END="11.697696457498267" CI_START="0.0593659142180342" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0681003477040096" LOG_CI_START="-1.226462839799259" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="210" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Small-1975" TOTAL_1="12" TOTAL_2="10" VAR="1.8166666666666667" WEIGHT="6.066957929583282"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="211" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="4.630224778920767"/>
<DICH_DATA CI_END="20.71711484984983" CI_START="0.23362326439171544" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3163292736583827" LOG_CI_START="-0.6314839120139702" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="212" O_E="0.0" SE="1.1441551070947107" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="1.309090909090909" WEIGHT="7.938043952859812"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" ORDER="213" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="5.0856636556729296"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="84.47903905104464" CI_START="0.22072569035271783" DF="0" EFFECT_SIZE="4.318181818181818" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="1.9267489651186873" LOG_CI_START="-0.6561471161854041" LOG_EFFECT_SIZE="0.6353009244666415" NO="2" P_CHI2="1.0" P_Z="0.33496402389205215" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.964163398065121">
<NAME>Due to adverse events</NAME>
<DICH_DATA CI_END="84.47903905104464" CI_START="0.22072569035271783" EFFECT_SIZE="4.318181818181818" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9267489651186873" LOG_CI_START="-0.6561471161854041" LOG_EFFECT_SIZE="0.6353009244666415" ORDER="214" O_E="0.0" SE="1.5172059436998282" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="2.301913875598086" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.261496792895358" CI_END="4.024987904865211" CI_START="0.57295307339901" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5185944786171075" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="24" I2="78.96433983356846" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.6047645796459521" LOG_CI_START="-0.2418809466162613" LOG_EFFECT_SIZE="0.1814418165148454" METHOD="MH" MODIFIED="2015-09-15 22:27:06 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="0.0025699844097009095" P_Q="1.0" P_Z="0.4008709065970052" Q="0.0" RANDOM="YES" SCALE="621.51" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6728587598048625" TOTALS="YES" TOTAL_1="62" TOTAL_2="53" WEIGHT="99.99999999999999" Z="0.8400668629966479">
<NAME>Global state: 1. Improved CGI</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2247337583656925" CI_START="0.7592237353008994" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.08804168883142832" LOG_CI_START="-0.11963022319789214" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2014-03-07 14:08:17 +0000" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.12198750911856666" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="0.014880952380952384" WEIGHT="35.96286951261918"/>
<DICH_DATA CI_END="3.4092902964919527" CI_START="0.5545508993309812" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5326639823954783" LOG_CI_START="-0.2560585860629154" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2014-03-07 14:08:21 +0000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.4632995409521411" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="0.21464646464646467" WEIGHT="27.868110346364674"/>
<DICH_DATA CI_END="318.1090669180796" CI_START="1.3027395582309618" EFFECT_SIZE="20.357142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.5025760477819055" LOG_CI_START="0.11485760087863876" LOG_EFFECT_SIZE="1.3087168243302723" MODIFIED="2014-03-07 14:08:22 +0000" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="1.4025576351079119" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="1.9671679197994985" WEIGHT="9.368501356089052"/>
<DICH_DATA CI_END="3.330510326941122" CI_START="0.4691473217664706" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5225107846154843" LOG_CI_START="-0.3286907585993715" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2014-03-07 14:08:24 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="26.80051878492709"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-09-15 22:27:24 +0100" MODIFIED_BY="Laura E  Prescott" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="330.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 2. Relapse</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.75787563087597" CI_START="0.009315361114584076" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6774130855511389" LOG_CI_START="-2.030800304800872" LOG_EFFECT_SIZE="-0.6766936096248666" ORDER="227" O_E="0.0" SE="1.5908179513652605" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="2.5307017543859645" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.229026540137655" CI_END="1.1872920432746041" CI_START="0.797546128088102" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9730982334910858" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="47" I2="0.0" I2_Q="42.03222232144844" ID="CMP-003.05" LOG_CI_END="0.07455755735607299" LOG_CI_START="-0.09824418902968064" LOG_EFFECT_SIZE="-0.011843315836803824" METHOD="MH" MODIFIED="2015-09-16 22:59:59 +0100" MODIFIED_BY="Laura E  Prescott" NO="5" P_CHI2="0.6647240104689539" P_Q="0.18903845565650446" P_Z="0.7881912121707011" Q="1.725096320830678" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="88" WEIGHT="200.0" Z="0.2686601609436288">
<NAME>Mental state: 1. General - number of participants with at least 20% BPRS/MS improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0155574730421755" CI_END="1.7623807409556167" CI_START="0.8270015184864845" DF="4" EFFECT_SIZE="1.2072661466808512" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.24609973826073034" LOG_CI_START="-0.08249369302339574" LOG_EFFECT_SIZE="0.08180302261866727" MODIFIED="2015-09-15 20:37:36 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.9074279344008146" P_Z="0.3291326970389583" STUDIES="5" TAU2="0.0" TOTAL_1="66" TOTAL_2="65" WEIGHT="100.0" Z="0.975862344737314">
<NAME>At least 20% BPRS improvement</NAME>
<DICH_DATA CI_END="2.3961749874179508" CI_START="0.591456620460709" EFFECT_SIZE="1.1904761904761905" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3795185304514297" LOG_CI_START="-0.22807710257519295" LOG_EFFECT_SIZE="0.07572071393811834" MODIFIED="2014-03-07 14:08:57 +0000" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.35690468248672835" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.12738095238095237" WEIGHT="29.24748098776036"/>
<DICH_DATA CI_END="2.617933806251692" CI_START="0.7323178908249642" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.41795866133503456" LOG_CI_START="-0.13530035574209592" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2014-03-07 14:08:49 +0000" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.3249870853074097" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.1056166056166056" WEIGHT="35.274490798243924"/>
<DICH_DATA CI_END="2.523907854293063" CI_START="0.22286867527402432" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40207349514318896" LOG_CI_START="-0.6519509683597887" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-07 14:08:59 +0000" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="9.718883433820988"/>
<DICH_DATA CI_END="3.0021127190965893" CI_START="0.5803912654300108" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4774269944904055" LOG_CI_START="-0.23627913207870568" LOG_EFFECT_SIZE="0.12057393120584989" MODIFIED="2014-03-07 14:09:01 +0000" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.41923451164900033" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="0.1757575757575758" WEIGHT="21.19721990307508"/>
<DICH_DATA CI_END="4.898310157597996" CI_START="0.14177224840841476" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.690046280884386" LOG_CI_START="-0.8484087729796358" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-03-07 14:09:02 +0000" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.9036961141150639" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.8166666666666667" WEIGHT="4.5619248770996474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.654772830615166E-31" CI_END="1.1322436828115212" CI_START="0.7092132239754381" DF="0" EFFECT_SIZE="0.8961038961038961" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="100.0" ID="CMP-003.05.02" LOG_CI_END="0.05393990627903898" LOG_CI_START="-0.14922317514949207" LOG_EFFECT_SIZE="-0.04764163443522657" MODIFIED="2015-09-15 20:37:40 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="0.0" P_Z="0.35797998835678324" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.9192210218618405">
<NAME>At least 20% MS improvement</NAME>
<DICH_DATA CI_END="1.1322436828115212" CI_START="0.7092132239754381" EFFECT_SIZE="0.8961038961038961" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.05393990627903898" LOG_CI_START="-0.14922317514949207" LOG_EFFECT_SIZE="-0.04764163443522657" MODIFIED="2014-03-07 14:09:16 +0000" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.11933899970459153" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.014241796850492497" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.508262210320969" CI_END="1.4688701752341804" CI_START="0.8276246827785404" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.102575717500185" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="32" I2="23.17457658557653" I2_Q="73.64782647347276" ID="CMP-003.06" LOG_CI_END="0.16698341276031745" LOG_CI_START="-0.08216656557195322" LOG_EFFECT_SIZE="0.0424084235941821" METHOD="MH" MODIFIED="2015-09-16 23:00:03 +0100" MODIFIED_BY="Laura E  Prescott" NO="6" P_CHI2="0.259853409245418" P_Q="0.0514134885423021" P_Z="0.5046313216490025" Q="3.7947533966917644" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07328546300503129" TOTALS="SUB" TOTAL_1="88" TOTAL_2="88" WEIGHT="200.0" Z="0.6672204705140827">
<NAME>Mental state: 2. General - number of participants with at least 35% BPRS/MS improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.673498033086053" CI_END="3.0979234173608834" CI_START="1.0154296867379735" DF="4" EFFECT_SIZE="1.7736187316413283" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.4910706775198071" LOG_CI_START="0.006649856131833552" LOG_EFFECT_SIZE="0.24886026682582033" MODIFIED="2015-09-15 20:37:47 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.7955259433106243" P_Z="0.04403320915768398" STUDIES="5" TAU2="0.0" TOTAL_1="66" TOTAL_2="65" WEIGHT="100.0" Z="2.0137745473619524">
<NAME>At least 35% BPRS improvement</NAME>
<DICH_DATA CI_END="4.83455002045234" CI_START="0.5745680086102156" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6843560579994051" LOG_CI_START="-0.24065855876669234" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-03-07 14:09:38 +0000" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.5433581647846062" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.29523809523809524" WEIGHT="27.425112181888213"/>
<DICH_DATA CI_END="5.983994736941696" CI_START="0.981167603457592" EFFECT_SIZE="2.423076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7769912028847832" LOG_CI_START="-0.008256799919255816" LOG_EFFECT_SIZE="0.3843672014827637" MODIFIED="2014-03-07 14:09:36 +0000" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.4612585638873958" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.21275946275946275" WEIGHT="38.05676973073498"/>
<DICH_DATA CI_END="5.772152615091743" CI_START="0.17324559253430377" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7613378052724571" LOG_CI_START="-0.7613378052724571" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 14:09:35 +0000" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.8944271909999159" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.8" WEIGHT="10.121172352839698"/>
<DICH_DATA CI_END="9.52546858854937" CI_START="0.5081114860657037" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9788863492206908" LOG_CI_START="-0.2940409875762782" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2014-03-07 14:09:34 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.7477238187264794" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="0.5590909090909091" WEIGHT="14.482327919510462"/>
<DICH_DATA CI_END="4.898310157597996" CI_START="0.14177224840841476" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.690046280884386" LOG_CI_START="-0.8484087729796358" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-03-07 14:09:33 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.9036961141150639" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.8166666666666667" WEIGHT="9.914617815026643"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.232413480650905E-31" CI_END="1.2984148830160187" CI_START="0.6651074011319531" DF="0" EFFECT_SIZE="0.9292929292929293" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" I2="100.0" ID="CMP-003.06.02" LOG_CI_END="0.11341348492560495" LOG_CI_START="-0.17710821942959432" LOG_EFFECT_SIZE="-0.03184736725199465" MODIFIED="2015-09-15 20:37:50 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="0.0" P_Z="0.6674083522006555" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.4297076044963165">
<NAME>At least 35% MS improvement</NAME>
<DICH_DATA CI_END="1.2984148830160187" CI_START="0.6651074011319531" EFFECT_SIZE="0.9292929292929293" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.11341348492560495" LOG_CI_START="-0.17710821942959432" LOG_EFFECT_SIZE="-0.03184736725199465" MODIFIED="2014-03-07 14:09:45 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.17065388724387406" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.02912274923144488" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.349932948644087" CI_END="1.647121010194872" CI_START="1.1155503928461943" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3555244335636705" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="61" I2="32.36671160350803" I2_Q="67.79140977020323" ID="CMP-003.07" LOG_CI_END="0.21672550695926657" LOG_CI_START="0.04748919348198845" LOG_EFFECT_SIZE="0.1321073502206275" METHOD="MH" MODIFIED="2015-09-16 23:00:10 +0100" MODIFIED_BY="Laura E  Prescott" NO="7" P_CHI2="0.16959512025051182" P_Q="0.04483523301588721" P_Z="0.002213886225303578" Q="6.209523564150792" RANDOM="YES" SCALE="184.67" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05168631260132041" TOTALS="SUB" TOTAL_1="164" TOTAL_2="164" WEIGHT="300.0" Z="3.059930143895662">
<NAME>Mental state: 3. General - number of participants with at least 50% BPRS/MS/PANSS improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.053646973569942" CI_END="5.421507823664365" CI_START="1.1695581612914623" DF="4" EFFECT_SIZE="2.518088306964665" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.7341200888312026" LOG_CI_START="0.0680218238363842" LOG_EFFECT_SIZE="0.4010709563337934" MODIFIED="2015-09-15 20:38:02 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.7258923823072421" P_Z="0.01826182264054317" STUDIES="5" TAU2="0.0" TOTAL_1="66" TOTAL_2="65" WEIGHT="100.0" Z="2.3602662579083185">
<NAME>At least 50% BPRS improvement</NAME>
<DICH_DATA CI_END="4.32212374238197" CI_START="0.4721790601501604" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6356971965741458" LOG_CI_START="-0.32589327660265943" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2014-03-07 14:10:14 +0000" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.319047619047619" WEIGHT="47.98398370606307"/>
<DICH_DATA CI_END="16.669089271039443" CI_START="1.1132109688794265" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2219118724514737" LOG_CI_START="0.046577476947253414" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2014-03-07 14:10:11 +0000" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.6903972419182682" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.47664835164835173" WEIGHT="32.118386019581884"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-07 14:10:10 +0000" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="6.161009754593813"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2014-03-07 14:10:09 +0000" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="6.878186519764365"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2014-03-07 14:10:08 +0000" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="6.858433999996872"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4001370821510788" CI_START="0.691483585185379" DF="0" EFFECT_SIZE="0.983957219251337" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.14617055789774505" LOG_CI_START="-0.16021812495167007" LOG_EFFECT_SIZE="-0.007023783526962484" MODIFIED="2015-09-15 20:38:05 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.9283968119487079" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.0898620838082203">
<NAME>At least 50% MS improvement</NAME>
<DICH_DATA CI_END="1.4001370821510788" CI_START="0.691483585185379" EFFECT_SIZE="0.983957219251337" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.14617055789774505" LOG_CI_START="-0.16021812495167007" LOG_EFFECT_SIZE="-0.007023783526962484" MODIFIED="2014-03-07 14:10:19 +0000" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.17997422895418674" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.03239072308765403" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7434041416616961" CI_END="1.898824774806722" CI_START="1.1623209977712627" DF="1" EFFECT_SIZE="1.4856123003146353" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="38" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="0.2784848895154908" LOG_CI_START="0.06532608356973568" LOG_EFFECT_SIZE="0.17190548654261323" MODIFIED="2015-09-15 20:38:10 +0100" MODIFIED_BY="Laura E  Prescott" NO="3" P_CHI2="0.38857261824623124" P_Z="0.0015707121472228285" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="3.161291515717149">
<NAME>At least 50% PANSS improvement</NAME>
<DICH_DATA CI_END="3.1014739404388374" CI_START="1.0658755119184384" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.49156813643725467" LOG_CI_START="0.027706484574257634" LOG_EFFECT_SIZE="0.2596373105057561" MODIFIED="2014-03-07 14:10:33 +0000" MODIFIED_BY="[Empty name]" ORDER="952" O_E="0.0" SE="0.2724746304565331" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.07424242424242428" WEIGHT="21.11687344202171"/>
<DICH_DATA CI_END="1.8553242741965237" CI_START="1.0676277122946896" EFFECT_SIZE="1.4074074074074074" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="27" LOG_CI_END="0.268419826719936" LOG_CI_START="0.02841983819570963" LOG_EFFECT_SIZE="0.14841983245782286" MODIFIED="2014-03-07 14:10:43 +0000" MODIFIED_BY="[Empty name]" ORDER="953" O_E="0.0" SE="0.14097718127823392" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.019874565641156028" WEIGHT="78.88312655797829"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="26.22915596932831" CI_END="-1.2106199112484188" CI_START="-4.4257641752425805" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8181920432454994" ESTIMABLE="YES" I2="77.12469281506334" I2_Q="91.81036542088536" ID="CMP-003.08" MODIFIED="2015-09-15 22:28:46 +0100" MODIFIED_BY="Laura E  Prescott" NO="8" P_CHI2="2.0178678376292503E-4" P_Q="4.977703543795897E-6" P_Z="5.904562940757809E-4" Q="24.421114039696448" RANDOM="YES" SCALE="43.42" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="20.290654616338646" TOTALS="SUB" TOTAL_1="149" TOTAL_2="150" UNITS="" WEIGHT="300.0" Z="3.4359608482492385">
<NAME>Mental state: 4. General - BPRS/MS/PANSS total score at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Favours Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0471759980582798" CI_END="0.573617257648841" CI_START="-7.100058257659562" DF="3" EFFECT_SIZE="-3.2632205000053607" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" NO="1" P_CHI2="0.7898388361574626" P_Z="0.09552549013148942" STUDIES="4" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.00000000000001" Z="1.6669442539925403">
<NAME>BRPS at endpoint</NAME>
<CONT_DATA CI_END="6.51718921641273" CI_START="-10.417189216412721" EFFECT_SIZE="-1.9499999999999957" ESTIMABLE="YES" MEAN_1="42.74" MEAN_2="44.69" ORDER="246" SD_1="15.19" SD_2="12.39" SE="4.320073880541088" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" WEIGHT="20.5337533206134"/>
<CONT_DATA CI_END="2.2833021043729325" CI_START="-17.54330210437293" EFFECT_SIZE="-7.629999999999999" ESTIMABLE="YES" MEAN_1="31.7" MEAN_2="39.33" ORDER="247" SD_1="5.98" SD_2="16.37" SE="5.057900136210559" STUDY_ID="STD-Simhandl-1996" TOTAL_1="11" TOTAL_2="12" WEIGHT="14.979943930389762"/>
<CONT_DATA CI_END="5.615910261484975" CI_START="-8.815910261484978" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" MEAN_1="40.4" MEAN_2="42.0" ORDER="248" SD_1="8.93" SD_2="7.47" SE="3.6816545193703334" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="28.27252672895939"/>
<CONT_DATA CI_END="2.87582707561152" CI_START="-9.87582707561152" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="14.2" ORDER="249" SD_1="7.0" SD_2="6.8" SE="3.2530327730015602" STUDY_ID="STD-Terao-1995" TOTAL_1="9" TOTAL_2="9" WEIGHT="36.21377602003745"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.502534542714834E-33" CI_END="2.9322282103367154" CI_START="-1.532228210336715" DF="0" EFFECT_SIZE="0.7000000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-003.08.02" NO="2" P_CHI2="0.0" P_Z="0.5388049115744564" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.6146212035242964">
<NAME>MS at endpoint</NAME>
<CONT_DATA CI_END="2.9322282103367154" CI_START="-1.532228210336715" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="3.7" ORDER="250" SD_1="3.72" SD_2="3.92" SE="1.138912871840629" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7608659315735824" CI_END="-5.622319314818388" CI_START="-11.436262299308208" DF="1" EFFECT_SIZE="-8.529290807063298" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.03" MODIFIED="2013-10-28 10:04:42 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3830577036455024" P_Z="8.887798287146396E-9" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="5.750693751249295">
<NAME>PANSS at endpoint</NAME>
<CONT_DATA CI_END="-4.043881571602136" CI_START="-11.176118428397864" EFFECT_SIZE="-7.609999999999999" ESTIMABLE="YES" MEAN_1="47.22" MEAN_2="54.83" MODIFIED="2013-10-28 10:03:44 +0000" MODIFIED_BY="[Empty name]" ORDER="954" SD_1="7.35" SD_2="6.73" SE="1.8194816111555876" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="66.44924061812775"/>
<CONT_DATA CI_END="-5.33131895477644" CI_START="-15.36868104522355" EFFECT_SIZE="-10.349999999999994" ESTIMABLE="YES" MEAN_1="66.78" MEAN_2="77.13" MODIFIED="2013-10-28 10:04:42 +0000" MODIFIED_BY="[Empty name]" ORDER="955" SD_1="12.21" SD_2="12.35" SE="2.5605986052857452" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" WEIGHT="33.550759381872254"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0016939890983602422" CI_END="1.3098499308276172" CI_START="0.7404360545574183" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9848147616909021" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.11722154149788369" LOG_CI_START="-0.13051244200706158" LOG_EFFECT_SIZE="-0.006645450254588938" METHOD="MH" MODIFIED="2015-09-16 23:00:28 +0100" MODIFIED_BY="Laura E  Prescott" NO="9" P_CHI2="0.9671698639247015" P_Q="0.9683224352088818" P_Z="0.9162553181037996" Q="0.0015770732939255443" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="33" WEIGHT="200.0" Z="0.10515184857378969">
<NAME>Mental state: 5.1 Specific - depression - at least 20% MADRS/BPRS-depression score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.996466114657857E-31" CI_END="1.349784084948202" CI_START="0.7222687747817045" DF="0" EFFECT_SIZE="0.9873737373737373" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="100.0" ID="CMP-003.09.01" LOG_CI_END="0.13026430315051543" LOG_CI_START="-0.14130116020980651" LOG_EFFECT_SIZE="-0.0055184285296455094" MODIFIED="2015-09-16 23:00:28 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.0" P_Z="0.936510785440797" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.07965608760059895">
<NAME>Montgomery-Asberg</NAME>
<DICH_DATA CI_END="1.349784084948202" CI_START="0.7222687747817046" EFFECT_SIZE="0.9873737373737373" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.13026430315051543" LOG_CI_START="-0.14130116020980646" LOG_EFFECT_SIZE="-0.0055184285296455094" MODIFIED="2014-03-07 14:11:05 +0000" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.15951889744857686" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.025446278643209586" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9504751056297827" CI_START="0.4846081073552171" DF="0" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="0.2901404116810784" LOG_CI_START="-0.31460932451510165" LOG_EFFECT_SIZE="-0.012234456417011635" MODIFIED="2014-03-07 14:11:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9367919889986487" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="0.07930253628085578">
<NAME>BPRS depression</NAME>
<DICH_DATA CI_END="1.9504751056297827" CI_START="0.4846081073552171" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.2901404116810784" LOG_CI_START="-0.31460932451510165" LOG_EFFECT_SIZE="-0.012234456417011635" MODIFIED="2014-03-07 14:11:11 +0000" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.3552329886011098" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.12619047619047621" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15718933689260195" CI_END="1.4424292625111725" CI_START="0.7143982444046149" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0151201568365318" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.15909452432043197" LOG_CI_START="-0.1460596213736044" LOG_EFFECT_SIZE="0.006517451473413758" METHOD="MH" MODIFIED="2015-09-16 23:00:56 +0100" MODIFIED_BY="Laura E  Prescott" NO="10" P_CHI2="0.691757711843846" P_Q="0.6966528064274894" P_Z="0.9332779212327394" Q="0.15197756841282184" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="33" WEIGHT="200.0" Z="0.08372142629637691">
<NAME>Mental state: 5.2 Specific - depression - at least 35% MADRS/BPRS-depression score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4521573277399764" CI_START="0.6615142325391066" DF="0" EFFECT_SIZE="0.9801136363636364" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="0.16201367068082026" LOG_CI_START="-0.17946080749053409" LOG_EFFECT_SIZE="-0.0087235684048569" MODIFIED="2015-09-16 23:00:47 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.9202320041983933" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.10014148045120501">
<NAME>Montgomery-Asberg</NAME>
<DICH_DATA CI_END="1.4521573277399764" CI_START="0.6615142325391066" EFFECT_SIZE="0.9801136363636364" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.16201367068082026" LOG_CI_START="-0.17946080749053409" LOG_EFFECT_SIZE="-0.0087235684048569" MODIFIED="2014-03-07 14:11:31 +0000" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.20058379880378172" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.04023386034255598" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5522332471208498" CI_START="0.5333020062514144" DF="0" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-003.10.02" LOG_CI_END="0.4069203617844632" LOG_CI_START="-0.2730267825232368" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2014-03-07 14:11:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6995326188798945" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="0.38595146006585135">
<NAME>BPRS depression</NAME>
<DICH_DATA CI_END="2.5522332471208498" CI_START="0.5333020062514144" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.4069203617844632" LOG_CI_START="-0.2730267825232368" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2014-03-07 14:11:32 +0000" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.15952380952380954" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06044699877157091" CI_END="1.54282000540157" CI_START="0.7430894797366836" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0707256021694822" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.18831526162982268" LOG_CI_START="-0.12895888715991344" LOG_EFFECT_SIZE="0.029678187234954675" METHOD="MH" MODIFIED="2015-09-16 23:00:33 +0100" MODIFIED_BY="Laura E  Prescott" NO="11" P_CHI2="0.8057908333089605" P_Q="0.8080654071329483" P_Z="0.7138617920449017" Q="0.05901136005551063" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="33" WEIGHT="200.0" Z="0.36667455151221084">
<NAME>Mental state: 5.3 Specific - depression - at least 50% MADRS/BPRS-depression score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.580030659749928" CI_START="0.6917430366728172" DF="0" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.19866551431582788" LOG_CI_START="-0.16005520392505465" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2015-09-16 23:00:33 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="1.0" P_Z="0.8329204528842908" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.2109574773626881">
<NAME>Montgomery-Asberg</NAME>
<DICH_DATA CI_END="1.580030659749928" CI_START="0.6917430366728172" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.19866551431582788" LOG_CI_START="-0.16005520392505465" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2014-03-07 14:11:53 +0000" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.21071432559088776" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.04440052700922266" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5522332471208498" CI_START="0.5333020062514144" DF="0" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="0.4069203617844632" LOG_CI_START="-0.2730267825232368" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2014-03-07 14:11:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6995326188798945" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="0.38595146006585135">
<NAME>BPRS depression</NAME>
<DICH_DATA CI_END="2.5522332471208498" CI_START="0.5333020062514144" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.4069203617844632" LOG_CI_START="-0.2730267825232368" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2014-03-07 14:11:55 +0000" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.15952380952380954" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.43350522766111393" CI_END="1.0028309600321814" CI_START="-1.580735947871615" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2889524939197167" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.12" MODIFIED="2015-09-16 23:22:56 +0100" MODIFIED_BY="Laura E  Prescott" NO="12" P_CHI2="0.5102740012123136" P_Q="0.5102740012123136" P_Z="0.6610859034063213" Q="0.43350522766111393" RANDOM="YES" SCALE="47.68198083957376" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="29" TOTAL_2="32" UNITS="" WEIGHT="200.0" Z="0.4384144103975822">
<NAME>Mental state: 5.4 Specific - depression- average HS or MAS at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.457024040089472" CI_START="-7.657024040089475" DF="0" EFFECT_SIZE="3.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.01" NO="1" P_CHI2="1.0" P_Z="0.5467197689194081" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="9" WEIGHT="100.0" Z="0.6026827402450197">
<NAME>Hamilton Depression Scale (HS)</NAME>
<CONT_DATA CI_END="14.457024040089474" CI_START="-7.6570240400894765" EFFECT_SIZE="3.3999999999999986" ESTIMABLE="YES" MEAN_1="40.5" MEAN_2="37.1" ORDER="257" SD_1="13.2" SD_2="7.9" SE="5.641442458793054" STUDY_ID="STD-Schulz-1999" TOTAL_1="7" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9606905572849174" CI_START="-1.6406905572849189" DF="0" EFFECT_SIZE="-0.34000000000000075" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.02" MODIFIED="2015-09-16 23:01:04 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="1.0" P_Z="0.6084174053830698" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="99.99999999999999" Z="0.5123338145351406">
<NAME>Montgomery-Asberg Scale (MAS)</NAME>
<CONT_DATA CI_END="0.9606905572849174" CI_START="-1.6406905572849189" EFFECT_SIZE="-0.34000000000000075" ESTIMABLE="YES" MEAN_1="4.14" MEAN_2="4.48" ORDER="258" SD_1="1.55" SD_2="2.76" SE="0.6636298256215927" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5169104576974621" CI_START="0.720527174867402" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="0.18095994540398427" LOG_CI_START="-0.14234963501321105" LOG_EFFECT_SIZE="0.019305155195386624" METHOD="MH" MODIFIED="2015-09-29 12:13:58 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.8149360520698672" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="22" TOTAL_2="23" WEIGHT="0.0" Z="0.23406302312532212">
<NAME>Mental state: 6.1 Specific - mania - at least 20% Bech-Rafaelsen Mania Scale improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5169104576974621" CI_START="0.720527174867402" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.18095994540398427" LOG_CI_START="-0.14234963501321105" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2014-03-07 14:12:31 +0000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.18991364794529467" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.03606719367588933" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8154260371219044" CI_START="0.6982342003436349" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1258741258741258" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.25897855987289703" LOG_CI_START="-0.15599888273932125" LOG_EFFECT_SIZE="0.051489838566787884" METHOD="MH" MODIFIED="2015-09-29 12:14:08 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.6266982313354534" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="22" TOTAL_2="23" WEIGHT="0.0" Z="0.4863793488408489">
<NAME>Mental state: 6.2 Specific - mania - at least 35% Bech-Rafaelsen Mania Scale improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8154260371219044" CI_START="0.6982342003436349" EFFECT_SIZE="1.1258741258741258" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.25897855987289703" LOG_CI_START="-0.15599888273932125" LOG_EFFECT_SIZE="0.051489838566787884" MODIFIED="2014-03-07 14:14:00 +0000" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.2437598039618872" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.05941884202753768" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8154260371219044" CI_START="0.6982342003436349" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1258741258741258" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="0.25897855987289703" LOG_CI_START="-0.15599888273932125" LOG_EFFECT_SIZE="0.051489838566787884" METHOD="MH" MODIFIED="2015-09-29 12:14:22 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.6266982313354534" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="22" TOTAL_2="23" WEIGHT="0.0" Z="0.4863793488408489">
<NAME>Mental state: 6.3 Specific - mania - at least 50% Bech-Rafaelsen Mania Scale improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8154260371219044" CI_START="0.6982342003436349" EFFECT_SIZE="1.1258741258741258" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.25897855987289703" LOG_CI_START="-0.15599888273932125" LOG_EFFECT_SIZE="0.051489838566787884" MODIFIED="2014-03-07 14:14:31 +0000" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.2437598039618872" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.05941884202753768" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.322765143362753" CI_START="-3.617234856637248" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.4700000000000006" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.16" MODIFIED="2015-09-29 12:14:36 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="2.445102624395392E-5" Q="0.0" RANDOM="YES" SCALE="5.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="4.219808188189213">
<NAME>Mental state: 6.4 Specific - mania - mean PANSS-EC at endpoint</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.322765143362753" CI_START="-3.617234856637248" EFFECT_SIZE="-2.4700000000000006" ESTIMABLE="YES" MEAN_1="6.02" MEAN_2="8.49" MODIFIED="2014-03-10 15:47:59 +0000" MODIFIED_BY="[Empty name]" ORDER="957" SD_1="1.93" SD_2="2.56" SE="0.5853346621093498" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.258044232058689" CI_END="1.1186360808767906" CI_START="0.8217372636905529" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9587621979225182" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" I2="56.794330425114744" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="0.04868882310324432" LOG_CI_START="-0.08526701843195168" LOG_EFFECT_SIZE="-0.018289097664353687" METHOD="MH" MODIFIED="2015-09-16 23:01:46 +0100" MODIFIED_BY="Laura E  Prescott" NO="17" P_CHI2="0.054963581056265975" P_Q="0.40967874144937977" P_Z="0.592517870446283" Q="1.784764159706885" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.16407482343385138" TOTALS="SUB" TOTAL_1="67" TOTAL_2="68" WEIGHT="300.0" Z="0.535190885609129">
<NAME>Mental state: 7.1 Specific - negative symptoms - at least 20% SANS/MS/PANSS-negative score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.220657045170701" CI_END="3.102273774091752" CI_START="0.6555317426141146" DF="2" EFFECT_SIZE="1.4260571283074295" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" I2="52.61401297012723" ID="CMP-003.17.01" LOG_CI_END="0.49168012143722895" LOG_CI_START="-0.18340627375516802" LOG_EFFECT_SIZE="0.15413692384103048" MODIFIED="2014-03-07 14:15:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12119819968772072" P_Z="0.370784472785896" STUDIES="3" TAU2="0.2430988589710281" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.8950049106829202">
<NAME>SANS</NAME>
<DICH_DATA CI_END="4.96585068682259" CI_START="1.13037116737424" EFFECT_SIZE="2.3692307692307693" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6959936570502193" LOG_CI_START="0.053221071336995676" LOG_EFFECT_SIZE="0.3746073641936075" MODIFIED="2014-03-07 14:14:58 +0000" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.3775677986235618" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.14255744255744254" WEIGHT="40.774954374866994"/>
<DICH_DATA CI_END="1.6868147556723339" CI_START="0.3659838382961304" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2270673914174301" LOG_CI_START="-0.4365380924574561" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2014-03-07 14:15:00 +0000" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.38980514612823153" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="0.15194805194805194" WEIGHT="39.80569817042416"/>
<DICH_DATA CI_END="7.288027342184427" CI_START="0.3811426120343286" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.862609993292267" LOG_CI_START="-0.41891249405955416" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-03-07 14:15:01 +0000" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.752772652709081" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.5666666666666667" WEIGHT="19.41934745470885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1134050734341743" CI_START="0.8112818203120118" DF="0" EFFECT_SIZE="0.9504132231404959" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-003.17.02" LOG_CI_END="0.0466531959177906" LOG_CI_START="-0.09082825584346736" LOG_EFFECT_SIZE="-0.022087529962838373" MODIFIED="2014-03-07 14:15:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5288458767343238" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.6297687823341968">
<NAME>MS negative subscore</NAME>
<DICH_DATA CI_END="1.1134050734341743" CI_START="0.8112818203120118" EFFECT_SIZE="0.9504132231404959" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.0466531959177906" LOG_CI_START="-0.09082825584346736" LOG_EFFECT_SIZE="-0.022087529962838373" MODIFIED="2014-03-07 14:15:07 +0000" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.08075728530872485" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.006521739130434787" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.13913386929134" CI_START="0.1168697310574681" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-003.17.03" LOG_CI_END="0.3302379640363697" LOG_CI_START="-0.932297955364332" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-03-07 14:15:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.349974143204844" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.9346394676005982">
<NAME>PANSS negative</NAME>
<DICH_DATA CI_END="2.13913386929134" CI_START="0.1168697310574681" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3302379640363697" LOG_CI_START="-0.932297955364332" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-03-07 14:15:11 +0000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.7416198487095663" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.55" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2952964152961672" CI_END="1.199215471899076" CI_START="0.8468967818561499" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0077756317273363" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.07889722300654022" LOG_CI_START="-0.07216951741653486" LOG_EFFECT_SIZE="0.003363852795002707" METHOD="MH" MODIFIED="2015-09-16 23:02:01 +0100" MODIFIED_BY="Laura E  Prescott" NO="18" P_CHI2="0.6816255884096919" P_Q="0.9098528048182173" P_Z="0.930443923321948" Q="0.1889450184278053" RANDOM="YES" SCALE="32.76" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="67" TOTAL_2="68" WEIGHT="300.0" Z="0.08728632535573759">
<NAME>Mental state: 7.2 Specific - negative symptoms - at least 35% SANS/MS/PANSS-negative score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9502720064254229" CI_END="2.0416173907708215" CI_START="0.6366128837687287" DF="2" EFFECT_SIZE="1.1400526017210786" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-003.18.01" LOG_CI_END="0.3099743564354826" LOG_CI_START="-0.19612457637627037" LOG_EFFECT_SIZE="0.05692489002960612" MODIFIED="2014-03-07 14:15:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3771411462675257" P_Z="0.6592818915055865" STUDIES="3" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="99.99999999999999" Z="0.4409048391470555">
<NAME>SANS</NAME>
<DICH_DATA CI_END="3.926999890143944" CI_START="0.7560463880561527" EFFECT_SIZE="1.7230769230769232" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5940608891212256" LOG_CI_START="-0.12145155706657343" LOG_EFFECT_SIZE="0.23630466602732605" MODIFIED="2014-03-07 14:15:27 +0000" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.42029555273444386" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.17664835164835166" WEIGHT="50.03068600349255"/>
<DICH_DATA CI_END="1.8609766747808414" CI_START="0.2889760979089699" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2697409297790993" LOG_CI_START="-0.5391380775740119" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2014-03-07 14:15:29 +0000" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.4751395329348798" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="0.22575757575757574" WEIGHT="39.14747128505452"/>
<DICH_DATA CI_END="4.898310157597996" CI_START="0.14177224840841476" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.690046280884386" LOG_CI_START="-0.8484087729796358" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-03-07 14:15:30 +0000" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.9036961141150639" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.8166666666666667" WEIGHT="10.82184271145292"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1952199838873496" CI_START="0.8294378817162652" DF="0" EFFECT_SIZE="0.9956709956709957" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" I2="0.0" ID="CMP-003.18.02" LOG_CI_END="0.07744784586644377" LOG_CI_START="-0.08121613361554661" LOG_EFFECT_SIZE="-0.0018841438745514144" MODIFIED="2014-03-07 14:15:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9628723852093767" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.04654936990574717">
<NAME>MS negative subscore</NAME>
<DICH_DATA CI_END="1.1952199838873496" CI_START="0.8294378817162652" EFFECT_SIZE="0.9956709956709957" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.07744784586644377" LOG_CI_START="-0.08121613361554661" LOG_EFFECT_SIZE="-0.0018841438745514144" MODIFIED="2014-03-07 14:15:34 +0000" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.09320000694708637" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.008686241294936947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.867772482168174" CI_START="0.07210963413813187" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.18.03" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 14:15:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>PANSS negative</NAME>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 14:15:38 +0000" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0816582461004356" CI_END="1.1957238272153763" CI_START="0.8392464369811922" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0017519461443634" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="0.077630883526575" LOG_CI_START="-0.07611049387225483" LOG_EFFECT_SIZE="7.601948271601459E-4" METHOD="MH" MODIFIED="2015-09-16 23:02:06 +0100" MODIFIED_BY="Laura E  Prescott" NO="19" P_CHI2="0.897171311505474" P_Q="0.7795996717466425" P_Z="0.9845358840186275" Q="0.49794948909144876" RANDOM="YES" SCALE="138.87" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="67" TOTAL_2="68" WEIGHT="300.0" Z="0.019382608737819242">
<NAME>Mental state: 7.3 Specific - negative symptoms - at least 50% SANS/MS/PANSS-negative score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4179497872379489" CI_END="2.169637526002874" CI_START="0.4976686208936" DF="2" EFFECT_SIZE="1.0391152560735755" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-003.19.01" LOG_CI_END="0.3363871837997256" LOG_CI_START="-0.30305974161960586" LOG_EFFECT_SIZE="0.016663721090059855" MODIFIED="2014-03-07 14:15:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8114157038329544" P_Z="0.918636270064825" STUDIES="3" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.10215169355461401">
<NAME>SANS</NAME>
<DICH_DATA CI_END="3.9499905668768514" CI_START="0.45876822914734067" EFFECT_SIZE="1.3461538461538463" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5965960584724799" LOG_CI_START="-0.3384066657135644" LOG_EFFECT_SIZE="0.1290946963794577" MODIFIED="2014-03-07 14:15:53 +0000" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.549225228525012" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.3016483516483517" WEIGHT="46.771710688578864"/>
<DICH_DATA CI_END="2.816298732974714" CI_START="0.2416735810128673" EFFECT_SIZE="0.825" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.44967871978875007" LOG_CI_START="-0.6167708226888999" LOG_EFFECT_SIZE="-0.08354605145007493" MODIFIED="2014-03-07 14:15:55 +0000" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.6264377402617457" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="0.39242424242424234" WEIGHT="35.95244102613533"/>
<DICH_DATA CI_END="4.898310157597996" CI_START="0.14177224840841476" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.690046280884386" LOG_CI_START="-0.8484087729796358" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2014-03-07 14:15:55 +0000" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.9036961141150639" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.8166666666666667" WEIGHT="17.275848285285804"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1952199838873496" CI_START="0.8294378817162652" DF="0" EFFECT_SIZE="0.9956709956709957" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" I2="0.0" ID="CMP-003.19.02" LOG_CI_END="0.07744784586644377" LOG_CI_START="-0.08121613361554661" LOG_EFFECT_SIZE="-0.0018841438745514144" MODIFIED="2014-03-07 14:16:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9628723852093767" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.04654936990574717">
<NAME>MS negative subscore</NAME>
<DICH_DATA CI_END="1.1952199838873496" CI_START="0.8294378817162652" EFFECT_SIZE="0.9956709956709957" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.07744784586644377" LOG_CI_START="-0.08121613361554661" LOG_EFFECT_SIZE="-0.0018841438745514144" MODIFIED="2014-03-07 14:16:00 +0000" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.09320000694708637" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.008686241294936947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="65.90289327402995" CI_START="0.13656456572516806" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.19.03" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-07 14:16:04 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.48584124712227683" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6969385642065118">
<NAME>PANSS negative</NAME>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-07 14:16:04 +0000" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.347967998379203" CI_END="0.7743693658800685" CI_START="-0.3339704542626741" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2201994558086972" ESTIMABLE="YES" I2="18.3447723054392" I2_Q="37.95255754583802" ID="CMP-003.20" MODIFIED="2015-09-16 23:23:26 +0100" MODIFIED_BY="Laura E  Prescott" NO="20" P_CHI2="0.28986228525968605" P_Q="0.18428504926320777" P_Z="0.4361023532022563" Q="4.835009923602045" RANDOM="YES" SCALE="30.27269141572956" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.3754439431084414" TOTALS="SUB" TOTAL_1="129" TOTAL_2="130" UNITS="" WEIGHT="400.0" Z="0.7787918379487302">
<NAME>Mental state: 7.4 Specific - negative symptoms - BPRS, MS, SANS, or PANSS negative score at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1439460277081261" CI_END="2.4260997291719972" CI_START="-1.309273851346121" DF="1" EFFECT_SIZE="0.558412938912938" ESTIMABLE="YES" I2="12.583288391369237" ID="CMP-003.20.01" NO="1" P_CHI2="0.2848200970885707" P_Z="0.5578737944432455" STUDIES="2" TAU2="0.2466576190476199" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="0.5860025644978271">
<NAME>BPRS negative subscore</NAME>
<CONT_DATA CI_END="3.410945784253358" CI_START="-0.8509457842533594" EFFECT_SIZE="1.2799999999999994" ESTIMABLE="YES" MEAN_1="9.33" MEAN_2="8.05" ORDER="277" SD_1="3.28" SD_2="3.66" SE="1.087237215102924" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" WEIGHT="63.55620903600701"/>
<CONT_DATA CI_END="2.236677553368484" CI_START="-3.6366775533684863" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="13.8" ORDER="278" SD_1="3.4" SD_2="3.3" SE="1.4983324063771697" STUDY_ID="STD-Wilson-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="36.443790963992996"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8890484636757879" CI_START="-0.30904846367578787" DF="0" EFFECT_SIZE="0.29000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.20.02" NO="2" P_CHI2="1.0" P_Z="0.34271184659578735" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.9488206547245815">
<NAME>MS negative subscore</NAME>
<CONT_DATA CI_END="0.8890484636757879" CI_START="-0.30904846367578787" EFFECT_SIZE="0.29000000000000004" ESTIMABLE="YES" MEAN_1="0.68" MEAN_2="0.39" ORDER="279" SD_1="1.1" SD_2="0.94" SE="0.3056425875174267" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3666679687546247" CI_END="2.7177253704328614" CI_START="-2.850053775955137" DF="1" EFFECT_SIZE="-0.06616420276113766" ESTIMABLE="YES" I2="0.0" ID="CMP-003.20.03" MODIFIED="2013-05-13 13:33:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5448264002204531" P_Z="0.9628462895117549" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="100.00000000000001" Z="0.04658211149117248">
<NAME>PANSS negative subscore</NAME>
<CONT_DATA CI_END="2.8168134500473605" CI_START="-4.336813450047364" EFFECT_SIZE="-0.7600000000000016" ESTIMABLE="YES" MEAN_1="17.79" MEAN_2="18.55" MODIFIED="2013-05-13 13:33:07 +0100" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="9.2" SD_2="8.28" SE="1.8249383551232625" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" WEIGHT="60.57751152051914"/>
<CONT_DATA CI_END="5.433839692300527" CI_START="-3.433839692300527" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="19.0" MODIFIED="2013-05-13 13:32:58 +0100" MODIFIED_BY="[Empty name]" ORDER="280" SD_1="5.89" SD_2="4.06" SE="2.2622046768583957" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="39.422488479480876"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9459425337152815" CI_END="-0.1942092335175838" CI_START="-8.808372732631465" DF="1" EFFECT_SIZE="-4.501290983074524" ESTIMABLE="YES" I2="0.0" ID="CMP-003.20.04" NO="4" P_CHI2="0.33075441646845727" P_Z="0.04052668754191369" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="2.0483400881974205">
<NAME>SANS</NAME>
<CONT_DATA CI_END="-0.6862953361180768" CI_START="-9.813704663881923" EFFECT_SIZE="-5.25" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="16.25" ORDER="281" SD_1="4.3" SD_2="6.7" SE="2.3284635329423615" STUDY_ID="STD-Simhandl-1996" TOTAL_1="11" TOTAL_2="12" WEIGHT="89.06994135875217"/>
<CONT_DATA CI_END="14.62782358160501" CI_START="-11.427823581605008" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="43.6" MEAN_2="42.0" ORDER="282" SD_1="14.2" SD_2="14.0" SE="6.646970905775218" STUDY_ID="STD-Terao-1995" TOTAL_1="9" TOTAL_2="9" WEIGHT="10.930058641247822"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.8753140271203064" CI_END="1.1887343870660831" CI_START="0.9482639833038456" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0617127695236313" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="0.07508482592395635" LOG_CI_START="-0.02307074437848291" LOG_EFFECT_SIZE="0.026007040772736696" METHOD="MH" MODIFIED="2015-09-16 23:02:24 +0100" MODIFIED_BY="Laura E  Prescott" NO="21" P_CHI2="0.41125160147704864" P_Q="0.6239648101185518" P_Z="0.29898441582474367" Q="0.943322740661362" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="57" TOTAL_2="57" WEIGHT="300.0" Z="1.0386137659221977">
<NAME>Mental state: 8.1 Specific - positive symptoms - at least 20% BPRS/MS/PANSS-positive score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5923607021283332" CI_END="1.8170383757616082" CI_START="0.8743213677266566" DF="1" EFFECT_SIZE="1.2604267046947681" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="0.0" ID="CMP-003.21.01" LOG_CI_END="0.2593640996831072" LOG_CI_START="-0.058328907666302506" LOG_EFFECT_SIZE="0.1005175960084024" MODIFIED="2014-03-07 14:16:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4415078510009609" P_Z="0.21487949104657278" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="1.2402593914970022">
<NAME>BPRS positive subscore</NAME>
<DICH_DATA CI_END="1.7749070331306656" CI_START="0.790640626958486" EFFECT_SIZE="1.1846153846153846" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.24917561031746607" LOG_CI_START="-0.10202087325821343" LOG_EFFECT_SIZE="0.0735773685296263" MODIFIED="2014-03-07 14:16:24 +0000" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.2062945529029852" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.042557442557442565" WEIGHT="81.83046028078905"/>
<DICH_DATA CI_END="3.9309966386143147" CI_START="0.7066344830956026" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.5945026724560905" LOG_CI_START="-0.15080517322337778" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-03-07 14:16:25 +0000" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.43779751788545657" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.19166666666666668" WEIGHT="18.169539719210952"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1764315314558769" CI_START="0.9255505754422314" DF="0" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-003.21.02" LOG_CI_END="0.0705666562241641" LOG_CI_START="-0.03359984483613781" LOG_EFFECT_SIZE="0.018483405694013133" MODIFIED="2014-03-07 14:16:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.48670702972105206" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.6955558476700036">
<NAME>MS positive subscore</NAME>
<DICH_DATA CI_END="1.1764315314558769" CI_START="0.9255505754422314" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.0705666562241641" LOG_CI_START="-0.03359984483613781" LOG_EFFECT_SIZE="0.018483405694013133" MODIFIED="2014-03-07 14:16:29 +0000" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.061187918355317596" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.0037439613526570117" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.402530460804138" CI_START="0.41622781326372665" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-003.21.03" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.3806689026362286" LOG_EFFECT_SIZE="0.0" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>PANSS positive</NAME>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.41622781326372665" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.3806689026362286" LOG_EFFECT_SIZE="0.0" ORDER="286" O_E="0.0" SE="0.447213595499958" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.20000000000000004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6983156732897818" CI_END="1.219378950561642" CI_START="0.7782143905033513" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9741346143136196" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="0.08613869377444544" LOG_CI_START="-0.10890074261681369" LOG_EFFECT_SIZE="-0.011381024421184103" METHOD="MH" MODIFIED="2015-09-16 23:02:19 +0100" MODIFIED_BY="Laura E  Prescott" NO="22" P_CHI2="0.8736000676738731" P_Q="0.8228651391738786" P_Z="0.8190730947566411" Q="0.38992607020164327" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="57" TOTAL_2="57" WEIGHT="300.0" Z="0.22873730959664892">
<NAME>Mental state: 8.2 Specific - positive symptoms - at least 35% BPRS/MS/PANSS-positive score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.15160397526993136" CI_END="1.9767427967330098" CI_START="0.6578848897424924" DF="1" EFFECT_SIZE="1.1403811717482721" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="0.0" ID="CMP-003.22.01" LOG_CI_END="0.29595016489976295" LOG_CI_START="-0.1818500883357777" LOG_EFFECT_SIZE="0.05705003828199261" MODIFIED="2014-03-07 14:16:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6970073937674497" P_Z="0.6397523794447796" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.4680450443135913">
<NAME>BPRS positive subscore</NAME>
<DICH_DATA CI_END="2.0117205012744623" CI_START="0.5765032035388294" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3035676417983455" LOG_CI_START="-0.23919827505554303" LOG_EFFECT_SIZE="0.032184683371401235" MODIFIED="2014-03-07 14:16:58 +0000" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.3188233862945936" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.10164835164835165" WEIGHT="77.49391727493916"/>
<DICH_DATA CI_END="4.42838251858425" CI_START="0.43560201441128343" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6462451276843918" LOG_CI_START="-0.3609101205469288" LOG_EFFECT_SIZE="0.14266750356873154" MODIFIED="2014-03-07 14:16:59 +0000" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.35" WEIGHT="22.506082725060825"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.211413568503001" CI_START="0.7308073315122182" DF="0" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" ID="CMP-003.22.02" LOG_CI_END="0.08329243369328918" LOG_CI_START="-0.13619710442386615" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2014-03-07 14:17:04 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6366270277906552" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.47242000751094887">
<NAME>MS positive subscore</NAME>
<DICH_DATA CI_END="1.211413568503001" CI_START="0.7308073315122182" EFFECT_SIZE="0.9409090909090909" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.08329243369328918" LOG_CI_START="-0.13619710442386615" LOG_EFFECT_SIZE="-0.02645233536528848" MODIFIED="2014-03-07 14:17:04 +0000" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.1289292411807534" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.016622749231444883" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.925649438310225" CI_START="0.3418044509726267" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-003.22.03" LOG_CI_END="0.4662222862019852" LOG_CI_START="-0.46622228620198514" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 14:17:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>PANSS positive</NAME>
<DICH_DATA CI_END="2.925649438310225" CI_START="0.3418044509726267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.4662222862019852" LOG_CI_START="-0.46622228620198514" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 14:17:08 +0000" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.30000000000000004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4192264592846326" CI_END="1.2061507734810588" CI_START="0.7152301771145031" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.928803225308597" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="0.08140159967647012" LOG_CI_START="-0.14555416999817838" LOG_EFFECT_SIZE="-0.03207628516085416" METHOD="MH" MODIFIED="2015-09-16 23:02:36 +0100" MODIFIED_BY="Laura E  Prescott" NO="23" P_CHI2="0.4900658650237414" P_Q="0.3863868021859175" P_Z="0.5795691055106837" Q="1.9018330305751177" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="57" TOTAL_2="57" WEIGHT="300.0" Z="0.5540142360181934">
<NAME>Mental state: 8.3 Specific - positive symptoms - at least 50% BPRS/MS/PANSS-positive score improvement</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03232057879825148" CI_END="2.2782404889081" CI_START="0.7070908287387885" DF="1" EFFECT_SIZE="1.2692213973016258" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" ID="CMP-003.23.01" LOG_CI_END="0.357599565877015" LOG_CI_START="-0.15052479569897365" LOG_EFFECT_SIZE="0.10353738508902072" MODIFIED="2014-03-07 14:17:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8573259196900824" P_Z="0.4244413785837525" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.7987396833268636">
<NAME>BPRS positive subscore</NAME>
<DICH_DATA CI_END="2.4234458264666614" CI_START="0.625057462752045" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3844333159797372" LOG_CI_START="-0.20408005528156112" LOG_EFFECT_SIZE="0.09017663034908803" MODIFIED="2014-03-07 14:17:22 +0000" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.34569566746705765" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.1195054945054945" WEIGHT="74.54651843183147"/>
<DICH_DATA CI_END="4.42838251858425" CI_START="0.43560201441128343" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.6462451276843918" LOG_CI_START="-0.3609101205469288" LOG_EFFECT_SIZE="0.14266750356873154" MODIFIED="2014-03-07 14:17:27 +0000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.35" WEIGHT="25.453481568168513"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.172080099454433E-31" CI_END="1.1299735697835755" CI_START="0.619044684704777" DF="0" EFFECT_SIZE="0.8363636363636363" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="100.0" ID="CMP-003.23.02" LOG_CI_END="0.05306828540254423" LOG_CI_START="-0.20827800102788382" LOG_EFFECT_SIZE="-0.0776048578126698" MODIFIED="2014-03-07 14:17:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.2444265513008217" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="99.99999999999999" Z="1.163993783234225">
<NAME>MS positive subscore</NAME>
<DICH_DATA CI_END="1.1299735697835755" CI_START="0.619044684704777" EFFECT_SIZE="0.8363636363636363" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.05306828540254423" LOG_CI_START="-0.20827800102788382" LOG_EFFECT_SIZE="-0.0776048578126698" MODIFIED="2014-03-07 14:17:32 +0000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.1535161023342155" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.02356719367588933" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.4869472965209996" CI_START="0.396210978264932" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.23.03" LOG_CI_END="0.6519509683597887" LOG_CI_START="-0.40207349514318896" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-03-07 14:17:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6421832215115779" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.4646484640638742">
<NAME>PANSS positive</NAME>
<DICH_DATA CI_END="4.4869472965209996" CI_START="0.396210978264932" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6519509683597887" LOG_CI_START="-0.40207349514318896" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-03-07 14:17:35 +0000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.470492878253058" CI_END="-0.01684073301176614" CI_START="-2.2407960487294813" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1288183908706237" ESTIMABLE="YES" I2="64.5829346282537" I2_Q="76.32928554893782" ID="CMP-003.24" MODIFIED="2015-09-16 23:03:01 +0100" MODIFIED_BY="Laura E  Prescott" NO="24" P_CHI2="0.037225918338322006" P_Q="0.014630778126427213" P_Z="0.04662979718006502" Q="8.449259122004463" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="2.882481454362888" TOTALS="SUB" TOTAL_1="99" TOTAL_2="99" UNITS="" WEIGHT="300.0" Z="1.9896473418836476">
<NAME>Mental state: 8.4 Specific - positive symptoms - mean BPRS, MS, or PANSS-positive subscore (high = poor)</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.725630262718079" CI_START="-3.445630262718078" DF="0" EFFECT_SIZE="0.14000000000000057" ESTIMABLE="YES" I2="0.0" ID="CMP-003.24.01" NO="1" P_CHI2="1.0" P_Z="0.9390004041136779" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.0765262834511008">
<NAME>BPRS positive subscore</NAME>
<CONT_DATA CI_END="3.725630262718079" CI_START="-3.445630262718078" EFFECT_SIZE="0.14000000000000057" ESTIMABLE="YES" MEAN_1="12.84" MEAN_2="12.7" ORDER="295" SD_1="6.28" SD_2="5.42" SE="1.829436811595046" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7955149511692057" CI_START="-1.3355149511692057" DF="0" EFFECT_SIZE="0.22999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-003.24.02" NO="2" P_CHI2="1.0" P_Z="0.773384188359056" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0" Z="0.28795107712483897">
<NAME>Manchester Scale positive subscore</NAME>
<CONT_DATA CI_END="1.7955149511692057" CI_START="-1.3355149511692057" EFFECT_SIZE="0.22999999999999998" ESTIMABLE="YES" MEAN_1="2.23" MEAN_2="2.0" ORDER="296" SD_1="2.88" SD_2="2.45" SE="0.7987467951032712" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.021233756248595206" CI_END="-1.3915545377013177" CI_START="-4.91099082997877" DF="1" EFFECT_SIZE="-3.1512726838400438" ESTIMABLE="YES" I2="0.0" ID="CMP-003.24.03" MODIFIED="2013-10-28 12:05:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8841439654745387" P_Z="4.483267499231932E-4" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="100.0" Z="3.509869452300603">
<NAME>PANSS positive subscore</NAME>
<CONT_DATA CI_END="-1.3221931511762175" CI_START="-5.077806848823781" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" MEAN_1="12.57" MEAN_2="15.77" MODIFIED="2013-10-28 12:05:54 +0000" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="4.38" SD_2="4.8" SE="0.9580823237751727" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" WEIGHT="87.81817096001102"/>
<CONT_DATA CI_END="2.2418144929418213" CI_START="-7.841814492941823" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="19.1" ORDER="297" SD_1="5.46" SD_2="6.03" SE="2.572401601616668" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.181829039988989"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.07742575399410834" CI_START="-2.7574257539941063" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.339999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.25" MODIFIED="2014-03-12 20:55:42 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.06389633309746923" Q="0.0" RANDOM="YES" SCALE="4.3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.852902511389383">
<NAME>Aggressive behaviour - mean PANSS supplemental aggression risk profile at endpoint</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.07742575399410834" CI_START="-2.7574257539941063" DF="0" EFFECT_SIZE="-1.339999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.25.01" MODIFIED="2013-10-28 11:42:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06389633309746923" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.852902511389383">
<NAME>PANSS Supplemental at endpoint</NAME>
<CONT_DATA CI_END="0.07742575399410834" CI_START="-2.7574257539941063" EFFECT_SIZE="-1.339999999999999" ESTIMABLE="YES" MEAN_1="7.11" MEAN_2="8.45" MODIFIED="2013-10-28 11:42:41 +0000" MODIFIED_BY="[Empty name]" ORDER="958" SD_1="2.25" SD_2="3.26" SE="0.7231896938793675" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.1823876850660513" CI_START="-13.617612314933943" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.899999999999998" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.26" MODIFIED="2015-09-29 12:16:23 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.044095872862625715" Q="0.0" RANDOM="YES" SCALE="21.18" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="11" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="2.0131783227891367">
<NAME>Medication use: 1. Mean haloperidol dose (high = poor)</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.18238768506605219" CI_START="-13.617612314933945" EFFECT_SIZE="-6.899999999999999" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="25.9" ORDER="298" SD_1="8.0" SD_2="7.7" SE="3.4274162014820755" STUDY_ID="STD-Wilson-1993" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.27" MODIFIED="2015-09-16 23:10:51 +0100" MODIFIED_BY="Laura E  Prescott" NO="27" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Medication use: 2. Mean dose of antipsychotics (unable to use - skewed data)</NAME>
<TR>
<TH>
<P>Mean + SD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-09-16 23:10:51 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="488" STUDY_ID="STD-Biederman-1979">
<TR>
<TD>
<P>1. Haloperidol + lithium: at week 5 mean (range) dose = 28 (10 to 60) mg/day, SD ?. N = 15.<BR/>2. Haloperidol + placebo: at week 5 mean (range) dose = 35 (8 to 70) mg/day, SD ?. N = 18. No statistically significant difference.<BR/>
</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-09-16 23:10:45 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="489" STUDY_ID="STD-Collins-1991">
<TR>
<TD>
<P>1. Antipsychotics + lithium: at week 4 mean dose in chlorpromazine equivalents = 1452 mg/day, SD ?. N = 21.<BR/>2. Antipsychotics + placebo: at week 4 mean dose in chlorpromazine equivalents = 1257 mg/day, SD ?. N = 23.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-09-16 23:10:32 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="490" STUDY_ID="STD-Feng-2006">
<TR>
<TD>
<P>1. Antipsychotics + lithium: clozapine mean dose = 425.66 ± 201.65 mg/d. N = 30.</P>
<P>2. Antipsychotics + placebo: clozapine mean dose = 438.70 ± 238.12 mg/d. N = 30.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-09-16 23:10:39 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="491" STUDY_ID="STD-He-2010">
<TR>
<TD>
<P>1. Antipsychotics + lithium: risperidone flexible dose, mean = 3.8 ± 1.4 mg/d. N = 46.</P>
<P>2. Antipsychotics + placebo: risperidone flexible dose, mean = 4.2 ± 1.6 mg/d. N = 46.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3822864389716412" CI_START="0.5023882350759947" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.28" LOG_CI_END="0.14059804736152123" LOG_CI_START="-0.29896053945677087" LOG_EFFECT_SIZE="-0.0791812460476248" METHOD="MH" MODIFIED="2015-09-29 12:16:40 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.4801083259862916" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0" Z="0.7061283531175958">
<NAME>Medication use: 3. Number of particpants taking benzodiazepines</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3822864389716412" CI_START="0.5023882350759947" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.14059804736152123" LOG_CI_START="-0.29896053945677087" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="301" O_E="0.0" SE="0.25819888974716115" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.06666666666666668" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.254926467997521E-5" CI_END="23.27694532058797" CI_START="0.28247143297288835" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5641903400368027" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.29" LOG_CI_END="1.3669259863963654" LOG_CI_START="-0.5490254668872605" LOG_EFFECT_SIZE="0.4089502597545525" METHOD="MH" MODIFIED="2015-09-15 22:38:58 +0100" MODIFIED_BY="Laura E  Prescott" NO="29" P_CHI2="0.9927507898352164" P_Q="1.0" P_Z="0.40276739567616626" Q="0.0" RANDOM="YES" SCALE="142.32" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="28" WEIGHT="100.0" Z="0.8366890290602469">
<NAME>Adverse events: 1. Central nervous system - delirium</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="59.93150212827431" CI_START="0.11200803715861513" EFFECT_SIZE="2.590909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7776551630267885" LOG_CI_START="-0.9507508133262184" LOG_EFFECT_SIZE="0.4134521748502851" ORDER="302" O_E="0.0" SE="1.6026791763371584" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="2.5685805422647525" WEIGHT="49.31181832487986"/>
<DICH_DATA CI_END="56.25027384808488" CI_START="0.11455565531380806" EFFECT_SIZE="2.5384615384615383" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7501246411020248" LOG_CI_START="-0.9409834659599233" LOG_EFFECT_SIZE="0.4045705875710507" ORDER="303" O_E="0.0" SE="1.5807702232881597" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.4988344988344986" WEIGHT="50.68818167512015"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2210281912491614" CI_END="1.386972575771832" CI_START="0.6257500676348037" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9316105318730794" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-003.30" LOG_CI_END="0.1420678739725556" LOG_CI_START="-0.20359909477859583" LOG_EFFECT_SIZE="-0.03076561040302008" METHOD="MH" MODIFIED="2015-09-16 23:24:01 +0100" MODIFIED_BY="Laura E  Prescott" NO="30" P_CHI2="0.8177929248024891" P_Q="0.9300896819015846" P_Z="0.7271735703303168" Q="0.44831877961487443" RANDOM="YES" SCALE="827.1016834537805" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="174" TOTAL_2="172" WEIGHT="400.0" Z="0.3488877665700266">
<NAME>Adverse events: 2. Movement disorder - dichotomous data</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0599520239721576" CI_END="9.401416741527099" CI_START="0.22188617137318378" DF="1" EFFECT_SIZE="1.444314497005829" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="51.45518010309176" ID="CMP-003.30.01" LOG_CI_END="0.9731933043087729" LOG_CI_START="-0.6538697634888633" LOG_EFFECT_SIZE="0.15966177040995483" MODIFIED="2015-09-16 23:03:16 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.1512149761718139" P_Z="0.7004909020226822" STUDIES="2" TAU2="1.1698778875464588" TOTAL_1="57" TOTAL_2="56" WEIGHT="100.0" Z="0.3846578856159433">
<NAME>At least one extrapyramidal side effect</NAME>
<DICH_DATA CI_END="1.4910173910457445" CI_START="0.442755566745597" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.17348270904062266" LOG_CI_START="-0.35383596973879866" LOG_EFFECT_SIZE="-0.09017663034908802" MODIFIED="2013-10-29 10:10:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1052" O_E="0.0" SE="0.3097496021845899" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.09594481605351171" WEIGHT="72.16242144343785"/>
<DICH_DATA CI_END="110.70884355637304" CI_START="0.3719089621792091" EFFECT_SIZE="6.416666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0441823142330944" LOG_CI_START="-0.42956335598338025" LOG_EFFECT_SIZE="0.8073094791248571" ORDER="304" O_E="0.0" SE="1.4530904519237133" STUDY_ID="STD-Wilson-1993" TOTAL_1="11" TOTAL_2="10" VAR="2.1114718614718613" WEIGHT="27.837578556562153"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0399793212954095" CI_END="1.6268796939853547" CI_START="0.5847256745358046" DF="1" EFFECT_SIZE="0.9753349816622953" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-003.30.02" LOG_CI_END="0.21135543851147262" LOG_CI_START="-0.23304783644418686" LOG_EFFECT_SIZE="-0.010846198966357128" NO="2" P_CHI2="0.8415211134321846" P_Z="0.9237822081418073" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.0" Z="0.09567057913934834">
<NAME>Use of antiparkinson medication</NAME>
<DICH_DATA CI_END="3.4430769834963186" CI_START="0.336839204922967" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5369467331705107" LOG_CI_START="-0.4725773664277082" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="305" O_E="0.0" SE="0.5929994533288809" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.3516483516483516" WEIGHT="19.378542935124926"/>
<DICH_DATA CI_END="1.6837606084015988" CI_START="0.5386926585241216" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.2262803449779686" LOG_CI_START="-0.2686589431178448" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="306" O_E="0.0" SE="0.29072978781646974" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="0.08452380952380953" WEIGHT="80.62145706487507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9912106182795823" CI_START="0.28249146264899055" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-003.30.03" LOG_CI_END="0.2991171995145256" LOG_CI_START="-0.5489946727311255" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-05-15 14:55:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5636286227939291" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.5774601960890298">
<NAME>Akathisia</NAME>
<DICH_DATA CI_END="1.9912106182795826" CI_START="0.28249146264899055" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2991171995145256" LOG_CI_START="-0.5489946727311255" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-10 15:58:06 +0000" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.4981851119785711" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.24818840579710144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2141687468901163" CI_START="0.34578439474197675" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-003.30.04" LOG_CI_END="0.34521071638484657" LOG_CI_START="-0.4611946103402201" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2014-05-15 14:55:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.778021527460547" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.28189825563583887">
<NAME>Tremor</NAME>
<DICH_DATA CI_END="2.2141687468901163" CI_START="0.34578439474197675" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.34521071638484657" LOG_CI_START="-0.4611946103402201" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2014-03-10 15:58:15 +0000" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.4736864806890499" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.22437888198757766" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.925100555381657" CI_START="-0.5251005553816581" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.31" MODIFIED="2015-09-29 12:17:01 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.0" P_Q="0.0" P_Z="0.10082878079133621" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="11" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="1.6408489184709787">
<NAME>Adverse events: 3. Movement disorder - average SAS score at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.925100555381657" CI_START="-0.5251005553816581" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="11.9" ORDER="307" SD_1="4.6" SD_2="2.8" SE="1.6454897032908966" STUDY_ID="STD-Wilson-1993" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-003.32" MODIFIED="2015-09-16 23:12:14 +0100" MODIFIED_BY="Laura E  Prescott" NO="32" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Adverse events: 4. Movement disorder - unable to use (skewed data)</NAME>
<TR>
<TH>
<P>Global EPS</P>
</TH>
<TH>
<P>Tardive dyskinesia</P>
</TH>
<TH>
<P>Akathisia</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-09-16 23:11:52 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="502" STUDY_ID="STD-Johnstone-1988">
<TR>
<TD>
<P>TAKE global score at endpoint (high = poor).<BR/>Pimozide + placebo: mean = 5.5, SD = 4.0. N = 23.<BR/>Pimozide + lithium: mean = 6.9, SD = 3.2. N = 21.</P>
</TD>
<TD>
<P>AIMS global score at endpoint (high = poor).<BR/>Pimozide + placebo: mean = 3.6, SD = 3.2. N = 23.<BR/>Pimozide + lithium: mean = 4.3, SD = 4.0. N = 21.</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-09-16 23:11:58 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="503" STUDY_ID="STD-Simhandl-1996">
<TR>
<TD>
<P>Mean SAS at endpoint (high = poor).<BR/>Lithium + antipsychotics: mean = 0.24, SD = 0.16. N = 11.<BR/>Placebo + antipsychotics: mean = 0.31, SD = 0.35. N = 12.</P>
</TD>
<TD>
<P>Mean AIMS at endpoint (high = poor).<BR/>Lithium + antipsychotics: mean = 8.1, SD = 7.3. N = 11.<BR/>Placebo + antipsychotics: mean = 13.08, SD = 14.2. N = 12.</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-09-16 23:12:14 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="504" STUDY_ID="STD-Wilson-1993">
<TR>
<TD>
<P>-</P>
</TD>
<TD>
<P>Mean AIMS at endpoint (high = poor).<BR/>Lithium + antipsychotics: mean = 1.7, SD = 2.2. N = 11.<BR/>Placebo + antipsychotics: mean = 1.2, SD = 0.9. N= 10.</P>
</TD>
<TD>
<P>Mean BAS at endpoint (high = poor).<BR/>Lithium + antipsychotics: mean = 1.3, SD = 2.0. N = 11.<BR/>Placebo + antipsychotics: mean = 2.1, SD = 1.7. N = 10.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="56.25027384808488" CI_START="0.11455565531380806" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5384615384615383" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.33" LOG_CI_END="1.7501246411020248" LOG_CI_START="-0.9409834659599233" LOG_EFFECT_SIZE="0.4045705875710507" METHOD="MH" MODIFIED="2015-09-29 12:17:19 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.0" P_Q="0.0" P_Z="0.5556556728623783" Q="0.0" RANDOM="YES" SCALE="203.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0" Z="0.5893065230360991">
<NAME>Adverse events: 5. Non-specific dyscomfort</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="56.25027384808488" CI_START="0.11455565531380806" EFFECT_SIZE="2.5384615384615383" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7501246411020248" LOG_CI_START="-0.9409834659599233" LOG_EFFECT_SIZE="0.4045705875710507" ORDER="311" O_E="0.0" SE="1.5807702232881597" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.4988344988344986" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.34" MODIFIED="2015-09-16 23:13:10 +0100" MODIFIED_BY="Laura E  Prescott" NO="34" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events: 6. UKU at endpoint - unable to use (skewed data)</NAME>
<TR>
<TH>
<P>Mean + SD</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-09-16 23:13:10 +0100" MODIFIED_BY="Laura E  Prescott" ORDER="506" STUDY_ID="STD-Terao-1995">
<TR>
<TD>
<P>Antipsychotics + placebo: mean = 8.2, SD = 5.4. N = 9.<BR/>Antipsychotics + lithium: mean = 8.3, SD = 4.6. N = 9.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="2.565584048762727" CI_END="1.2762966949961485" CI_START="0.9195293189183922" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0833246192566675" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-003.35" LOG_CI_END="0.10595164462145548" LOG_CI_START="-0.036434418854967045" LOG_EFFECT_SIZE="0.03475861288324425" METHOD="MH" MODIFIED="2015-09-29 12:17:50 +0100" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="0.9953130082911977" P_Q="0.9970772749772829" P_Z="0.3386105298574168" Q="2.3098701996493785" RANDOM="YES" SCALE="70.84" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="504" TOTAL_2="504" WEIGHT="1200.0" Z="0.9569142897894561">
<NAME>Adverse events: Specific</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5399299880525907" CI_START="0.5022070447093165" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-003.35.01" LOG_CI_END="0.5489946727311255" LOG_CI_START="-0.29911719951452553" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-03-10 16:01:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5636286227939293" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.5774601960890297">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="3.5399299880525907" CI_START="0.5022070447093164" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5489946727311255" LOG_CI_START="-0.29911719951452564" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-10-29 09:46:25 +0000" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.4981851119785711" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.24818840579710144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.698485942633469" CI_START="0.2128345199303729" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.35.02" LOG_CI_END="0.671957931830753" LOG_CI_START="-0.6719579318307531" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-10 16:02:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.0">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="4.698485942633469" CI_START="0.2128345199303729" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.671957931830753" LOG_CI_START="-0.6719579318307531" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-29 09:41:34 +0000" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.7894228308055838" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.6231884057971014" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2062188989831335" CI_START="0.4245222032540553" DF="0" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-003.35.03" LOG_CI_END="0.5059931697259057" LOG_CI_START="-0.3720995904646793" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2014-03-10 16:02:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7650470505586779" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.2988597617593439">
<NAME>Dry mouth</NAME>
<DICH_DATA CI_END="3.2062188989831335" CI_START="0.4245222032540553" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5059931697259057" LOG_CI_START="-0.3720995904646793" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2013-10-29 09:46:50 +0000" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.5157960339652141" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.26604554865424435" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3948925816226532" CI_START="0.9073279309634877" DF="0" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" I2="0.0" ID="CMP-003.35.04" LOG_CI_END="0.14454076459545367" LOG_CI_START="-0.042235719700691156" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2015-09-16 23:03:33 +0100" MODIFIED_BY="Laura E  Prescott" NO="4" P_CHI2="1.0" P_Z="0.2830236926189563" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.0735516528545488">
<NAME>Electroencephalogram abnormalities</NAME>
<DICH_DATA CI_END="1.3948925816226532" CI_START="0.9073279309634877" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.14454076459545367" LOG_CI_START="-0.042235719700691156" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2013-10-29 09:40:24 +0000" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.10971343143406384" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.012037037037037027" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.47893341023911" CI_START="0.4980238259467751" DF="0" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" ID="CMP-003.35.05" LOG_CI_END="0.39426486079197437" LOG_CI_START="-0.30274987967062406" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2014-05-15 14:55:45 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.7969204210936938" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.257334682656305">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="2.47893341023911" CI_START="0.4980238259467751" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.39426486079197437" LOG_CI_START="-0.30274987967062406" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2013-10-29 09:48:55 +0000" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="0.409429908826341" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.1676328502415459" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.324206176718926" CI_START="0.04695535666766082" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.35.06" LOG_CI_END="0.7262548649238969" LOG_CI_START="-1.3283148562518594" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-05-15 14:55:45 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.5657396174844884" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.5743372382904695">
<NAME>Lactation</NAME>
<DICH_DATA CI_END="5.324206176718926" CI_START="0.04695535666766082" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7262548649238969" LOG_CI_START="-1.3283148562518594" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-10-29 09:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="1.2068644245027833" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="1.4565217391304346" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.633535878489302" CI_START="0.27521401561494013" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-003.35.07" LOG_CI_END="0.5603294528884348" LOG_CI_START="-0.5603294528884348" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-15 14:55:45 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Liver function abnormalities</NAME>
<DICH_DATA CI_END="3.633535878489302" CI_START="0.27521401561494013" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5603294528884348" LOG_CI_START="-0.5603294528884348" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-29 09:39:25 +0000" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6238556663227564" CI_START="0.38111852448098477" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-003.35.08" LOG_CI_END="0.41893994158639797" LOG_CI_START="-0.41893994158639797" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-15 14:55:45 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="2.6238556663227564" CI_START="0.38111852448098477" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41893994158639797" LOG_CI_START="-0.41893994158639797" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-29 09:47:32 +0000" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.4921747909480132" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.2422360248447205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.692181118468888" CI_START="0.7381804077964911" DF="0" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-003.35.09" LOG_CI_END="0.22844684483890013" LOG_CI_START="-0.13183748568978998" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2014-05-15 14:55:45 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.599194281621403" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5255595330052041">
<NAME>QTC/ECG abnormalities</NAME>
<DICH_DATA CI_END="1.692181118468888" CI_START="0.7381804077964911" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.22844684483890013" LOG_CI_START="-0.13183748568978998" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2013-10-29 09:38:32 +0000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.21163279918875158" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.04478844169246645" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7855643796306688" CI_START="0.37490750557074337" DF="0" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" ID="CMP-003.35.10" LOG_CI_END="0.25177551356788663" LOG_CI_START="-0.4260758650056869" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2014-05-15 14:55:45 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.6142766011247627" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.5039783381862419">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="1.7855643796306688" CI_START="0.37490750557074337" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.25177551356788663" LOG_CI_START="-0.4260758650056869" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2013-10-29 09:44:57 +0000" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.3981732551925566" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.1585419411506368" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.562219151065646" CI_START="0.2627823418558454" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.35.11" LOG_CI_END="0.9325863394619066" LOG_CI_START="-0.5804038213505444" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-05-15 14:55:45 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.6482276611142735" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.45622573719331705">
<NAME>Tachycardia</NAME>
<DICH_DATA CI_END="8.56221915106565" CI_START="0.26278234185584537" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9325863394619068" LOG_CI_START="-0.5804038213505445" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-10-29 09:47:59 +0000" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="0.8887379098833177" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.7898550724637681" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5739880012144873" CI_START="0.3759342357596079" DF="0" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-003.35.12" LOG_CI_END="0.1970014173329569" LOG_CI_START="-0.42488812194663034" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2014-05-15 14:55:45 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.47262539193456843" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="0.7182139357348386">
<NAME>Weight gain</NAME>
<DICH_DATA CI_END="1.5739880012144873" CI_START="0.3759342357596079" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.1970014173329569" LOG_CI_START="-0.42488812194663034" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2013-10-29 09:45:42 +0000" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.36530099377569686" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.13344481605351172" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-09-16 23:24:33 +0100" MODIFIED_BY="Laura E  Prescott" NO="4">
<NAME>Subgroup analyses: antipsychotics + lithium versus antipsychotics + placebo/no adjunctive treatment</NAME>
<DICH_OUTCOME CHI2="22.791148329365498" CI_END="2.344089813353648" CI_START="0.9825488220516921" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5176240261981877" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="51" I2="56.123316581133416" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.36997424757499414" LOG_CI_START="-0.007645860676858555" LOG_EFFECT_SIZE="0.18116419344906778" METHOD="MH" MODIFIED="2015-09-16 23:24:33 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.01154431213602436" P_Q="0.6426791976094861" P_Z="0.06002699586042806" Q="0.2152552831361889" RANDOM="YES" SCALE="307.33862583242916" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.21976390465885026" TOTALS="SUB" TOTAL_1="196" TOTAL_2="190" WEIGHT="200.0" Z="1.8805952685740115">
<NAME>Clinically significant response - participants with or without schizoaffective or prominent affective symptoms</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="20.335042452001723" CI_END="2.8144013943520454" CI_START="0.9533229505336899" DF="6" EFFECT_SIZE="1.6379967769351145" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="42" I2="70.49428338218505" ID="CMP-004.01.01" LOG_CI_END="0.44938603727798565" LOG_CI_START="-0.020759951538675683" LOG_EFFECT_SIZE="0.21431304286965502" MODIFIED="2015-09-15 20:39:44 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.002413538558894701" P_Z="0.07395783937431702" STUDIES="7" TAU2="0.2898585752233126" TOTAL_1="134" TOTAL_2="138" WEIGHT="100.0" Z="1.7868741005275874">
<NAME>Participants without schizoaffective disorder or prominent affective symptoms</NAME>
<DICH_DATA CI_END="3.375390052295833" CI_START="1.0695060256945985" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.5283239661364544" LOG_CI_START="0.02918323576920342" LOG_EFFECT_SIZE="0.2787536009528289" MODIFIED="2014-03-07 14:19:42 +0000" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="0.2931977358041869" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.08596491228070177" WEIGHT="20.29349066279236"/>
<DICH_DATA CI_END="4.868921183833246" CI_START="1.1584958529887723" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6874327444158161" LOG_CI_START="0.0638944835059546" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2014-03-07 14:19:42 +0000" MODIFIED_BY="[Empty name]" ORDER="478" O_E="0.0" SE="0.36626946102262364" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.13415331807780323" WEIGHT="17.987161574981013"/>
<DICH_DATA CI_END="1.3048701219375713" CI_START="0.575621357622783" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.11556728705143023" LOG_CI_START="-0.2398631005491191" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2014-03-07 14:19:42 +0000" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.2087815690853567" STUDY_ID="STD-Johnstone-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.043589743589743574" WEIGHT="22.87242131455051"/>
<DICH_DATA CI_END="16.669089271039443" CI_START="1.1132109688794265" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2219118724514737" LOG_CI_START="0.046577476947253414" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2014-03-07 14:19:42 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.6903972419182682" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.47664835164835173" WEIGHT="9.950034588268924"/>
<DICH_DATA CI_END="1.5088502307125549" CI_START="0.6627563025441894" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.17864613361048765" LOG_CI_START="-0.17864613361048765" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 14:19:42 +0000" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.20987524639084762" STUDY_ID="STD-Small-2001" TOTAL_1="3" TOTAL_2="7" VAR="0.044047619047619" WEIGHT="22.84105705548072"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2014-03-07 14:19:42 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="3.0317703404579235"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2014-03-07 14:19:42 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="3.024064463468535"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.561691308421012" CI_END="2.7406331886001" CI_START="0.6367289850003286" DF="3" EFFECT_SIZE="1.3209998442223811" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.43785091265471837" LOG_CI_START="-0.19604537985316464" LOG_EFFECT_SIZE="0.12090276640077682" MODIFIED="2015-09-15 20:39:49 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="0.4642452084926876" P_Z="0.45467361385071214" STUDIES="4" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="99.99999999999999" Z="0.7476461704462015">
<NAME>Participants with schizoaffective disorder or prominent affective symptoms</NAME>
<DICH_DATA CI_END="4.444461774072338" CI_START="0.2938764051474398" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6478191752717338" LOG_CI_START="-0.5318352813163605" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-07 14:19:58 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.6929348671835831" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="0.48015873015873" WEIGHT="28.875319472947783"/>
<DICH_DATA CI_END="132.89880114989023" CI_START="0.5072486869632472" EFFECT_SIZE="8.210526315789474" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.123521063287836" LOG_CI_START="-0.2947790684845707" LOG_EFFECT_SIZE="0.9143709974016326" MODIFIED="2014-03-07 14:19:59 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.4205214681818263" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="2.0178812415654517" WEIGHT="6.8709379152076036"/>
<DICH_DATA CI_END="3.7159033804812984" CI_START="0.15137637941682514" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5700644131070339" LOG_CI_START="-0.8199418863236337" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-07 14:20:01 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Johnstone-1988" TOTAL_1="2" TOTAL_2="3" VAR="0.6666666666666667" WEIGHT="20.79710509658738"/>
<DICH_DATA CI_END="4.32212374238197" CI_START="0.4721790601501604" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6356971965741458" LOG_CI_START="-0.32589327660265943" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2014-03-07 14:20:02 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.319047619047619" WEIGHT="43.45663751525722"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.97957568192274" CI_END="2.6331541265053495" CI_START="0.9540850796285336" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5850088531175648" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="44" I2="46.995141877533335" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.42047628042462415" LOG_CI_START="-0.020412895772139405" LOG_EFFECT_SIZE="0.20003169232624235" METHOD="MH" MODIFIED="2015-09-16 23:03:52 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="0.0490368334552872" P_Q="0.5247633900871601" P_Z="0.07532607988448589" Q="0.40452146015778767" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.24305212695873996" TOTALS="SUB" TOTAL_1="203" TOTAL_2="193" WEIGHT="199.99999999999997" Z="1.778473747566272">
<NAME>Clinically significant response - participants with or without treatment-resistant schizophrenia</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.652896324397188" CI_END="4.013331358317808" CI_START="0.8956674695407467" DF="3" EFFECT_SIZE="1.895945764554735" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" I2="46.929859883465795" ID="CMP-004.02.01" LOG_CI_END="0.6035050184799119" LOG_CI_START="-0.04785319898583189" LOG_EFFECT_SIZE="0.27782590974704" MODIFIED="2015-09-16 23:03:46 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.1297745429912287" P_Z="0.09452837442386017" STUDIES="4" TAU2="0.25325279503853093" TOTAL_1="99" TOTAL_2="100" WEIGHT="100.0" Z="1.671979449940422">
<NAME>Treatment-resistant participants</NAME>
<DICH_DATA CI_END="1.8956094710381146" CI_START="0.4273032037323649" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.27774886989933845" LOG_CI_START="-0.3692638510206887" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-03-07 14:20:56 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.380058475033046" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.14444444444444446" WEIGHT="36.80971209395394"/>
<DICH_DATA CI_END="4.868921183833246" CI_START="1.1584958529887723" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6874327444158161" LOG_CI_START="0.0638944835059546" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2014-03-07 14:20:53 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.36626946102262364" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.13415331807780323" WEIGHT="37.78753197302438"/>
<DICH_DATA CI_END="16.669089271039443" CI_START="1.1132109688794265" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2219118724514737" LOG_CI_START="0.046577476947253414" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2014-03-07 14:20:47 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.6903972419182682" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.47664835164835173" WEIGHT="20.05630618937574"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-07 14:20:46 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="5.346449743645947"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.659951538064009" CI_END="2.71474525967216" CI_START="0.6835548478669311" DF="5" EFFECT_SIZE="1.3622324628978255" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" I2="34.72543559637572" ID="CMP-004.02.02" LOG_CI_END="0.43372908346108174" LOG_CI_START="-0.16522663227352055" LOG_EFFECT_SIZE="0.13425122559378058" MODIFIED="2015-09-16 23:03:52 +0100" MODIFIED_BY="Laura E  Prescott" NO="2" P_CHI2="0.17599903041702636" P_Z="0.3796067568802951" STUDIES="6" TAU2="0.23495665430393553" TOTAL_1="104" TOTAL_2="93" WEIGHT="99.99999999999997" Z="0.878621107142966">
<NAME>Non-treatment-resistant participants</NAME>
<DICH_DATA CI_END="4.444461774072338" CI_START="0.2938764051474398" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6478191752717338" LOG_CI_START="-0.5318352813163605" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-07 14:21:19 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.6929348671835831" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="0.48015873015873" WEIGHT="17.309658911255827"/>
<DICH_DATA CI_END="132.89880114989023" CI_START="0.5072486869632472" EFFECT_SIZE="8.210526315789474" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.123521063287836" LOG_CI_START="-0.2947790684845707" LOG_EFFECT_SIZE="0.9143709974016326" MODIFIED="2014-03-07 14:21:17 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.4205214681818263" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="2.0178812415654517" WEIGHT="5.494582370944801"/>
<DICH_DATA CI_END="1.282357944877448" CI_START="0.5780418365006762" EFFECT_SIZE="0.8609625668449198" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.10800926682647895" LOG_CI_START="-0.23804072783577748" LOG_EFFECT_SIZE="-0.06501573050464926" MODIFIED="2014-03-07 14:21:16 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.20327147983970956" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.041319294516225444" WEIGHT="44.80449145176191"/>
<DICH_DATA CI_END="4.32212374238197" CI_START="0.4721790601501604" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6356971965741458" LOG_CI_START="-0.32589327660265943" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2014-03-07 14:21:14 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.319047619047619" WEIGHT="22.343516074984045"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2014-03-07 14:21:12 +0000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="5.030410779121999"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2014-03-07 14:21:11 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="5.017340411931405"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-09-15 22:45:39 +0100" MODIFIED_BY="Laura E  Prescott" NO="5">
<NAME>Sensitivity analysis 1: participants with affective symptoms excluded</NAME>
<DICH_OUTCOME CHI2="20.335042452001726" CI_END="2.8144013943520467" CI_START="0.95332295053369" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6379967769351147" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="42" I2="70.49428338218503" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.4493860372779859" LOG_CI_START="-0.02075995153867563" LOG_EFFECT_SIZE="0.21431304286965508" METHOD="MH" MODIFIED="2015-09-15 22:45:39 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.002413538558894812" P_Q="1.0" P_Z="0.07395783937431699" Q="0.0" RANDOM="YES" SCALE="369.74" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.28985857522331265" TOTALS="YES" TOTAL_1="134" TOTAL_2="138" WEIGHT="100.0" Z="1.7868741005275877">
<NAME>Clinically significant response</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.375390052295833" CI_START="1.0695060256945985" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.5283239661364544" LOG_CI_START="0.02918323576920342" LOG_EFFECT_SIZE="0.2787536009528289" MODIFIED="2014-03-11 17:53:03 +0000" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="0.2931977358041869" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.08596491228070177" WEIGHT="20.29349066279237"/>
<DICH_DATA CI_END="4.868921183833246" CI_START="1.1584958529887723" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6874327444158161" LOG_CI_START="0.0638944835059546" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2014-03-07 14:22:03 +0000" MODIFIED_BY="[Empty name]" ORDER="478" O_E="0.0" SE="0.36626946102262364" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.13415331807780323" WEIGHT="17.987161574981016"/>
<DICH_DATA CI_END="1.3048701219375713" CI_START="0.575621357622783" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.11556728705143023" LOG_CI_START="-0.2398631005491191" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2014-03-07 14:21:59 +0000" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.2087815690853567" STUDY_ID="STD-Johnstone-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.043589743589743574" WEIGHT="22.87242131455051"/>
<DICH_DATA CI_END="16.669089271039443" CI_START="1.1132109688794265" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2219118724514737" LOG_CI_START="0.046577476947253414" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2014-03-07 14:21:58 +0000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.6903972419182682" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.47664835164835173" WEIGHT="9.950034588268926"/>
<DICH_DATA CI_END="1.5088502307125549" CI_START="0.6627563025441894" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.17864613361048765" LOG_CI_START="-0.17864613361048765" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-07 14:21:56 +0000" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.20987524639084762" STUDY_ID="STD-Small-2001" TOTAL_1="3" TOTAL_2="7" VAR="0.044047619047619" WEIGHT="22.841057055480725"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2014-03-07 14:21:55 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="3.031770340457925"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2014-03-07 14:21:54 +0000" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="3.024064463468536"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2015-09-15 22:46:03 +0100" MODIFIED_BY="Laura E  Prescott" NO="6">
<NAME>Sensitivity analysis 2: studies with attrition &gt; 50% excluded</NAME>
<DICH_OUTCOME CHI2="17.140687532713486" CI_END="3.002115213950988" CI_START="0.9338536572608312" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6743763830353415" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="40" I2="53.32742642480487" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.4774273554032524" LOG_CI_START="-0.02972117604367079" LOG_EFFECT_SIZE="0.22385308967979078" METHOD="MH" MODIFIED="2015-09-15 22:46:03 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.028677034347406205" P_Q="1.0" P_Z="0.08358764669341377" Q="0.0" RANDOM="YES" SCALE="218.95" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3165976625504485" TOTALS="YES" TOTAL_1="182" TOTAL_2="173" WEIGHT="100.0" Z="1.7302386436914003">
<NAME>Clinically significant response</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.444461774072338" CI_START="0.2938764051474398" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6478191752717338" LOG_CI_START="-0.5318352813163605" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-07 14:22:53 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.6929348671835831" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="0.48015873015873" WEIGHT="11.138327718526867"/>
<DICH_DATA CI_END="1.8956094710381146" CI_START="0.4273032037323649" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.27774886989933845" LOG_CI_START="-0.3692638510206887" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-03-07 14:22:52 +0000" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.380058475033046" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.14444444444444446" WEIGHT="19.248857488681452"/>
<DICH_DATA CI_END="4.868921183833246" CI_START="1.1584958529887723" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6874327444158161" LOG_CI_START="0.0638944835059546" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2014-03-07 14:22:50 +0000" MODIFIED_BY="[Empty name]" ORDER="480" O_E="0.0" SE="0.36626946102262364" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.13415331807780323" WEIGHT="19.688329466209687"/>
<DICH_DATA CI_END="132.89880114989023" CI_START="0.5072486869632472" EFFECT_SIZE="8.210526315789474" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.123521063287836" LOG_CI_START="-0.2947790684845707" LOG_EFFECT_SIZE="0.9143709974016326" MODIFIED="2014-03-07 14:22:48 +0000" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="1.4205214681818263" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="2.0178812415654517" WEIGHT="3.8015052516343175"/>
<DICH_DATA CI_END="1.282357944877448" CI_START="0.5780418365006762" EFFECT_SIZE="0.8609625668449198" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.10800926682647895" LOG_CI_START="-0.23804072783577748" LOG_EFFECT_SIZE="-0.06501573050464926" MODIFIED="2014-03-07 14:22:46 +0000" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.20327147983970956" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.041319294516225444" WEIGHT="24.79495212117861"/>
<DICH_DATA CI_END="16.669089271039443" CI_START="1.1132109688794265" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2219118724514737" LOG_CI_START="0.046577476947253414" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2014-03-07 14:22:45 +0000" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.6903972419182682" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.47664835164835173" WEIGHT="11.18761853822819"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-07 14:22:43 +0000" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="3.1678402321122197"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2014-03-07 14:22:42 +0000" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="3.4906741906501852"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2014-03-07 14:22:41 +0000" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="3.48189499277847"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2015-09-16 23:24:59 +0100" MODIFIED_BY="Laura E  Prescott" NO="7">
<NAME>Sensitivity analysis 3: non-double-blind studies excluded</NAME>
<DICH_OUTCOME CHI2="13.027680986366367" CI_END="3.9607792539482793" CI_START="0.837621023461627" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.821436787922583" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="26" I2="53.94422072294312" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.5977806385508111" LOG_CI_START="-0.07695243082922305" LOG_EFFECT_SIZE="0.26041410386079394" METHOD="MH" MODIFIED="2015-09-16 23:24:59 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.04259849882763789" P_Q="1.0" P_Z="0.13030473487557478" Q="0.0" RANDOM="YES" SCALE="611.6939607087154" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4837405733104074" TOTALS="YES" TOTAL_1="117" TOTAL_2="107" WEIGHT="100.0" Z="1.5129012873265657">
<NAME>Clinically significant response</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.444461774072338" CI_START="0.2938764051474398" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6478191752717338" LOG_CI_START="-0.5318352813163605" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-07 14:23:30 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.6929348671835831" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="0.48015873015873" WEIGHT="16.296994891188415"/>
<DICH_DATA CI_END="132.89880114989023" CI_START="0.5072486869632472" EFFECT_SIZE="8.210526315789474" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.123521063287836" LOG_CI_START="-0.2947790684845707" LOG_EFFECT_SIZE="0.9143709974016326" MODIFIED="2014-03-07 14:23:29 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.4205214681818263" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="2.0178812415654517" WEIGHT="6.279391205675161"/>
<DICH_DATA CI_END="1.282357944877448" CI_START="0.5780418365006762" EFFECT_SIZE="0.8609625668449198" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.10800926682647895" LOG_CI_START="-0.23804072783577748" LOG_EFFECT_SIZE="-0.06501573050464926" MODIFIED="2014-03-07 14:23:28 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.20327147983970956" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.041319294516225444" WEIGHT="29.91784934788308"/>
<DICH_DATA CI_END="4.32212374238197" CI_START="0.4721790601501604" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6356971965741458" LOG_CI_START="-0.32589327660265943" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2014-03-07 14:23:26 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.319047619047619" WEIGHT="19.567629636050842"/>
<DICH_DATA CI_END="16.669089271039443" CI_START="1.1132109688794265" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2219118724514737" LOG_CI_START="0.046577476947253414" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2014-03-07 14:23:24 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.6903972419182682" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.47664835164835173" WEIGHT="16.35656307149852"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2014-03-07 14:23:23 +0000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="5.797627885318946"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2014-03-07 14:23:22 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="5.783943962385027"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2015-09-15 22:47:14 +0100" MODIFIED_BY="Laura E  Prescott" NO="8">
<NAME>Sensitivity analysis 4: fixed-effect model</NAME>
<DICH_OUTCOME CHI2="17.708343173069032" CI_END="2.3656550442798103" CI_START="1.32919401728258" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.773249709378541" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="44" I2="49.17649882860154" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.37395141683969757" LOG_CI_START="0.12358837784666013" LOG_EFFECT_SIZE="0.24876989734317884" METHOD="MH" MODIFIED="2015-09-15 22:47:14 +0100" MODIFIED_BY="Laura E  Prescott" NO="1" P_CHI2="0.03871210734712127" P_Q="1.0" P_Z="9.820513535602988E-5" Q="0.0" RANDOM="NO" SCALE="241.28" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="203" TOTAL_2="193" WEIGHT="100.00000000000003" Z="3.8949841892909487">
<NAME>Clinically significant response</NAME>
<GROUP_LABEL_1>Lithium</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.444461774072338" CI_START="0.2938764051474398" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6478191752717338" LOG_CI_START="-0.5318352813163605" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2014-03-07 14:24:24 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.6929348671835831" STUDY_ID="STD-Biederman-1979" TOTAL_1="21" TOTAL_2="18" VAR="0.48015873015873" WEIGHT="7.021990316316238"/>
<DICH_DATA CI_END="3.375390052295833" CI_START="1.0695060256945985" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.5283239661364544" LOG_CI_START="0.02918323576920342" LOG_EFFECT_SIZE="0.2787536009528289" MODIFIED="2014-03-07 14:24:24 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.2931977358041869" STUDY_ID="STD-Feng-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.08596491228070177" WEIGHT="21.734731931455023"/>
<DICH_DATA CI_END="4.868921183833246" CI_START="1.1584958529887723" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6874327444158161" LOG_CI_START="0.0638944835059546" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2014-03-07 14:24:22 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.36626946102262364" STUDY_ID="STD-He-2010" TOTAL_1="46" TOTAL_2="46" VAR="0.13415331807780323" WEIGHT="17.387785545164018"/>
<DICH_DATA CI_END="132.89880114989023" CI_START="0.5072486869632472" EFFECT_SIZE="8.210526315789474" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.123521063287836" LOG_CI_START="-0.2947790684845707" LOG_EFFECT_SIZE="0.9143709974016326" MODIFIED="2014-03-07 14:24:18 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.4205214681818263" STUDY_ID="STD-Hogarty-1995" TOTAL_1="18" TOTAL_2="11" VAR="2.0178812415654517" WEIGHT="1.3321287312827272"/>
<DICH_DATA CI_END="1.282357944877448" CI_START="0.5780418365006762" EFFECT_SIZE="0.8609625668449198" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.10800926682647895" LOG_CI_START="-0.23804072783577748" LOG_EFFECT_SIZE="-0.06501573050464926" MODIFIED="2014-03-07 14:24:17 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.20327147983970956" STUDY_ID="STD-Johnstone-1988" TOTAL_1="22" TOTAL_2="23" VAR="0.041319294516225444" WEIGHT="36.12795441050746"/>
<DICH_DATA CI_END="4.32212374238197" CI_START="0.4721790601501604" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6356971965741458" LOG_CI_START="-0.32589327660265943" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2014-03-07 14:24:15 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Schulz-1999" TOTAL_1="21" TOTAL_2="20" VAR="0.319047619047619" WEIGHT="8.905938937766937"/>
<DICH_DATA CI_END="16.669089271039443" CI_START="1.1132109688794265" EFFECT_SIZE="4.3076923076923075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2219118724514737" LOG_CI_START="0.046577476947253414" LOG_EFFECT_SIZE="0.6342446746993636" MODIFIED="2014-03-07 14:24:14 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.6903972419182682" STUDY_ID="STD-Simhandl-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.47664835164835173" WEIGHT="4.18594837198393"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-07 14:24:12 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Small-2001" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.0867365965727511"/>
<DICH_DATA CI_END="101.54624195667168" CI_START="0.29299032187126384" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0066638555824765" LOG_CI_START="-0.5331467251316393" LOG_EFFECT_SIZE="0.7367585652254186" MODIFIED="2014-03-07 14:24:12 +0000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.4918973073766089" STUDY_ID="STD-Terao-1995" TOTAL_1="10" TOTAL_2="11" VAR="2.2257575757575756" WEIGHT="1.0394871793304576"/>
<DICH_DATA CI_END="79.09554041147649" CI_START="0.2263011061168061" EFFECT_SIZE="4.230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8981519976659926" LOG_CI_START="-0.6453133232911785" LOG_EFFECT_SIZE="0.626419337187407" MODIFIED="2014-03-07 14:24:11 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.4940441198866357" STUDY_ID="STD-Wilson-1993" TOTAL_1="12" TOTAL_2="10" VAR="2.232167832167832" WEIGHT="1.1772979796204803"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram of trial selection from 2012 and 2015 search.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeIAAAIJCAYAAAB5gj5/AABXIklEQVR42u2dcYRW2R//v6y1kpVI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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAAEyCAMAAADp82f9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYcAAARhCAIAAABGWd4RAABM/klEQVR42u2dvW7kyJK2CQgQZMho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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-10-14 09:49:23 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-10-14 09:44:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-02-09 13:40:17 +0000" MODIFIED_BY="[Empty name]">Previous methods sections</TITLE>
<APPENDIX_BODY MODIFIED="2015-09-29 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Selection of trials</HEADING>
<P>Material downloaded from electronic sources included details of author, institution, or journal of publication.</P>
<P>The principal reviewer (SL) inspected all reports. JM then re-inspected thesein order to ensure reliable selection. We resolved any disagreement by discussion, and where there was still doubt, we acquired the full article for further inspection. Upon obtaining the full articles, we decided whether the studies met the review criteria. If we could not resolve disagreement by discussion, we sought further information and added these trials to the list of those awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Quality assessment</HEADING>
<P>We assessed the methodological quality of the trials included in this review using the criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). These criteria are based on the evidence of a strong relationship among the potential for bias in the results and the allocation concealment (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and is defined below:</P>
<UL>
<LI>A. Low risk of bias (adequate allocation concealment).</LI>
<LI>B. Moderate risk of bias (some doubt about the results).</LI>
<LI>C. High risk of bias (inadequate allocation concealment).</LI>
</UL>
<P>For the purpose of the analysis in this review, we included trials if they met the criteria A or B in the <I>Cochrane Handbook</I> <I>for Systematic Reviews of Interventions</I>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Data extraction</HEADING>
<P>We (SL and JM) independently extracted the data from included studies. We discussed any disagreement, documented the decisions, and, if necessary, contacted the authors of the studies for clarification. We documented justification for excluding references from the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Data management</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Intention-to-treat</HEADING>
<P>For studies that did not specify the reasons for people leaving the study early (dropped out), we assumed that these people had no change in the clinical outcome variables. <LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK> highlighted the problem of high dropout rates in randomised trials of drug treatments for schizophrenia. Since there is no evidence on the degree of attrition that makes a reasonable analysis of the data possible, we included all trials in the main analysis. However, we used a sensitivity analysis to test whether the exclusion of trials with dropout rates higher than 50% significantly changed the results of the primary outcome parameters. When insufficient data were provided to identify the original group size (prior to dropouts), we contacted the authors and allocated the trials to the 'awaiting assessment' list.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Cross-over design</HEADING>
<P>We expected that some trials would use a cross-over design. In order to exclude the potential additive effect in the second or more stages of these trials, we only analysed data from the first stage.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Data types</HEADING>
<P>We assessed outcomes using continuous (for example, changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change', or 'much change'), or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently, RevMan does not support categorical data, so they could not be analysed as such.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.3.1 Dichotomous data</HEADING>
<P>Where possible, we converted outcome measures to dichotomous data. This may be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. If the authors of a study had used a predefined cut-off point for determining clinical effectiveness, we used this where appropriate. Otherwise, we generally assumed that we could consider a 50% reduction of a scale (e.g., the Brief Psychiatric Rating Scale - <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or a rating of 'at least much improved' according to the Clinical Global Impression Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) as a clinically significant response.</P>
<P>For dichotomous outcomes, we estimated a relative risk (RR) with the 95% confidence interval (CI) based on a fixed-effect model in case of homogeneous outcomes and based on a random-effects model in the case of heterogeneous outcomes. When overall results were significant, we calculated the number needed to treat (NNT) or the number needed to harm (NNH) or both as the inverse of the risk reduction. It has been shown that RRs are more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that clinicians tend to interpret odds ratios as relative risks (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. However, we inspected data to see if an analysis using a Mantel-Haenszel odds ratio and a random-effects model made a substantive difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.2 Continuous data</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">4.3.2.1 Normal distribution</HEADING>
<P>Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards to data derived from continuous measures of endpoint ('state' data). The criteria were used before inclusion:<BR/>When a scale started from zero, the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and endpoint, and this rule can be applied to them.<BR/>When continuous data are presented on a scale that includes a possibility of negative values (such as change on a scale), it is impossible to tell whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale endpoint data, which typically cannot have negative values. If endpoint data were not available, we chose to use change data, because the statistics used in MetaView are rather robust towards skewness. If a scale starts from a positive value (such as Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210), the calculation described above in (b) should be modified to take the scale starting point into account. In these cases, skewness is present if 2 SD &gt; (S-S min), where S is the mean score and S min is the minimum score.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.3.2.2 Intention-to-treat versus completer analyses</HEADING>
<P>We assumed that for incomplete continuous data, intention-to-treat analyses would be impossible. In these cases, we analysed data as they were presented in the original publications.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.3.2.3 Summary statistic</HEADING>
<P>For continuous outcomes, we estimated a weighted mean difference (WMD) between groups. Again, we used a fixed-effect model for homogeneous outcomes and a random-effects model for heterogeneous outcomes. Whenever possible, we took the opportunity to make direct comparisons between trials that used the same measurement instrument to quantify specific outcomes. Where continuous data were presented from different scales rating the same effect, we presented both sets of data and inspected the general direction of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.3.2.4 Rating scales</HEADING>
<P>A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid or even ad hoc. For outcome instruments, some minimum standards have to be set. We only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), the instrument was either a self report or completed by an independent rater or relative (not the therapist), and the instrument could be considered a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, we commented on such data as 'prone to bias'.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4 Data display</HEADING>
<P>We entered data into RevMan in such a way that the area to the left of the line of no effect indicated a favourable outcome for lithium alone or lithium augmentation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5 Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals are unduly narrow, and statistical significance is overestimated causing type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Secondly, RevMan does not currently support meta-analytic pooling of clustered dichotomous data, even when these are correctly analysed by the authors of primary studies, since the 'design effect' (a statistical correction for clustering) cannot be incorporated.</P>
<P>Where clustering was not accounted for in primary studies, we presented data in a table, with an asterisk (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies, to seek intraclass correlation coefficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering had been incorporated into the analysis of primary studies, we presented these data in a table. We will attempt no further secondary analysis (including meta-analytic pooling) until there is consensus on the best methods of doing so and until RevMan, or any other software, allows this. A Cochrane Statistical Methods Workgroup is currently addressing this issue. In the interim,we very crudely classified individual studies as positive or negative, according to whether a statistically significant result (P &lt; 0.05) was obtained for the outcome in question, using an analytic method that allowed for clustering.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Heterogeneity</HEADING>
<P>After considering the likelihood of clinical heterogeneity based on comparisons of the included studies, we visually inspected graphs to investigate the possibility of statistical heterogeneity. We calculated the value of the I² statistic to provide an estimate of the percentage of variability due to heterogeneity rather than chance alone. We interpreted an I² statistic value of 50% or greater as indicating high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). When the results were statistically significantly heterogeneous, we sought reasons for the heterogeneity, and if these were identified, we excluded these studies. If reasons were not found, we combined the studies using a random-effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Publication bias</HEADING>
<P>We entered data from all included trials into a funnel graph (trial effect versus trial size or 'precision') in an attempt to investigate the likelihood of overt publication bias. We undertook a formal test of funnel plot asymmetry (suggesting potential publication bias) where appropriate (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). We set significance levels of P &lt; 0.1 a priori to accept the presence of asymmetry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Sensitivity analysis</HEADING>
<P>We examined whether the exclusion of schizoaffective participants led to a significant change of the primary outcomes by carrying out a sensitivity analysis. We also used a sensitivity analysis to test whether the exclusion of trials with attrition rates of higher than 50% significantly changed the results of the primary outcome parameters.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Posthoc amendment to the protocol</HEADING>
<P>For a number of studies, we were able to examine individual participant data. This enabled us to dichotomise many scale-derived data. As explained above (see 4.3.1), we used a clinical rating of 'at least much improved' or a 50% reduction of a rating scale as a cut-off for a clinically significant response whenever the original authors did not present a definition of their own. However, since there is an uncertainty about which cut-off is best, we also analysed the data using a relatively low threshold (at least 20% reduction) and an intermediate threshold (at least 35% reduction) as in the review on carbamazepine (<LINK REF="REF-Leucht-2014" TYPE="REFERENCE">Leucht 2014</LINK>). Furthermore, when original participant data were available, we used the Kolmogornov-Smirnoff test to assess normal distribution (<LINK REF="REF-SPSS-2001" TYPE="REFERENCE">SPSS 2001</LINK>). Therefore, continuous data could sometimes be used for meta-analytic calculations, although these data did not meet the criteria stipulated in 4.3.2.1 above.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-10-14 09:49:23 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-02-09 13:40:50 +0000" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2015-10-14 09:49:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">2.1 Search in 2002 and 2006</HEADING>
<P>We searched the Cochrane Schizophrenia Group Trials Study-Based Register in November 2006 using the following phrase:<BR/>[((lithium* or lithicarb* or eskalith* or lithobid* or lithane* or cibalith-s* or quilonum* or hypnorex*) in title, abstract and index fields in REFERENCE) OR (lithium* in interventions field in STUDY)]. This register is compiled by systematic searches of major databases, handsearches, and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group's Module</A>).</P>
<P>In March 2002, we also searched the Cochrane Schizophrenia Group's Trials Study-Based Register with the same phrase.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2.2 2012 search</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.2.1 Abstract section</HEADING>
<P>We searched the Cochrane Schizophrenia Group's Trials Study-Based Register (July 6, 2012). This register is compiled by methodical searches of MEDLINE, EMBASE, BIOSIS, CINAHL (Cumulative Index to Nursing and Allied Health Literature), Dissertation Abstracts, LILACS (Latin American and Caribbean Health Science Information database), PSYNDEX, PsycINFO, RUSSMED, and Sociofile, supplemented with handsearching of relevant journals and numerous conference proceedings. For the first version of the review, we also contacted pharmaceutical companies and authors of relevant studies to identify further trials and to obtain original participant data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2.2 Electronic searches</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2.2.1 Cochrane Schizophrenia Group Trials Study-Based Register</HEADING>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group's Trials Study-Based Register (July 6, 2012):</P>
<P>1.1 Intervention search</P>
<P>The 'Intervention' field was searched using the following phrase:</P>
<P>(lithium* or lithicarb* or eskalith* or lithobid* or lithane* or cibalith-s* or quilonum* or hypnorex*)</P>
<P>The Cochrane Schizophrenia Group's Trials Study-Based Register is compiled by systematic searches of major resources (including MEDLINE, EMBASE, AMED (the Allied and Complementary Medicine Database), BIOSIS, CINAHL, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates; handsearches; grey literature; and conference proceedings. The searches do not have language limitation (for details of databases searched by the Schizophrenia Group, please see their <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group's Module</A>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2.3 Searching other resources</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2.3.1 Reference searching</HEADING>
<P>We inspected references of all included studies for further relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.3.2 Personal contact</HEADING>
<P>For the original search, we contacted the first author of each included study for information regarding unpublished trials and additional information (however, this was not done in this update).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;22 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;22 studies now included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Update search in 2012 identified 4 further potentially relevant studies&lt;/p&gt;&lt;p&gt;Update search in 2015 identified 23 citations&lt;/p&gt;">
<OUT TEXT="&lt;p&gt;2 records from 2012 search excluded&lt;/p&gt;&lt;p&gt;13 citations from 2015 search excluded, 2 awaiting assessment, 7 references to studies already included, and 1 reference to study already in awaiting assessment.&lt;/p&gt;&lt;p&gt;Total number of excluded studies now 64&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Including 2 records from 2012 search&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Including 2 records from 2012 search&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>